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Résumé Large Public 
 
Les cellules dendritiques sont des cellules du système immunitaire. Dans le corps, les cellules 
dendritiques circulent continuellement afin de détecter les éléments étrangers. Quand elles 
reconnaissent une protéine étrangère, c’est-à-dire un antigène, elles l‘absorbent, pour ensuite 
s’activer et subir diverses modifications afin de pouvoir la présenter aux lymphocytes T. Les 
lymphocytes T sont d‘autres cellules du système immunitaire. Elles sont capables de mettre en 
place une réponse immunitaire adaptive afin de combattre et vaincre une infection. Lors de ce 
processus, les cellules dendritiques vont interagir avec les lymphocytes T et transmettre les 
informations nécessaires pour que ces cellules produisent différentes protéines de façon à 
éliminer le pathogène. En fonction du type de pathogène, les informations échangées entre les 
cellules dendritiques et les lymphocytes seront différentes de manière à produire la réponse 
immunitaire la mieux adaptée pour supprimer l’élément infectieux. Les cellules dendritiques ne 
présentent pas seulement des protéines provenant des pathogènes aux lymphocytes T, mais 
également des éléments du soi. Les cellules dendritiques doivent alors être capables de 
différencier les molécules du soi et du non-soi de façon à ne pas induire une réponse auto-immune 
en présentant un antigène du soi aux lymphocytes T. D’autant plus que lors de leur 
développement, les lymphocytes T capables de reconnaître le soi sont éliminés. Cependant, ce 
système n’est pas parfait, en conséquence, certains lymphocytes T auto-réactifs peuvent se 
trouver dans le corps. C’est pourquoi, il existe d’autres mécanismes en périphérie du site de 
développement pour inhiber ces lymphocytes T auto-réactifs. Ce sont les mécanismes de 
tolérance. Les cellules dendritiques détiennent par conséquent une fonction essentielle non 
seulement dans le but de initier une réponse immunitaire contre des pathogènes mais aussi pour 
prévenir une réaction contre soi-même. 
Dans ce projet de recherche, nous avons travaillé avec des lignées de cellules dendritiques, c’est-
à-dire des cellules dendritiques semblables à celles que l’on peut trouver chez l’homme ou les 
autres animaux vertébrés. Néanmoins, étant immortalisées, elles peuvent être cultivées et 
manipulées dans in environnement artificiel (in vitro). Nous avons génétiquement modifiés ces 
lignées cellulaires pour qu’elles expriment des molécules immunosuppressives ainsi que des 
molécules pro-inflammatoires. Ceci nous permet d’étudier si l’expression de ces molécules génère 
ou, au contraire, évite une réponse immunitaire. Pour cela, nous avons testé in vitro si ces lignées 
dendritiques sont capables de supprimer ou augmenter l’activation des lymphocytes T. Dans un 
deuxième temps, nous avons utilisé des modèles murins de tumeurs et de maladies auto-
immunes. Nous avons démontré que l’expression des molécules immuno-modulatrices par les 
cellules dendritique empêchent le développement des maladies auto-immunes. En revanche, en 
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utilisant les cellules dendritiques pour augmenter la réponse immunitaire, nous avons pu ralentir 
la croissance des tumeurs. 
Pour résumer, nous avons montré que ces lignées de cellules dendritiques peuvent être un outil 
de recherche précieux. En effet, grâce à ces lignées, nous aurons la possibilité d’étudier les 
bénéfices de différentes molécules afin de modifier la réponse immunitaire à notre avantage. 
.  
 III Resumé 
Resumé 
Les cellules dendritiques (CD) jouent un rôle central dans l'élaboration des réponses 
immunitaires adaptatives de par leur capacité à présenter des antigènes, fournir un signal de 
costimulation et à sécréter des cytokines. En outre, elles sont importantes pour induire et 
maintenir la tolérance centrale et périphérique en induisant l'anergie, en supprimant les 
lymphocytes effecteurs ou en induisant des cellules T régulatrices. 
Une lignée cellulaire de cellules dendritiques murines CD8α+ (MuTu) a précédemment été dérivée 
et décrite dans notre laboratoire. Il a été démontré que les cellules de cette lignée MuTu possède 
les caractéristiques phénotypiques ainsi que fonctionnelles des cellules dendritiques CD8α+ 
endogènes. En particulier, elles ont maintenu la capacité de la présentation croisée (cross-
présentation) des antigènes exogènes aux cellules T CD8+, et l’aptitude à produire de 
l’interleukine 12 (IL-12) suite à l’activation des récepteurs Toll like. Cette lignée cellulaire 
constitue une source infinie de cellules dendritiques homogènes et bien définies. Cela nous 
permet d'étudier le rôle et le potentiel de molécules spécifiques dans l’induction ainsi que dans 
la régulation des réponses immunitaires par les CDs de manière rationnelle et standardisée. 
Dans un premier projet, la lignée de cellules dendritiques MuTu a été génétiquement modifiée 
afin d'exprimer de façon stable les molécules immunosuppressives interleukine (IL) -10, IL-35 et 
TGF-β (respectivement IL-10+DC, IL-35+DC ou actTGFβ+DC). Nous avons étudié la capacité de ces 
cellules dendritiques, potentiellement suppressives ou tolérogènes, à induire une tolérance 
immunitaire dans le but d’explorer les mécanismes se cachant derrière ce phénomène. 
L'expression de TGF-β par la lignée dendritique exprimant cette cytokine n'a pas affecté sa propre 
maturation. Lors de leur 'activation, les IL-10+ et IL-35+DCs présentaient un taux plus faible de 
CMH (complexe majeur d’histio-compatibilité) classe I et II, ainsi qu’un niveau plus bas de 
molécules de costimulation. D’autre part, une réduction de la sécrétion de cytokines pro-
inflammatoires a été observée.  
Lors de la co-culture in vitro entre les lymphocytes T CD4+ / CD8+ et les IL-35+ DC, les IL-10+ DC 
ou les active TGFβ+ DC, la fonction et la prolifération des cellules T se sont trouvées altérées. De 
plus, les lignées dendritiques produisant de l’IL-35 et/ou du TGF-β actif ont induit un phénotype 
régulateur sur les cellules T CD4+ in vitro, avec ou sans expression de FoxP3. Dans d’autres 
modèles murins de cancer, la vaccination au moyen de CD exprimant l’IL-35 ou le TGF-β actif a 
entraîné une croissance plus rapide de la tumeur. Fait intéressant, cette croissance accélérée 
observée lors de l’injection de IL-35+ DC a pu être retrouvée dans des souris RAG-/-, déficientes en 
cellules T. Curieusement, les vaccins utilisant les CD exprimant l’IL-10 ont plutôt eu l’effet inverse, 
c’est-à-dire retarder la croissance tumorale. Etonnamment, nous avons trouvé que l'expression 
d'IL-35 ou l'adjonction d'IL-35 dans le milieu peut prolonger la viabilité des neutrophiles et 
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augmente la prolifération des cellules endothéliales. Nos résultats indiquent que la cytokine IL-
35 pourrait non seulement être un puissant régulateur de la réponse immunitaire adaptative, 
mais impliquent aussi que l’IL-35 provoque divers effets sur une multitude de cibles cellulaires. 
Ces capacités font de l’IL-35 une cible prometteuse pour le traitement de maladies auto-immunes 
ainsi qu’une molécule clef pour améliorer les immunothérapies contre le cancer. En effet, en 
utilisant les CDs activeTGFβ+ nous avons pu inhiber complétement le développement de 
l’encéphalite auto-immune, alors que avec les IL-35+DC l’on n’a pu que réduire l'incidence et la 
gravité de la maladie. En outre, il a été démontré que le transfert préventif de IL-35+ DC retarde 
le rejet d’allogreffe cutanée au même niveau que la combinaison de CD exprimant de l’IL-10 et 
activeTGFβ. Ainsi, l'expression d’un seul type de molécule tolérogène peut être suffisante pour 
interférer avec l’activation et la fonction adéquate des cellules dendritiques et des lymphocytes T 
co-cultivées. Les mécanismes de tolérance ne semblent toutefois que partiellement se chevaucher 
c’est pourquoi l’application d'une combinaison de plusieurs molécules tolérogène pourrait agir 
en synergie afin de surmonter l’ (auto-)immunité. 
Dans un deuxième projet, nous avons essayé par deux approches différentes d'augmenter 
l'immunogénicité des vaccins contre le cancer grâce aux cellules dendritiques. Tout d'abord, la 
lignée dendritiques MuTu, dérivée de C57BL/6, a été génétiquement modifiée afin d'exprimer la 
molécule CMH classe I H-2Kd. Nous avons émis l'hypothèse que l'expression de CMH classe I 
haplotype spécifique pour BALB/c (H-2Kd) permet à ces CD, une fois injecté dans des souris 
BALB/c, de stimuler des cellules T CD8+ spécifiques contre la tumeur. Effectivement, nous avons 
pensé qu’un transfert de H-2Kd+ DC dans des souris BALB/c entraînerait un environnement 
fortement inflammatoire. Ces cellules pourraient, par conséquent agir en tant qu’adjuvant, ce qui 
permettrait de lever la suppression immunitaire induite par la tumeur. En utilisant ce que l’on 
appelle l’approche par vaccination "semi-allogénique", nous pourrions démontrer que l’injection 
de CD H-2Kd+ pulsées avec lysat de la tumeur retarde considérablement la croissance tumorale 
par rapport au vaccin autologue ou allogénique standard. Cependant, nous n'avons pas été en 
mesure d’élucider les mécanismes cellulaires sous–jacents. Deuxièmement, nous avons généré 
des lignées dendritiques MuTu exprimant les cytokines pro-inflammatoires IL-2, IL-12 ou IL-15 
de façon stable. Nous avons examiné si en combinant vaccination de CD et l’exposition locale aux 
cytokines pro-inflammatoires, nous pourrions améliorer les réponses T spécifiques contre les 
cellules tumorales. En effet, nous avons observé une prolifération accrue de cellules T. De plus, 
celles-ci deviennent activées lorsque cultivées in vitro avec des CD exprimant l'IL-12 ou IL-2. Mais 
nous n’avons malheureusement pas pu observer un impact bénéfique, ou même un effet 
synergique, sur le développement de la tumeur lorsque l’exposition aux cytokines était combinée 
avec la vaccination de CD semi-allogéniques. 
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Abstract 
Dendritic cells (DCs) are the most efficient antigen presenting cells, they provide co-stimulation, 
are able to secrete various proinflammatory cytokines and therefore play a pivotal role in shaping 
adaptive immune responses. Moreover, they are important for the promotion and maintenance 
of central and peripheral tolerance through several mechanisms like the induction of anergy or 
apoptosis in effector T cells or by promoting regulatory T cells. 
The murine CD8α+ (MuTu) dendritic cell line was previously derived and described in our 
laboratory. The MuTu cell line has been shown to maintain phenotypical and functional 
characteristics of endogenous CD8α+ DCs. They are able to cross-present exogenous antigens to 
CD8+ T cells and produce interleukin (IL-) 12 upon engagement of Toll like receptors. The cell line 
constitutes an infinite source of homogenous, phenotypically well-defined dendritic cells. This 
allows us to investigate the role and potential of specific molecules in the induction as well as 
regulation of immune responses by DCs in a rational and standardized way.  
In a first project the MuTu dendritic cell line was transduced in order to stably express the 
immunosuppressive molecules IL-10, IL-35 or the active form of TGF-β (termed IL-10+DC, IL-
35+DC or actTGFβ+DC). We investigated the capability of these potentially suppressive or 
tolerogenic dendritic cell lines to induce immune tolerance and explore the mechanisms behind 
tolerance induction. The expression of TGF-β by the DC line did not affect the phenotype of the 
DCs itself. In contrast, IL-10+ and IL-35+DCs were found to exhibit lower expression of co-
stimulatory molecules and MHC class I and II, as well as reduced secretion of pro-inflammatory 
cytokines upon activation. In vitro co-culture with IL-35+, IL10+ or active TGFβ+ DCs interfered 
with function and proliferation of CD4+ and CD8+ T cells. Furthermore, IL-35 and active TGF-β 
expressing DC lines induced regulatory phenotype on CD4+ T cells in vitro without or with 
expression of Foxp3, respectively. In different murine cancer models, vaccination with IL-35 or 
active TGF–β expressing DCs resulted in faster tumor growth. Interestingly, accelerated tumor 
growth could be observed when IL-35-expressing DCs were injected into T cell-deficient RAG-/- 
mice. IL-10expressing DCs however, were found to rather delay tumor growth. Besides the 
mentioned autocrine effects of IL-35 expression on the DC line itself, we surprisingly observed 
that the expression of IL-35 or the addition of IL-35 containing medium enhances neutrophil 
survival and induces proliferation of endothelial cells. Our findings indicate that the cytokine IL-
35 might not only be a potent regulator of adaptive immune responses, but it also implies IL-35 
to mediate diverse effects on an array of cellular targets. This abilities make IL-35 a promising 
target molecule not only for the treatment of auto-inflammatory disease but also to improve anti-
cancer immunotherapies. Indeed, by applying active TGFβ+ in murine autoimmune encephalitis 
we were able to completely inhibit the development of the disease, whereas IL-35+DCs reduced 
disease incidence and severity. Furthermore, the preventive transfer of IL-35+DCs delayed 
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rejection of transplanted skin to the same extend as the combination of IL-10/actTGF-β 
expressing DCs. Thus, the expression of a single tolerogenic molecule can be sufficient to interfere 
with the adequate activation and function of dendritic cells and of co-cultured T lymphocytes. The 
respective mechanisms of tolerance induction seem to be different for each of the investigated 
molecule. The application of a combination of multiple tolerogenic molecules might therefore 
evoke synergistic effects in order to overcome (auto-) immunity. 
In a second project we tried to improve the immunogenicity of dendritic cell-based cancer 
vaccines using two different approaches. First, the C57BL/6 derived MuTu dendritic cell line was 
genetically modified in order to express the MHC class I molecule H-2Kd. We hypothesized that 
the expression of BALB/c specific MHC class I haplotype (H-2Kd) should allow the priming of 
tumor-specific CD8+ T cells by the otherwise allogeneic dendritic cells. At the same time, the 
transfer of these H-2Kd+ DCs into BALB/c mice was thought to evoke a strong inflammatory 
environment that might act as an “adjuvant”, helping to overcome tumor induced immune 
suppression. Using this so called “semi-allogeneic” vaccination approach, we could demonstrate 
that the delivery of tumor lysate pulsed H-2Kd+ DCs significantly delayed tumor growth when 
compared to autologous or allogeneic vaccination. However, we were not able to coherently 
elucidate the cellular mechanisms underlying the observed effect. Second, we generated MuTu 
DC lines which stably express the pro-inflammatory cytokines IL-2, IL-12 or IL-15. We 
investigated whether the combination of DC vaccination and local delivery of pro-inflammatory 
cytokines might enhance tumor specific T cell responses. Indeed, we observed an enhanced T cell 
proliferation and activation when they were cocultured in vitro with IL-12 or IL-2-expressing DCs. 
But unfortunately we could not observe a beneficial or even synergistic impact on tumor 
development when cytokine delivery was combined with semi-allogeneic DC vaccination.  
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1 General Introduction 
 
1.1 A brief introduction to the immune system 
Our body is constantly challenged with infectious pathogens like bacteria, viruses, fungi and other 
parasites. It further has to cope with stressed and aberrant, potentially tumorigenic cells. These 
constant threats led to the evolution of a wide variety of molecules, specialized cells and physical 
structures specifically adapted to detect and protect from infectious pathogens. Together, these 
components constitute the immune system. In order to elicit functional immune responses while 
avoiding reactivity to self, the components have to operate in a highly coordinated manner. This 
is accomplished by a high level of organization and regulation of the different components of the 
immune system. The immune system can roughly be subdivided in two overlapping and 
interacting systems: The innate or nonspecific and the adaptive or acquired immunity. 
 
Figure 1 Schematic overview over the components and functions of the innate and adaptive immune 
system 
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1.2 Innate immune system 
Primitive immune systems co-evolved along with infectious microbes during evolution. Specific 
mechanisms preventing microbial infections can therefore be found in all multicellular organisms. 
Transplantation experiments with porifera have shown that phagocyte-like cells attack foreign 
tissue transplants while grafts from the same colony are not rejected. These finding indicating 
that already evolutionary primitive organisms express molecules that allow them to distinguish 
between self and foreign [1].  
In order to enter the body, microorganisms have to overcome a first line of defense which is 
composed of the epithelial lining covering the surfaces of all animals. The tight junctions 
connecting epithelial cells impose a physical barrier. Furthermore, epithelial cells of mucosal 
surfaces can secrete antimicrobial peptides like defensins and cathelicidins [2]. 
Second line of innate defense comprises bone-marrow derived phagocytic cells including 
granulocytes, monocytes, macrophages and dendritic cells. The primary function of these cells is 
to identify, ingest and destroy microbes as well as to secrete inflammatory cytokines. Innate 
immune, endothelial and epithelial cells and some other cell types express germline–encoded 
pattern recognition receptors (PRR). PRRs allow to recognize conserved microbial motifs called 
pathogen associated molecular pattern (PAMPs) as well as danger associated molecular pattern 
(DAMPs) which are released by stressed and injured cells. The nature of PAMPs and DAMPs 
recognized by innate receptors is very diverse and includes proteins such as flagellin, nucleic acid 
motifs or lipopolysaccharides (LPS). The receptors can be classified into several major groups, 
including Toll-like receptors (TLR), Nod-like receptors (NLR), C-type lectins (CLR), RIG-I-like 
helicases (RLH) and others. PRR engagement leads to increased efficiency of intracellular killing, 
augments the production of antimicrobial agents and facilitate the secretion of pro-inflammatory 
cytokines. In addition to cell mediated recognition of PAMPs, several soluble PRRs have been 
described that circulate in blood and extracellular fluids. Engagement of these receptors triggers 
the activation of proteins of the complement system. Complement activation promotes the killing 
of microbes either by opsonization or by pore formation and induces inflammatory responses.  
Natural killer (NK) cells are derived from a common NK/T lymphocyte precursor but are 
classified as a part of the innate immunes system because they express only invariant, germline-
encoded receptors. The primary function of NK cells is to recognize and kill virus infected, 
stressed and tumor cells and are a major source for IFN-γ.  
In addition to their anti-microbial functions, cells of the innate immune system have also been 
shown to exert regulatory functions. Several innate cell types, including dendritic cells and innate 
lymphoid cells, are involved in the maintenance of tolerance against commensal bacteria in the 
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intestine [3]. Moreover, in pathologic conditions like chronic infection and cancer, M2 
alternatively activated macrophages and monocyte or granulocyte derived myeloid derived 
suppressor cells (MDSCs) have been found to modulate immune responses. The mechanisms by 
which innate cells suppress immunity will be discussed further below. 
 
1.3 The Adaptive Immune System 
Jawed vertebrates have developed an additional, more powerful defense system; the adaptive or 
acquired immune system. Two defining characteristics distinguish the adaptive from innate 
immunity: specificity and memory. 
The key players of adaptive immunity are termed B and T lymphocytes. B lymphocytes mediate 
humoral responses through the secretion of antibodies that opsonize or neutralize pathogens in 
the blood and other body fluids. T lymphocytes mediated cellular immunity involves the secretion 
of inflammatory cytokines and the killing of infected or degenerated cells. All lymphocytes are 
derived from a common lymphoid precursor cell in the bone marrow. While B cells complete their 
development in the bone marrow, T precursor cells migrate to the thymus where they finalize 
differentiation. 
In contrast to its innate counterpart, the adaptive immune system does not rely on predetermined 
molecular patterns to recognize pathogens, but is able to respond to a vast variety of not 
predetermined antigens. That is, it is able to adapt to the nature of the infection. During the 
development of lymphocytes, recombination activating gene (RAG) mediated, somatic 
recombination of the receptor gene segments generates clonal T - respectively B cell receptors 
with a unique antigen specificity. This process is termed V(D)J recombination, according to gene 
segments that are rearranged. Somatic recombination allows the generation of a receptor 
repertoire comprising approximately 107 to 109 distinct antigenic determinants. Thus, every 
mature T and B lymphocyte is unique in respect to its ability to recognize a specific antigenic 
determinant or epitope.  
Antigen-specific stimulation of T- resp. B cell receptor leads to the activation of multiple signaling 
cascades, including NFκB and RAS/ERK pathways which result in the clonal expansion and the 
differentiation into effector cells. The functional outcome of TCR or BCR activation is dependent 
on different factors like the nature of the antigen, the intensity and duration of antigen 
engagement, cytokines and signals from costimulatory receptors. Indeed, additional signals are 
needed to mount functional adaptive immune responses: They are provided in the form of 
costimulation as well as cytokine signals by antigen presenting cells in the case of inflammation. 
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This implies that the induction of adaptive immune responses imperatively depends on innate 
immunity. The final maturation into effector cells takes place in specialized structures within 
secondary lymphoid organs as lymph nodes or the white pulp of the spleen. 
Depending on the nature of the antigen, the costimulatory signal and the cytokine environment, 
naïve lymphocytes mature into different subsets of effector cells. These subsets can be 
distinguished by their expression of effector molecules and allow to adapt the immune response 
to the nature of the infection. CD4+ effector T cells can produce distinct sets of cytokines which 
allow them to activate distinct effector functions in response to different types of infections. 
Similarly, activated B cells are able to secrete different classes of antibodies. Each class of these 
immunoglobulins exhibit specialized functions and are selectively distributed to various body 
compartments.  
The initiation of functional adoptive immune responses are complex and multi-stepped 
processes: Professional antigen presenting cells have to encounter, process and deliver antigens 
to the local lymphoid organs where they can induce clonal expansion and differentiation of 
effector lymphocytes. Protective adaptive immune responses against pathogens encountered for 
the first time therefore requires several days. Adaptive immune responses in response to 
subsequent infection with the same pathogen however, have been shown to be mounted more 
rapid and are more efficient. This effect is associated with the formation of long-lived memory B 
and T cells during the primary infection. Memory lymphocytes in fact are primarily responsible 
for immune responses against a recurrent infection [4]. The artificial induction of long-lasting, 
protective immunity against disease-causing pathogens is the base for the outstanding success of 
vaccines. Whether memory lymphocytes develop directly upon activation from naïve cells or 
effector cells become memory cells is not completely resolved [5].  
 
1.3.1 T lymphocytes 
T cell progenitors develop from hematopoietic stem cells in the bone marrow but mature into 
functional T lymphocytes in the thymus. According to the expression of the TCR co-receptors CD4 
and CD8, T cells are classified into two populations with different functional properties.  
T cell precursor cells entering the thymus do not express any of the coreceptors CD4 or CD8. 
Positive and negative selection in discrete thymic regions. In contrast to the BCR, the TCR only 
recognizes peptide antigens presented in the context of self but not foreign MHC molecules. This 
so-called MHC restriction was discovered by Zinkernagel and Doherty [6]. During the positive 
selection step in the thymic cortex, CD4+ CD8+ double positive thymocytes recognizing self-
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peptides/MHC complex with moderate affinity receive survival signals and are therefore rescued 
from undergoing apoptosis. Cells that are able to bind to MHC class II differentiate into CD4 single 
positive T cells while cells recognizing MHC class I molecules give rise to CD8+ lymphocytes. 
Autoimmune regulator (Aire) gene expression by medullary dendritic cells and thymus medullary 
epithelial cells (mTECs) activates the ectopic transcription of genes specific for various peripheral 
tissues [7]. CD4 or CD8 single-positive thymocytes relocate from the cortex to the medulla where 
they interact with the medullary antigen presenting cells. TCRs exhibiting a high avidity for the 
MHC:self-antigen complex are negatively selected through the induction of apoptosis. Self-
reactive T cells with an intermediate affinity for the MHC:self-antigen complex can escape 
negative selection and leave the Thymus as natural regulatory T cells (nTregs), which will be 
discussed further below.  
Antigen recognition is mediated by the heterodimeric T cell receptor that is composed of two 
transmembrane protein chains termed α and β chain. Each chain consists of an amino terminal 
variable and a constant region. Random rearrangement of TCR α and β chain variable regions 
creates a unique antigen receptor for virtually each developing T cell. This enables T lymphocytes 
to recognize an enormously diverse range of peptide antigens. In order to induce primary T cells 
responses, the specific recognition of peptide:MHC class I/II complex by the T cell receptor alone 
is not sufficient. Two more signals, provided by antigen presenting cells (APCs), are required: So 
called second signals comprises co-stimulatory receptors as for examples CD80/86 that engage 
CD28 on the T cells. They promote survival and expansion of the T cells. More recently it was 
shown that for both, CD4+ and CD8+ T cells, inflammatory cytokines produced by APCs provide a 
third signal that is needed for optimal proliferation, effector function and to avoid tolerance 
induction in response to a specific antigen [8]. 
 
 
Figure 2 T cell plasticity: Depending on the 
signals provided by the antigen presenting cells, 
different T effector phenotypes develop figure 
adapted from [9] 
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CD4+ T cells organize cell mediated immunity and regulate antibody secretion by B cells. They 
recognize exogenous antigens presented by professional antigen presenting cells in the context 
of MHC class II molecules. CD4+ helper T cells orchestrate cellular immune responses against 
different classes of pathogens by providing cytokine and other stimulatory signals to various cells 
of the innate immune system. They further induce Ig class switching in B cells and are required 
for the activation of cytotoxic functions of CD8+ T cells. Depending on the cytokine environment, 
naïve CD4+ T cells can differentiate into at least four distinct types of effectors cells termed Th1, 
Th2, Th17 Tfh and iTr. Th1 help to fight intracellular bacterial and viral infections as well against 
malignant cells through the secretion of cytokines like IFN-γ, TNFα or CD40L that increase the 
function of macrophages, NK and dendritic cells. Th2 responses are characterized by the secretion 
of IL-4 and IL-13. They mediate protection from parasitic infections by the activation of basophils 
and mast cells and the induction of IgE secretion by plasma cells. Th17 cells are associated with 
the cytokine IL-17A/E which recruit and activate neutrophils and induces chemokine expression 
in epithelial cells. Th17 cells therefore are involved in the defense against extracellular bacteria 
and fungi at mucosal and epithelial barriers. More recent studies have shown that CD4+ T cells 
themselves are able to exert cytotoxic functions in a MHC class II dependent manner in vivo [10], 
CD8+ T lymphocytes are specialized to destroy virus and bacteria infected as well as aberrant cells 
without affecting healthy tissue. Activation of CD8+ T lymphocytes is initiated by the presentation 
of cytoplasmic pathogen derived peptides on MHC class I molecules, which are expressed by all 
nucleated cells. As additional costimulation and/or adequate cytokine stimuli are required to 
induce cytotoxic functions of CD8+ T cells, the majority of viral infections depend on CD4+ T cell 
help. Effector CD4+ T cells can fortify the costimulating potential of APCs presenting related 
antigens and provide the T cell growth factor IL-2. Once activated, CD8+ T cells mature into 
cytotoxic effector or memory cells. Cytotoxic lymphocytes (CTL) exert their functions by the 
induction of apoptosis in the target cells. This is achieved by the release of granules containing 
the cytotoxic molecules perforin and granzymes. While perforin creates pores in the target cell 
membrane, granzymes induce apoptosis of the target cells. In addition, the expression of the cell 
surface associated molecule FasL mediates killing of target cells expressing its receptor Fas 
through the activation of the extrinsic apoptosis pathway. Besides the induction of apoptosis, 
most CTLs are capable to secrete proinflammatory cytokines like IFN-γ, TNFα and LTα. IFN-γ 
contributes to host defense by interfering with viral replication, inducing MHC I expression in 
infected cells and activation of macrophages. TNFα and LTα can further induce target cell 
apoptosis.  
After the successful elimination of a primary infection the predominant proportion of the antigen 
reactive effector T cell pool dies. However, a small percentage of the cells can persist for years as 
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so called memory T cells and provide an enhanced protection against recurring infection. CD4+ 
and CD8+ memory T cells can be divided into three subsets with distinct characteristics. Effector 
memory T cells (TEM) circulate in the blood and peripheral tissue and are able to mature rapidly 
into effector cells upon activation. Central memory T cells (TCM) on the other hand express CCR7 
and CD62L and can therefore predominantly be found in secondary lymphoid tissue. TCM cells 
can persist for the rest of the life of an animal but they take longer to mature into effector cells 
compared to TEM cells. As TEM cells have an abbreviated lifespan or convert into TCM cells, 
peripheral adaptive immunity is lost over time [11]. Recent studies therefore identified a third 
memory T cell population termed tissue-resident memory T cells, that contributes to the 
sustained control of residual or persisting infection in peripheral tissues [12]. 
1.3.2 B lymphocytes 
B lymphocytes mediate humoral immunity by the secretion of large amounts of immunoglobulins 
called antibodies into the extracellular fluids. Antibody secretion causes the destruction of 
extracellular pathogens and helps to prevent the dissemination of intracellular infections. B 
lymphocytes are derived from common lymphocyte progenitor cells and completely undergo 
their differentiation in the bone marrow. Antigens are recognized by the B cell receptor (BCR) 
which is a membrane bound immunoglobulin M (IgM) or IgD. The variable, antigen binding region 
of the immunoglobulins (and therefore also the BCR) undergoes random recombination. This 
allows the generation of antigen receptors that able to bind specifically to a broad variety of 
chemical structures like antigenic peptides or pathogen derived molecules such as LPS. Naive B 
lymphocytes circulate between blood and lymphoid organs where they congregate in B cell 
follicles and search their environment for antigens. Activation of B cells is induced by antigen 
recognition and usually requires help from helper T cells. CD4+ T cell help provides a secondary 
stimulus and cytokine environment Activated B cells differentiate into antibody secreting plasma 
cells or memory B cells that allow rapid and responses to subsequent antigen encounter.  
Five classes or isotypes of antibodies can be distinguished in placental mammals: while the two 
isotypes IgM and IgD can be found as membrane-bound receptors on naïve B cells, IgG, IgA and 
IgE are only secreted by plasma cells. The different isotypes differ in the constant region of the Ig 
heavy chains and have defined roles in humoral immune responses. Antibodies protect against 
pathogens by different ways: The direct binding to viruses or bacterial products is termed 
neutralization. This allows to prevent viruses from infecting host cells or the binding of bacterial 
toxins to their respective receptors thereby inhibiting their biological effects. The coating of 
larger pathogens like bacteria or parasites by antibodies is not sufficient to stop their replication. 
The constant region of antibodies can be recognized by specific receptors expressed by 
phagocytic cells like macrophages or neutrophils. Antibody coating thereby enhances pathogen 
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uptake and destruction. This process is called opsonization. A third protective mechanism of 
antibodies is their ability to activate the complement system. Antibodies coating the surface of a 
pathogen provide a platform to initiate the complement cascade that attracts neutrophils and 
leads to the formation of membrane pores. Presentation of previously encountered antigens by 
memory B lymphocytes to their cognate CD4+ T cell leads to a rapid proliferative response of both 
B and T cells. Antibodies secreted by memory B cells are predominantly of the IgG and IgA isotype 
and exhibit a much higher affinity than those produced in primary responses due to ongoing 
somatic hypermutation. 
 
1.4 Immune Tolerance 
Innate immune responses are not known to react against self in not inflamed tissue as the innate 
system has developed to recognize a limited number of molecules that are normally not present 
in vertebrates. In contrast, the random rearrangement of the respective coding regions create a 
diverse repertoire of antigen specific B and T cell receptors. This includes receptors recognizing 
harmless environmental or self – antigens which have to be eliminated or silenced in order to 
prevent inappropriate or autoimmune responses. Uncontrolled, overshooting immune responses 
can lead to life threatening conditions as for example sepsis or the development of autoimmune 
diseases like type II diabetes mellitus or Crohn’s disease. Furthermore, the failure to down-
regulate inflammatory responses can lead to chronic inflammation which is considered as a 
critical factor in the initiation and progression of neoplastic disease [13]. Several safety 
mechanisms have therefore been set in place to eliminate or suppress auto-reactive lymphocytes. 
Depending on their site of action, the various mechanisms of immune tolerance can be divided 
into two elemental groups. Central tolerance describes the elimination of potentially auto-
reactive lymphocytes during their development in the bone marrow respectively the thymus. As 
central tolerance alone is not sufficient, different mechanisms in the periphery ensure and help 
to regulate inflammation.  
 
1.4.1 Central tolerance  
The random rearrangement of immunoglobulin heavy and light chains of B cells, respectively the 
α and β chains of T cell receptors, allows the generation of an enormously diverse receptor 
repertoire that includes self-antigen specific receptors. Thus, during the development of both B 
and T cells, several checkpoints ensure the elimination or inactivation of autoreactive 
lymphocytes. The generation of self-tolerant B and T cells in primary lymphoid organs is called 
central tolerance. 
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During their development in the bone marrow, the antigen receptors of immature B cells are 
tested for reactivity against self-antigens present in their environment. B cells recognizing self-
molecules  either rearrange the Ig light chain in order to generate a new BCR or they undergo 
apoptosis [14]. 
As described above, positive and negative selection in the thymus generates a T cell receptor 
repertoire that is restricted to self MHC molecules and tolerant against many self-antigens. 
Deletion of auto-reactive T cells is mediated by bone marrow derived dendritic cells as well as 
mTECs presenting tissue restricted antigens (TRA) in the context of MHC class I and II molecules. 
The ectopic expression of TRA is dependent on Aire gene expression. The importance of a 
functional central tolerance is shown by the observation that mice and humans lacking the 
transcription factor AIRE have self-reactive T cells in the periphery resulting in the development 
of severe autoimmunity [[7], reviewed in [15]]. CD4+ thymocytes recognizing self-antigens with 
an intermediate affinity can induce the transcription of Foxp3 which acts as a master regulator 
for the development and suppressive function of natural regulatory T cells [16].  
 
 
Figure 3 Central and peripheral 
tolerance mechanisms: Negative 
selection in the thymus eliminates 
most of the T and B cells expressing 
receptors that exhibit high affinity 
for self-antigens. Lymphocytes 
escaping negative selection are 
suppressed or eliminated in the 
periphery by several different 
mechanisms. Adapted from [17]. 
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1.4.2 Peripheral or induced tolerance 
Adoptive transfer of CD4+ T cells derived from mice without functional negative selection into 
irradiated, syngeneic host succumb quickly to graft versus host disease. However, the transfer 
into not irradiated hosts did not lead to overt clinical disease symptoms [18]. These findings 
indicate the existence of peripheral mechanisms that are capable to regulate self-reactive 
immunity. In fact, thymic deletion of auto-reactive T cells is not complete. In order to suppress 
auto-reactive lymphocytes, different mechanisms of peripheral tolerance have developed.  
Ignorance: The circulation of naïve T cells is restricted to blood, lymph and secondary lymphoid 
organs. Thus, they are excluded from non-lymphoid peripheral tissue where the probability to 
encounter tissue-restricted antigens is much higher. Only activated T cells express the respective 
adhesion molecules allowing to efficiently enter parenchymal tissue. And only tissue in an 
inflamed or infected state express the respective ligands that allow efficient extravasation of T 
lymphocytes. 
Anergy: Antigen presenting cells, and especially dendritic cells play an essential role in inducing 
and maintaining peripheral tolerance. In the absence of inflammatory signals, lymphoid and 
tissue resident DCs maintain an immature state and present antigens in poorly immunogenic 
fashion. T cells repetitively encountering these antigens without further immunogenic signals 
may proliferate initially but are then quickly deleted [19]. Surviving T cells remain unresponsive 
or anergic to further antigen stimulation, resulting in a systemic antigen-specific tolerance. DCs, 
macrophages but also nonlymphoid cells can express coinhibitory receptors of the CD28 family 
like PD-1l., These molecules seem to induce an unresponsive, so called anergic state on T cells and 
have been shown to be essential for the maintenance of T cell homeostasis and self-tolerance [20]. 
The function of dendritic cells in peripheral tolerance are described below in more detail. 
Suppression and apoptosis induction by regulatory T cells: Already early experiments in various 
animal models suggested the existence of a population of CD4+ T cells that prevents the 
development of autoimmune diseases (reviewed by [21]). More recent observations revealed a 
minor population (around 5% of CD4+ T cells in the periphery) of CD4+ CD25+ Foxp3+ T cell 
population to be able to prevent autoimmunity [22], [23]. Expression of the transcription factor 
Foxp3 is essential for the generation and function of naturally occurring regulatory T cells (nTreg) 
as mutation or deletion of Foxp3 gene is associated with the development of autoimmunity in 
mice and human [24]. Thymocytes expressing a TCR with an avidity for self-antigen that is too 
high for the induction of conventional CD4+ T cell development but is not high enough to succumb 
to negative selection can leave the thymus as CD4+ CD25+ Foxp3+ naturally occurring regulatory 
T cells [16]. The main function of nTregs is to suppress the priming and expansion of effector T 
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cells. This can be achieved by multiple mechanisms: The IL-2 receptor expressing Treg compete 
with effector T cells for IL-2 which may lead to the consumption of the cytokine, impairing 
expansion of effector T cells. nTregs have further shown to produce immunoregulatory cytokines 
like IL-10, TGF-β or IL-35 which can interfere with target T cell proliferation and function. Finally, 
through the expression of coinhibitory molecules like cytotoxic T-lymphocyte-associated protein 
4 (CTLA4) or neuropilin-1 (Nrp1), nTregs can interfere with APC function. Finally, nTregs have 
been shown to directly kill antigen presenting cells, but also NK and CTLs in tumor environment 
by granzyme B and perforin (reviewed in [25]). 
Tregs and various other cell types can induce conversion of conventional CD4+ T cells into so 
called induced regulatory T cells (iTregs). The presentation of self- or foreign antigen by APCs 
and the presence of certain cytokines can lead to a thymus independent maturation of naïve T 
cells into Tregs. The conversion of naïve T cells into iTregs is dependent on TCR signaling as well 
as adequate second and cytokine signals. Especially dendritic cells but also B cells and MDSCs 
have therefore been shown to induce Treg (reviewed by [26]). In addition, natural Tregs are 
capable to induce a regulatory phenotype on naïve CD4+ T cells. This conversion has been shown 
to be dependent on direct cell-cell contact and the regulatory cytokines TGF-β, IL-10 or IL-35 [27], 
[28]. This mechanism ensures the sustained regulation of effector cells by maintaining and 
renewing adequate Treg populations and has been termed infectious tolerance [28]. iTregs, 
contribute to the maintenance of peripheral tolerance mainly by the secretion of anti-
inflammatory cytokines, while cell-cell contact dependent mechanisms seem to be less important 
[29]. Depending on the main effector molecule, two subtypes of iTregs were originally 
distinguished: Th3 are predominantly found in the oral and intestinal mucosa, They are 
characterized by the production of TGF-β, which can suppress proliferation of Th1 and Th2 [30]. 
The cytokine IL-10 leads to the induction of a regulatory population termed type-1 regulatory T 
cells (Tr1). Regulation by Tr1 cells is dependent mainly on the secretion of IL-10 which 
antagonizes APC functions and renders T cell anergic [31]. More recently a third iTreg 
subpopulation was described which is induced and produces IL-35 (iTr35) [32]. A more detailed 
introduction to suppressive functions of the cytokines IL-10, TGF-β and IL-35 is given below. 
Recent studies identified even more populations of Foxp3+ Tregs with different gene expression 
profiles. As it is proposed for effector T cells, Tregs might adopt different functional “programs” 
depending on differentiation signals or the anatomical location. 
There is experimental evidence that many additional cell types may act as regulators of immune 
responses. These include invariant natural killer T (iNKT) cells that respond to lipid antigens, 
CD8+ T cells, γδ-T cells, regulatory B-cells and myeloid derived suppressor cells (MDSC) [33]–[35]. 
Probably the best evidence for a pathophysiological role in immune regulation has been found 
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for MDSC. They constitute a heterogeneous cell population of myeloid origin and can be classified 
into CD11b+Ly6ChiLy6G- monocytic and CD11b+Ly6CloLy6G+ granulocytic subsets. MDSCs are able 
to restrain immune responses through a variety of direct and indirect mechanisms. The direct 
mechanisms comprise the local depletion of the essential amino acids arginine and cysteine 
mediated by the enzyme arginase1. The degradation of tryptophan and generation of cytotoxic 
metabolites through indoleamine 2,3-dioxygenase (IDO) or the generation of reactive oxygen and 
nitrogen species (NOS, resp. ROS) trough NADPH-Oxidase respectively NO synthetase 2. 
Expression of those enzymes interferes with the proliferation and function of T cells. MDSCs have 
furthermore been shown to be attracted to tumor environment where they act as tolerogenic 
antigen presenting cells. In association with the effects of Arg1 or Ido1 expression, MDSCs can 
induce and expand regulatory T cells [36]. Although MDSCs have mainly been investigated in the 
context of murine tumor models, their physiological role seems to be to resolve immune 
responses and promote repair and remodeling of the injured tissue once an infection has been 
cleared (Reviewed in [33]). 
 
1.5 Cytokines – messengers of the immune system 
In a complex system, such as the mammalian immune system, the myriad of involved cells have 
to be orchestrated in order to get a directed and adequate immune response to a wide diversity 
of pathogens while maintaining tolerance to self-antigens. This various interactions among the 
immune, as well as non-immune cells are mediated by a group of proteins collectively termed 
cytokines. Cytokines are low-molecular weight (glyco-) proteins secreted by leukocytes and 
various other cells in response to a number of stimuli, like antigen recognition or binding of other 
cytokines. The ability of these proteins to act in pleiotropic, redundant, synergic and antagonistic 
ways on their targets permits the restricted number of different cytokines to regulate activity of 
both, innate and adaptive immunity in a coordinated and interactive way. Binding of cytokines to 
their respective membrane-bound receptors generally activates specific signal transduction 
pathways which ultimately induces changes in gene expression of the target cell. Many of these 
changes result in differentiation and/or proliferation of T and B lymphocytes or activation of 
effector cells such as macrophages. Both cytokine production as well as cellular responses to them 
are tightly regulated by different mechanisms and are often self-limited trough the action of 
inhibitory feedback loops [17]. 
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1.5.1 Interleukin-35 
IL-35 is the most recently described member of the interleukine-12 cytokine family. IL-35 is a 
heterodimeric protein, comprised of the IL12p35α subunit and the Epstein-Barr virus (EBV) - 
induced gene 3 (ebi3) which is shared with IL-27. IL-35 is thought to signal trough a 
heterodimeric receptor, consisting of IL-12Rβ2 and IL-6gp130 in T cells or IL-12Rβ2 and IL-27Rα 
in B cells. Furthermore, signaling via homodimers of either receptor subunits has been proposed 
[34], [37]. Engagement of the receptor leads to phosphorylation of STAT1 and STAT4 in T cells 
whereas in B cells phosphorylation of STAT1 and STAT3 have been detected [38]. In contrast to 
the other members of the IL-12 cytokine family, IL-35 cytokine has been reported to be produced 
by murine natural regulatory T cells. Ebi3 in fact was shown to be a Foxp3 target gene as the 
conditional knock-out of Foxp3 resulted in the downregulation of Ebi3 expression in peripheral 
Tregs. Furthermore, Ebi3 and IL12a deficiency in regulatory T cell has been found to drastically 
impair the regulatory function of Tregs in vitro and in vivo [39]. Collison et al. were also the first 
to describe IL-35 to be able to suppress CD4+ T cells proliferation and the induction of a regulatory 
T cell population that is characterized by the secretion of IL-35 but does not express the classical 
Treg markers CD25 and Foxp3 [32]. Thus, IL-35 seems to be involved in the negative regulation 
of T cell responses and mediation of infectious tolerance. Several recent studies indicate IL-35 to 
be an important mediator of immune tolerance in various experimental immunopathologies and 
have broadened the range of cells that secrete and/or can be targets of the cytokine. EBI3 but not 
IL-27p28 deficient mice exhibited increased pathologic features of experimental enterocolitis 
with increased Th1 and Th17 responses. Ebi3 and IL-12p35 have been found to be transcribed in 
colonic epithelial cells of healthy mice [40]. Interleukin-35 has been shown to induce IL-10 
producing regulatory B cells conferring protection to the development of auto immune uveitis 
[34]. Mice lacking IL-35 expression in B cells have been shown to reduce susceptibility to 
Salmonella infection but were not able to recover from experimental autoimmune encephalitis 
(EAE) [38]. Furthermore, the administration of recombinant IL-35 prevented the development of 
collagen induced arthritis by the induction of IL-10 producing CD39+ regulatory T cells 
suppressing Th1 and Th17 mediated immunity [41].  
In addition to its role in the regulation of autoimmunity, IL-35 has also been found to be exploited 
by tumor cells to evade immune surveillance. Expression of EBI3, but not IL27p28, has been found 
in (Epstein-Barr virus-associated) Hodgkin lymphoma, adult T cell leukemia as well as 
nasopharyngeal carcinoma cells [42], [43]. Ebi3 and IL-12p35 transcription has not only been 
found in neoplastic but also in tumor associated cells, such as tumor associated dendritic cells 
[43]. Wang and colleagues were able to detect increased CD11b+ Gr1+ myeloid cell accumulation 
and neo-genesis of blood vessels in the environment of IL-35 secreting tumors. Despite these 
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recent insights the biological functions of the cytokine IL-35, especially its effect on cells other 
than T and B lymphocytes, are poorly understood.  
 
1.5.2 Transforming growth factor β (TGF-β) 
In contrast to IL-35, TGF-β has been studied for almost 30 years and its role in immune tolerance 
is much better understood. In mammals, the TGF-β family consists of the three highly homologous 
members TGF-β1,2 and 3. Although they fulfill very similar functions on vitro, TGF-β1 is the 
predominant isoform in mice. The TGF-β genes encode an N-terminal latency-associated peptide 
(LAP) and the C-terminal mature TGF-β that assembles into homodimers. During the peptide 
procession, LAP is cleaved but remains noncovalently associated to the mature cytokine, forming 
the latent cytokine complex. The latent TGF-β complex is not able to engage the TGF-β receptor 
but allows its storage in the extracellular matrix. In order to become biologically active, TGF-β has 
to be separated from the LAP. Different peptidases and more recently also mechanical 
interactions with integrins have been shown to activate latent TGF-β in a context sensitive, well 
regulated way. Active TGF-β mediates its function mostly through a receptor complex consisting 
of two type I and two type II TGF-β receptors. Classical TGF-β intracellular signaling involves the 
phosphorylation of SMAD2/3 which, together with SMAD4, translocate to the nucleus where they 
act as a transcription factor. In addition to SMAD associated signaling, PI3K, MAP kinase signaling 
pathways can be activated by TGF-β (reviewed by [44].  
Activated effector as well as regulatory T cells are thought to be the principal source for TGF-β. 
However, while the T cell specific ablation of Tgfb expression is associated with a disordered T 
cell homeostasis and inflammation, the phenotype is mild compared to mice completely lacking 
TGF-β expression. This suggests other cells to be important sources for TGF-β. Indeed, a wide 
array of cells have been found to secrete TGF-β. 
Mice lacking TGF-β develop multiorgan inflammation and mostly die embryonically, indicating 
the importance of the cytokine for immune regulation [45]. T cell specific abrogation of TGF-β 
signaling results in the spontaneous activation of T cells and lethal multifocal inflammation while 
crossing TGFb1-/- to MHC-II deficient mice inhibits exaggerated inflammation [46], [47]. These 
findings indicate T lymphocytes to be the main targets of TGF-β. Indeed TGF-β has been shown to 
regulate T cell proliferation by suppressing transcription of the T cell growth factor IL-2 [48]. The 
cytokine has been shown to suppress the transcription of the Th1 master-regulator T-bet as well 
the Th2 specific transcription factor GATA3 thereby effectively inhibiting the differentiation of 
functional T helper cells [49]. Similarly, TGF-β has been found to regulate CD8+ T cell 
proliferation as well as their differentiation into functional CTLs by the downregulation of 
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effector molecules like Fas ligand [50]. TGF-β has been shown to indirectly suppress T cell 
responses through the regulation of Foxp3+ Tregs. The cytokine protects thymic nTregs from 
apoptosis and, at least in vitro, promotes the induction of a regulatory phenotype on naïve CD4+ 
T cells through the upregulation of Foxp3 [51]. However, the regulation of T cell proliferation 
differentiation and survival by TGF-β is highly dependent on the inflammatory context, i.e. the 
presence of costimulatory or cytokine signals. Accordingly, it was shown that TGF-β, together 
with the pro-inflammatory cytokines IL-6 and IL-21 is crucial for the differentiation of Th17 cells 
[52]. 
In addition to the impact on T cell function, TGF-β is an important regulator for many other cell 
types including B lymphocytes, NK cell, macrophages and dendritic cells. Regarding dendritic 
cells, TGF-β1 has been found to promote the generation of DCs with an immature phenotype in 
vitro and to inhibit the expression of MHC class II and costimulatory molecules as well as the 
secretion of IL-12 cytokine in differentiated DCs [53]. Dendritic cell specific ablation of TGF-βRII 
resulted in the development of multiorgan inflammation and death of the mice similar to Tgfb-/- 
mice. These results indicate that, apart from direct effect of TGF-β on the regulation of T cell 
homeostasis, impaired DC function might contribute to pathogenesis in TGF-β deficient mice [54]. 
 
1.5.3 Interleukin-10 
Interleukin 10 has pleiotropic immunoregulatory functions and is implicated in the regulation of 
infectious responses and in the protection from autoimmunity and allergy. Bioactive IL-10 forms 
a homodimeric molecule that is able to bind to the IL-10 receptor (IL-10R). The Il-10R is a 
tetrameric complex consisting of two IL-10R1 and two IL-10R2 proteins. Engagement of the IL-
10R induces an intracellular signaling involving Jak1/Stat3 phosphorylation which is assumed to 
be necessary for the inhibitory functions of IL-10 [55]. Interleukin 10 has been shown to be 
produced by and to affect a wide range of immune cells, including DCs, macrophages, neutrophils, 
NK and B cells. The cytokine was shown to inhibit the production of proinflammatory cytokines 
and antigen presentation by activated macrophages. Monocyte derived DC exhibit an immature 
phenotype when cultured in the presence of IL-10. The cytokine furthermore counteracts 
chemokine expression implicated to DC, macrophage or neutrophil recruitment during 
inflammation (reviewed by [56]). Most prominently investigated is the effect of IL-10 on T cells. 
In in vitro experiments, the presence of IL-10 led to proliferative inhibition of CD4+ T cells by 
reducing IL-2 production [57]. IL-10 deficient mice were shown to develop chronic colitis which 
is lethal in most cases [58]. Interestingly this chronic inflammation of the gut was ameliorated 
under germ-free conditions, implicating an important role in the maintenance of intestinal 
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homeostasis [59]. IL-10 deficient mice were further shown to exhibit dysregulated, detrimental 
helper T cell effector responses upon infection with various pathogens including Toxoplasma 
gondii, Leishmania major or murine cytalomegavirus as well as in autoimmune models like 
rheumatoid arthritis or EAE (reviewed in [60]). IL-10 secretion substantially contributes to the 
regulatory function of natural Tregs as shown by the finding that IL-10 deficient Foxp3+ cells 
develop colitis, in a manner similar to completely IL-10 deficient mice [61]. IL-10 directly inhibits 
T cell proliferation and reduces IL-2 production [62]. Naïve CD4+ T cells cultured in high 
concentrations of IL-10 and in the presence of APCs can acquire a regulatory phenotype 
characterized by IL-10 secretion but do not express Foxp3. This induced regulatory T cell 
population was termed Tr1 cells and was shown to induce long-lasting T cell anergy [63]. The 
dependence on APC for the generation of Tr1 cells suggest that IL-10 alone is not sufficient to 
convert CD4 T cells. Indeed, a IL-10 and immunoglobulin-like transcript 4 (Ilt4) expressing 
tolerogenic DC subpopulation has been described in mouse and human and was shown to be 
required for Tr1 induction by IL-10 [64]. More recent work showed that under certain conditions 
not only Tregs, but also Th1, Th2 and Th17 cells can co-express IL-10 in order to limit infection-
driven immunopathology or autoimmunity (reviewed by [60]). In addition to its regulatory 
functions, IL-10 has also been found to drive proliferation and maintain cytotoxic effector 
functions of CD8+ T cells [65], [66]. 
 
1.6 Dendritic Cells: Bridging and integrating innate and adaptive immune 
responses 
In 1973, Steinman and Cohn described a new population of cells in the spleen with a characteristic 
dendritic morphology and coined the term “dendritic cells”[67]. Over the past years, further 
studies showed dendritic cells to constitute a heterogeneous population of lymphoid but also 
non-lymphoid tissue resident cells. Even though their generation depends on different stimuli, 
they fulfill different functions and express different surface markers, all DCs share several 
features which distinguishes them from other antigen presenting cells. 
Dendritic cells develop in the bone marrow from hematopoietic stem cell and migrate via lymph 
or blood stream into the tissues where they terminally differentiate into immature DCs. Immature 
conventional dendritic cells (cDCs) reside in blood and peripheral tissue and constitutively 
sample their environment for the presence of infection, stress or injury through phagocytosis and 
pinocytosis. The ingested antigens are processed and presented to T lymphocytes via classical 
(MHC class I and II) and non-classical (CD1 family) pathways. Engagement of TLR or other innate 
receptors by microbial products, necrosis, mechanical trauma or pro-inflammatory cytokines 
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leads to the maturation of the DCs. This leads to a down-regulation of endocytic activity and a 
reduced MHC turnover, resulting in retention of peptide-MHC complexes formed at the time of 
maturation. Furthermore, mature DCs up-regulate expression of co-stimulatory molecules and 
migrate from the periphery to lymphoid tissue where they interact with T cells in an antigen-
specific manner. Cytokine microenvironment and other factors encountered during maturation 
control the cytokine secretion profile of the DCs. Co-stimulatory signals provided by receptors 
like B7 family molecules as well the cytokine expression pattern govern the subsequent 
differentiation of the responding T cells.  
 
Figure 4 Dendritic cell development and subtypes: Depending on progenitors derived, surface 
markers, anatomical location and function, a variety of dendritic cells can be discriminated. Taken 
from [68]. 
 
1.6.1 DC subsets and their development in mouse 
Dendritic cells, except for the plasmacytoid DC population, are originally derived from a common 
hematopoietic stem cell (HSC) in the bone marrow. HSCs differentiate progressively into 
precursor cells that are committed to particular lineages. Due to their functional resemblance to 
other myeloid cells like macrophages, DCs were initially thought to be mainly derived from 
common myeloid precursor cells. However, studies conducted by Manz et al. and other groups 
suggested that all DC subgroups can also be derived from common lymphoid precursor cells and 
that the important steps of DC lineage commitment are downstream of both myeloid and 
lymphoid precursors cells [69]. Successive commitment stages include granulocyte-macrophage 
precursor cells, macrophage/DC progenitors and common dendritic cell precursor localized in 
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the bone marrow [70]. However, a recent study was not able to determine a common precursor 
cell restricted to the production of macrophages and lymphoid-resident cDCs [71]. These finding 
illustrates that DC differentiation seems to be more complex than initially thought and implicate 
a high degree of developmental flexibility. While all differentiation steps mentioned afore take 
place in the bone marrow, there is more accordance that the final development of cDCs and pDCs 
occurs in peripheral tissues. The overall differentiation process is dependent on various cytokines 
and transcription factors, most of which exert various different functions during hematopoiesis. 
However, a few molecules are crucial for the generation of dendritic cells. FMS-related tyrosine-
kinase 3 ligand (Flt3l) deficient mice have been shown to have only little levels of pDCs and cDCs 
[72] whereas the addition of Flt3l to bone marrow cells generates a mixture of steady-state pDCs, 
as well as cDCs [73]. Deficiency of the transcription factors IRF8 as well as Batf3 results in the 
selective deficiency of CD8α+ DCs while mice lacking IRF4 do not generate CD4+ cDCs [74], [75]. 
As resumed in table 1 the different dendritic cell subsets can been discriminated according to 
expression of surface molecules, their functional characteristics as well as their localization. 
Murine DCs can be classified into three major lineages: plasmacytoid DC (pDC) conventional DC 
(cDC) and induced DCs. 
Plasmacytoid DCs, have a round shape, do not form characteristic dendrites and exhibit a survival 
time of about 15 days in vivo. pDCs circulate through the organism and can be isolated from bone 
marrow and peripheral tissue. Their main function is to respond to viral infections by the 
secretion of large quantities of type I interferons. However viral infection has been shown to 
convert some pDCs into a dendritic form that is able to present antigen and resembles also 
phenotypically cDCs [76]. 
Conventional dendritic cells can further be subdivided in migratory and lymphoid resident DCs. 
Migratory DCs represent the classical text-book dendritic cells. They patrol in peripheral tissues 
and sample their environment for antigens. Activation of migratory cDCs allows them to enter 
lymph nodes where they present antigen to T cells and provide costimulation. This class of 
dendritic cells includes dermal and interstitial DCs as well as Langerhans cells. Lymph node 
resident DCs remain in the lymphoid organ itself, where they sample blood and lymph for 
antigens and present them to T cells. Lymphoid resident cDC populations comprise most thymic 
and splenic DCs. Several subpopulations, which exert different immune functions, can be 
classified based on the expression of CD4 or CD8α homodimers and. cDCs are generally short- 
lived, having a turn-over time of about 3 days [77]. 
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So called inflammatory dendritic cells can be found under inflammatory conditions. These cells 
can be identified as CD11b+ CD11c+ F4/80+ Ly6C+ MHC-II+. Inflammatory DCs (infDC) are absent 
from peripheral and lymphoid organs during steady-state conditions but develop in situ from 
monocytes upon infection with various pathogens or under pathologic autoinflammatory 
conditions. In contrast to inflammatory monocytes or macrophages, infDC are able to migrate to 
draining lymph nodes and activate T lymphocytes (reviewed in[78]). Through the in vitro 
addition of granulocyte-macrophage stimulating factor (GM-CSF) and IL-4 monocytes can acquire 
a DC like phenotype. Similarly to infDC these in vitro generated DCs are able to process and 
present antigen to T lymphocytes [79]. 
Interestingly, several lines of evidence support the notion of division of labor and cross-talk 
within the DC network. Altogether, DC subsets display differences in their capacity to monitor 
specific tissue or to circulate, in the expression of PRRs, the production of cytokines, as well as 
antigen uptake and presentation mechanisms [80], [81]. 
 Plasmacytoid 
DC  
 
Conventional DC  inflammatory 
DC 
Lymphoid tissue resident migratory  
Phenotype  CD4+CD8- CD4-CD8+ 
CD4-
CD8- 
Langerhans 
DC 
Dermal 
DC 
 
CD11b - + - - + +/- + 
CD11c Intermediate + + + + + + 
B220 Intermediate - - - - - - 
Langerin - - - - + +/- - 
CD4 + + - - - - - 
CD8α - - + - - +/- - 
Function Main Type 1 
Interferon 
producers 
Main IL-4 
Producers 
 
Involved in 
Th2 
response 
Main IL-12 
Producers 
 
Cross prime 
CD8+ T 
Cells 
 
Th1response 
IL-4, IFNγ 
Producers 
 
Rather 
involved 
in Th2 
response 
Sentinels 
Carry antigen 
from 
epidermis to 
dLNs 
 
CD8+ T cell 
priming 
Sentinels 
Carry 
antigen 
from 
dermis 
to dLNs 
 
IL-12, IL-23, IFNγ 
producers  
 
Cross prime 
CD8+ T 
Cells 
Localization Blood: DC 
precursors 
 
T cell zones 
of spleen 
 
Marginal 
zone of 
spleen 
 
subcapsular 
sinus of 
lymph 
nodes 
T cell zone 
of lymphoid 
organs 
 
thymic 
cortex 
Spleen  
 
Thymus 
  
T cell zones 
of lymphoid 
organs 
 
Epithelia 
Skin Tissue 
precursors  
 
Tcell zone of 
lymphoid organs 
Table 1 Overview over murine dendritic cell subtypes and their principal functions 
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1.6.2 The CD8α+ dendritic cell subset 
Murine conventional dendritic cells (cDC) can broadly be divided into CD8α- and CD8α+ DC 
subsets. CD8α+ represent about 20% of splenic DCs and about 70% of thymic DCs, whereas no 
CD8α expressing DCs could be found in non-lymphatic organs. In contrast to CD8+ T cells the CD8 
molecules are formed by a homodimer of two α chains. However, no role for CD8 in the 
development or function of the DC subset has been attributed so far. Transgenic mice lacking CD8 
expression actually develop functionally normal DCs of this subset[82]. In contrasts to the mouse, 
no CD8α+ DC subset was found in humans. However, CD103+ DCs seem to be functional analog to 
CD8α+ DCs in humans. In order to distinguish from CD8α- cDCs general accepted as CD11c+ CD8α+ 
MHC-II+ CD205+ (a multilectin) CD24+ Clec9a+ (a C-type lectin) but CD11blo Sirpα- cells. FMS-
related tyrosine kinase 3 ligand (FLT3L) mediates the expansion of CD8α+ DCs in peripheral 
lymphoid organs and mice lacking FLT3l expression developed a markedly reduced amount of 
this DC subtype [72], [83]. Furthermore development of CD8α+ DCs was shown to be dependent 
on the transcription factors IRF8 and Batf3 [74], [75]. The cells have a short turnover rate of only 
3 days in vivo. Lymphoid organ resident DCs therefore must be continuously replaced by 
precursors from the bone marrow. Bone marrow derived pre-DCs that already express CD11c but 
not MHC class II migrate via the blood stream and differentiate in spleen and lymph nodes into 
CD8α+ and CD8α- DCs [84]. Expression of CD24 within the pre-DC population was shown to be 
associated with the development into CD8α+ DC. However, it remains under debate in which 
developmental stage this commitment happens.  
CD8α+ dendritic cells exhibit a unique cytokine secretion profile which is characterized by their 
ability to secrete large amounts of IL-12 upon activation. Together with the ability to efficiently 
cross-present extracellular antigens to CD8+ T cells, CD8α+ DCs are able to mount Th1 and 
cytotoxic T cell (CTL) responses [85]. Resting CD8α+ DCs on the other hand are described to limit 
T cell proliferation and are potent inducers of Foxp3+ Tregs through the secretion of TGF-β [86]. 
 
1.6.3 Dendritic cell function in peripheral tolerance and autoimmunity 
Dendritic cells play a central role in linking and integrating innate and adaptive immune systems, 
thereby orchestrating functional immune responses. Upon recognition of microbial or tumor 
associated antigens, migratory as well as lymphoid tissue resident DCs are activated and undergo 
maturation. They upregulate antigen presentation, provide costimulatory signals and secrete a 
plethora of inflammatory cytokines. In addition, thymic dendritic cells are involved in the 
establishment of central tolerance through the (cross-)presentation of self-antigens [87]. In the 
absence of infection or inflammation, peripheral DCs are characterized by a high level of 
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endocytosis and pinocytosis but only low expression levels of MHC molecules as well as co-
stimulatory receptors [88]. The primary function of these immature DCs is to maintain peripheral 
tolerance to self-antigens through various mechanisms, which can be grouped into three 
overlapping mechanistic groups: 1) Low expression of co-stimulatory signals, respectively up-
regulation of inhibitory receptors induce T cell anergy [20]. 2) The secretion of cytokines or other 
soluble factors like IL-10 or transforming growth factor (TGF)-β induce regulatory T lymphocytes 
[89]. 3) Inhibition of T cell proliferation through secretion of molecules like IDO [90] (Fig.5). 
While the underlying mechanism for the induction and shaping of adaptive immune responses to 
infections by DCs is well investigated, their role in the induction and maintenance of peripheral 
tolerance is much less understood. First evidences for the importance of immature DCs in the 
induction of self-tolerance were given by Hawiger and colleagues. By targeting antigens to, or 
expressing them in immature DCs, they could observe proliferation of antigen specific CD4+ T 
lymphocytes. However, T cell proliferation was not linked to effector cell differentiation. Instead 
the initial proliferation was not sustained and the remaining antigen specific T cells were 
unresponsive to re exposure to the antigen [91]. Similarly, applying a Cre/loxP based system that 
allows the inducible antigen presentation by DCs, Probst and colleagues found that immature DCs 
induced complete unresponsive CD8+ T cells. In addition, the DC induced tolerance could not be 
broken by subsequent antigen-specific restimulation of the CD8+ T cells [92]. However, depletion 
of conventional DCs did not help to shed further light on the role of immature DCs in peripheral 
tolerance: While a first study found no apparent effect on T cell responses [93], a similar study 
described development of severe autoimmunity upon DC ablation [94]. More recent, the specific 
ablation of CD11c+ cells has been shown to enhance the severity of experimental autoimmune 
encephalitis [95]. The deletion of specific DC subsets like CD8α+ conventional [96] or 
plasmacytoid [97] DCs led to an increased susceptibility towards viral infections. However, no 
exacerbated autoimmunity could be observed. Although the absence of dendritic cells by its own 
might not lead to exacerbated immunity, defects in various molecular mechanisms have been 
associated with a reduced tolerogenic capability of DCs. Deficiency for the transcription factor 
Blimp-1, for example, led to an elevated level of MHC II and increased IL-6 secretion by DCs, 
resulting in development of lupus-like symptoms [98]. STAT3 deficient DCs have been shown to 
express higher levels of MHC-II as well as co-stimulatory molecules and were unresponsive to IL-
10 suppression. STAT3 deficient DCs have further been shown to cause spontaneous 
inflammation and/or autoimmunity in the gut [99]. Inconsistent with these findings, the deletion 
of STAT3 did not improve anti-tumor immunogenicity upon prophylactic DC vaccination [100]. 
The absence of NF-κB1 signaling in DCs has been shown to lead to the production of tumor 
necrosis factor α (TNFα) by unstimulated DCs. This TNFα secretion led to an increased granzyme 
B expression by CD8+ T cells causing autoimmune diabetes [101]. CD80/86 expression by 
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dendritic cells has been shown to be necessary for the maintenance of peripheral regulatory T 
cells. Interestingly, the depletion of conventional DCs reduced the Treg compartment but did not 
result in formation of spontaneous autoimmunity [102]. Taken together, dendritic cells seem to 
hold a central role in the induction and maintenance of peripheral tolerance. Nevertheless, their 
actual role appears to be ambiguous and complex. While increased or reduced numbers of 
dendritic cells do not seem to directly cause autoimmunity, genetic deficiencies can indeed lead 
to aberrant inflammation. This might be due to the redundancy of peripheral tolerogenic 
mechanisms or might reflect the crucial role of DCs in the induction of T cell responses. However, 
there is good evidence that dendritic cells are able to promote immune tolerance through various 
mechanisms and failure of DC function contributes to the development of autoimmune diseases. 
 
1.6.4 Autoimmune diseases  
Inappropriate activation of T or B cells and imbalanced central and/or peripheral tolerance can 
lead to chronic immune responses against the body’s own tissues. Autoimmune diseases (AID) 
can affect virtually all tissues and manifest itself by affecting certain organs or systemically 
involve a particular tissue. AID like type I diabetes, autoimmune thyroiditis or gastritis affect 
about 5%-8% of individuals in developed countries and shows an increasing prevalence 
worldwide. Interestingly, almost all AID predominately affect women and tend to cluster in 
 
Figure 5 Dendritic cell function 
between immunity and 
tolerance: While the presentation 
of antigens in the context of 
inflammation leads to the 
maturation of effector T cells, 
(self-) antigen presentation in the 
absence of inflammatory stimuli 
promotes immunologic tolerance 
[103]. 
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families and individuals [104]. Together with the observation that autoimmune disease share 
clinical symptoms, (epi-) genetic factors and can be attributed to aberrant lymphocyte activation, 
common mechanisms are thought to be involved in disease susceptibility. However, the etiology 
of autoimmune diseases is still largely unknown. The data accumulated over the last decades 
indicate the development of AID to be complex and multifactorial. Environmental risk factors like 
exposure to chemical agents or air pollution but also viral and bacterial infections (trough 
molecular mimicry) may enhance the development of AID [105]. Current standard treatment 
approaches against auto-reactive inflammation consist of non-specific and systemic suppression 
of a broad spectrum of immune cells. This indiscriminate immunosuppression can cause severe 
adverse effects and toxicity and renders the patient susceptible for infections. In addition, the 
chronic nature of AID imposes a significant burden on the quality of life of the patient as well as 
on the utilization of medical care. The need for more specific treatments exhibiting less side 
effects, but longer-lasting effects is therefore evident.  
 
1.7 Dendritic cell based approaches for treatment of (auto-) immune 
diseases and cancer 
Due to their dual role in inducing and regulating adaptive immune responses, dendritic cells are 
particularly interesting targets for the development of novel immunotherapeutic approaches. 
Over the last years, several different strategies have been employed in order to control DC 
function. Namely for the treatment of cancer as well as of autoimmune diseases or 
transplantation-related complications. Modification of DCs by immunogenic respectively 
tolerogenic agents or genetic manipulation have been shown to restore immune tolerance, to 
inhibit autoimmune pathogenesis or increase immunogenic properties for cancer therapy.  
Besides application specific obstacles, several common problems for the successful 
implementation of DC vaccination have to be taken into consideration: 
 Selection of the appropriate DC subtype / differentiation protocol to obtain dendritic cells 
suitable for a particular task. 
 Practical considerations like the nature of the applied antigen, the delivery route of the 
antigen or the DCs, the frequency of antigen respectively DC transfer may have an critical 
impact on the efficacy of DC immunotherapy. 
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Disease model DC modulation Effect Reference 
Autoimmune non-
obese diabetes 
(NOD) 
Bone marrow 
derived, NF-κB 
inhibitor treated DC 
Hyporesponsive 
autoreactive T cells 
[106] 
Collagen-induced 
arthritis (CIA)  
IL-10 or 
Dexamethasone 
stimulated, CII 
peptide pulsed DC 
Th3 skewing (IL-10), 
respectively 
induction of 
hyporesponsive Th1 
cells (Dex) 
[107] 
Experimental 
autoimmune 
encephalitis (EAE) 
DC targeted MOG 
expression 
PD-1 dependent 
induction of antigen-
specific Treg 
[95] 
Experimental 
autoimmune 
myocarditis (EAM) 
Flt3L induced, MyHC-
α peptide pulsed 
CD8α+ DC  
Induction of 
protective Th1 
responses 
[108] 
Skin allograft 
Donor derived semi-
mature DC 
Activation of antigen 
specific Treg 
[109] 
Table 2 Examples of beneficial application of tolerogenic DCs in different animal models of autoimmune 
diseases 
 
1.7.1 Establishment of immune tolerance by dendritic cell-based therapy  
Autoimmunity and autoimmune diseases are thought to be the result of a breakdown of central 
and/or peripheral tolerance mechanisms. Different strategies to generate have been described to 
create “tolerogenic DCs” (tolDC) with the ability to induce antigen specific T cell anergy or 
regulatory T cells: Differentiation of monocyte-derived in the presence of anti-inflammatory 
cytokines like IL-10, or TGF-β, immunosuppressive molecules like vitamin D3. Another approach 
is the genetic modification of DC in order to express anti-inflammatory molecules like IL-10 or 
CTLA4, apoptosis inducing molecules such as FasL or inhibit the secretion of pro-inflammatory 
cytokines like IL-12 (reviewed in [110]). So far the prophylactic and therapeutic application of 
DCs has predominantly been investigated in animal models and was shown to elicit promising, 
beneficial effects on several autoimmune and transplantation models (see table 2 for a short 
summary). Interestingly, the work performed by Fu et al. indicate that so called “semi-mature” 
DCs may be more efficient for inducing immune tolerance than immature DCs. exhibit an 
intermediate expression of costimulatory molecules but do not secrete. The elevated expression 
levels of CD80 and CD86 on semi-mature DCs, have been shown to be optimal for the induction 
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of regulatory T cells [111], while the lack of pro-inflammatory cytokines might maintain T cell 
hyporesponsiveness. These findings emphasize the importance of the maturation status on the 
different tolerogenic functions of dendritic cells. 
1.7.2 Dendritic cell-based cancer treatments 
The clinical goal of cancer immunotherapy is to elicit innate and/or adaptive immune responses 
against a weakly immunogenic or immune suppressing neoplasm and thereby providing active 
or passive immunity. The aim of such cancer vaccines is to break tumor-induced immune 
suppression and boost tumor associated antigens (TAA) -specific T cell immunity, therefore 
preventing or at least prolonging the time to recurrence. Especially the expansion of CD8+ T cells 
recognizing TAA with a high avidity and with high cytolytic activity is regarded as the main target 
of a cancer vaccine. The formulation of a successful cancer vaccine is dependent on how well 
defined the TAA are and whether they are shared among tumors in different individuals. Thus, 
various DC cancer vaccine approaches have been investigated. Classical vaccination approaches 
use whole tumor cells [112], tumor cell lysates or tumor specific peptides vaccines that can be 
captured and presented by dendritic cells in vivo [113], [114]. Antigens can also be delivered to 
DCs in vivo using specific antibodies or viruses (Reviewed by [115]). Protein respectively peptide 
vaccines are generally poorly immunogenic and the application of a potent adjuvant is crucial to 
increase the immunogenicity of the vaccines both during the induction of immunity and in the 
effector phase of the response. Especially (combinations of) TLR agonists have been evaluated 
(reviewed by [116]). The availability of techniques to expand or generate dendritic cells ex vivo 
from hematopoietic stem cells or blood monocytes gave rise to new vaccination approaches. Ex 
vivo culture enables the maturation and antigen pulsing of the DCs in a controllable manner. 
Furthermore, ex vivo generated or expanded DCs can be genetically modified in order to express 
immunologically defined molecules as “adjuvants”. Some candidate cytokines like, IFN-α or IL-2 
help to boost and maintain immunity, whereas for example IL-12 also specifically drives Th1 
responses, which is associated with an improved anti-tumor immunity [117]. Many of these 
vaccination approaches were shown to evoke tumor specific immune responses and tumor 
regression in different animal models [112], [118]. In contrast, clinical phase I and II trials (mostly 
conducted with late-stage patients who display strong immunosuppressive mechanisms), 
although eliciting measurable tumor-specific immune reaction [114], translated only rarely into 
clinical benefit. So far only a single DC based cancer vaccine has been approved for clinical 
application [119]. 
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2 Aim of the project 
Dendritic cells play a central role in promoting and regulating adaptive immune responses. 
Through the expression of specific cytokines we intended to modulate DC maturation or the 
interactions between DC and T lymphocytes. The application of a homogenous, well-defined 
dendritic cell line allowed us to investigate the role and the potential of pro-inflammatory as well 
as tolerogenic molecules in the regulation of immune responses by dendritic cells in a rational 
and standardized way.  
In a first part, the tolerogenic potential of the previously established IL-10 or TGF-β expressing 
DC lines were evaluated in vivo. Applying the experimental autoimmune encephalitis (EAE) and 
a skin transplantation model we sought to answer the question whether the transfer of 
tolerogenic DC lines may help to restore T cell tolerance. In addition, a DC line expressing the 
recently described immunosuppressive cytokine IL-35 was generated. We were especially 
interested in the effects of IL-35 on in vitro DC maturation and its potential to suppress adaptive 
as well as innate immune responses in vivo.  
In a second part, we intended to apply the CD8α+ MuTu DC line as an experimental tumor vaccine 
and how the immunogenicity of such a vaccination can be increased. We were especially 
interested whether the provision of allogeneic antigens might augment tumor specific T cell 
responses. Moreover we addressed the hypothesis that pro-inflammatory cytokines expressed by 
the transferred dendritic cells might further improve anti-tumor immunity respectively help to 
reverse the suppressive tumor environment.  
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3 The CD8α+ MuTu conventional Dendritic Cell line 
 
Although they play a central role in immunity, research on dendritic cells is limited by various 
restrictions. First of all, the natural scarcity of DCs in vivo, but also their functional and anatomical 
heterogeneity drastically limits the cellular material for experimentation. Isolation of dendritic 
cells from lymphoid tissue is a labor-intensive procedure yielding only limited numbers of cells. 
In addition, isolated DCs exhibit an activated phenotype which leads to apoptosis and limits their 
usability for in vitro experiments [120]. Differentiation of so called bone marrow derived DCs 
(BMDC) by culturing murine bone marrow progenitors with granulocyte-macrophage colony 
stimulating factor (GMCSF) (and IL-4, depending on the protocol) or Flt3l, has been widely used 
for in vitro research [121], [122]. Generation of BMDCs allows the generation of large quantities 
of DCs. Nevertheless, the procedure is dependent on the availability of bone marrow or blood 
derived precursor cells and requires 6-10 days of in vitro differentiation. The resulting cells are 
short-lived and represent heterogeneous DC populations. Especially GMCSF + IL-4 derived 
BMDCS are of a mixed, not well characterized phenotype, whereas Flt3l-derived BMDCs are a 
mixture of cells equivalent to CD8α+ and CD8α- DCs as well as pDCs. Unlike to the T or B cell 
research fields, only few DC lines have been described and none of them have been thoroughly 
characterized or is widely accepted [123]–[126]. Three oncogene-driven, immortalized DC lines 
have been derived from mice: the DC 2.4 [124], the CD8α+ SRDC line [126] and the SVDC line [125]. 
However, they depend on particular culture conditions or growth factors and may not be 
equivalent to endogenous DCs. The need for easily cultivable DC lines that retain the biological 
functions of specific DC subsets was obvious. 
 
3.1 Generation of the CD11c:SV40lgT transgenic mice 
In 2005 Steiner et al. generated C57BL/6 mice expressing the SV40 large T oncogene under the 
control of the CD11c promoter (Fig.6a). Bicistronic expression of eGFP allowed to identify and 
monitor expression of the transgene. The transgenic mice spontaneously developed pallor and 
subsequently became rapidly moribund. Correlating with the expression levels of the transgene, 
median onset of the disease varied between 4 months (Tg line 1) and 13 month (Tg line 2). 
Diseased mice exhibited formation of solid tumors in spleen and liver which were accompanied 
by hepatosplenomegalie and drastically decreased hematocrit levels. Thus, CD11c-SV40LgT mice 
exhibit phenotypic characteristics of human multisystemic histiocytosis and represent an 
adequate animal model for the disease [127]. Flow cytometric analysis revealed the accumulation 
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of tumoral, GFP+ cells in spleen, liver and bone marrow. In vitro cultivation of splenocytes from 
tumor-burdened animals led to the derivation of an easily cultivable cell line thereafter named 
“MuTu” (for Murine Tumor) line. Further characterization showed the derived cells to express 
CD11c, CD8α, CD24 and CD205 but no or low expression of B220, CD11b and CD4. Cell surface 
levels of MHC-II and the co-stimulatory molecules CD40, CD80 and CD86 closely correlated with 
splenic CD8α + dendritic cells in steady- as well as in an activated state. The comparison of gene 
expression as well as proteome profile confirmed the equivalence of the transformed cells to 
endogenous CD8α+ cDCs. When activated with TLR-ligands in the presence of IL-4, IFN-γ and anti-
CD40 stimuli, MuTu DCs secreted high levels of IL-12p40 and p70, which is a particular quality of 
CD8α+ DCs. The transgenic DCs were also capable to (cross-) present antigens to CD4+ or CD8+ T 
cells and to induce Th1 and CTL responses (Fig.6b). These findings highlighted that the MuTu DC 
line not only share phenotypic characteristics but also retained biological function of splenic 
CD8a+ DCs [128]. In addition, it was shown that MuTu DCs can easily be genetically altered by 
crossing CD11c-SV40LgT mice to any other transgenic mouse strains. Alternatively, lentiviral 
transduction of the DC line allowed the stable expression of transgenes. Taken together, the 
CD11c+ cells derived from the transgenic mice form a transformed cell population that can easily 
be maintained in vitro. The cells phenotypically resemble endogenous CD8α+ cDCs and maintain 
their functional characteristics. The proliferating cells can be harvested from spleen and liver of 
transgenic mice and cultured in vitro to form a homogenous CD8α+ dendritic cell line, which is 
stable for more than 60 passages representing an excellent tool for immunologic research. 
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Figure 6 Generation and characterization of the MuTu DC line: A) Transgenic expression of the simian virus 40 
(SV40) T antigen under control of the CD11c promoter leads to the formation of tumors in spleen and liver of the 
transgenic mice. In vitro cultivation of the transformed cells allowed the generation of CD8α+ DC lines. B) 
Comparison of the derived cell line to endogenic CD8α+ or CD8α- DCs by flow cytometry. The transformed cells were 
found to resemble splenic CD8α+ conventional dendritic cells and maintain their phenotype, function and 
maturation capacity. Images adapted from [127], [128] 
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II. Results 
4 Induction of immune tolerance by DC lines secreting 
tolerogenic molecules 
 
4.1 Generation of tolerogenic dendritic cell lines 
 
4.1.1 Cloning Strategy and generation of transgenic dendritic cell lines 
A number of transgenic CD8α+ MuTu dendritic cell lines, including the IL-10 and TGF-β expressing 
lines, were previously generated and described by Anaïs Duval ([129], In preparation) (Fig.7). 
Briefly, gene coding sequences were amplified from cDNA generated from CpG stimulated CD8α+ 
MuTu dendritic cells (IL-10, Ebi3) or from appropriate plasmids (active and latent form of TGF-β 
(courtesy from Prof. S. Werner, ETH Zürich), IL-12p35 (courtesy from Prof. B. Becher, University 
of Zürich). The different coding sequences were cloned into a lentiviral expression (kindly 
provided by Prof. D. Trono, University of Geneva). Replication deficient lentiviral particles were 
generated by the transfection of 293T HEK cells. MuTu dendritic cells were transduced using the 
highest lentiviral concentration not interfering with DC viability. The CD8α+ MuTu dendritic cell 
line was also transduced with the empty lentiviral vector as a control (mockDC). Transgene 
transcription was assayed by measuring the respective gene product by real-time PCR and 
western blot (IL-35) or ELISA (IL-10, active TGFβ). The transgene expression exhibited some 
variation, especially for the IL-35+DC line (data not shown). The resulting, stably transduced 
dendritic cell lines IL-10+DC, actTGFβ+DC (active form of TGFβ) and IL-35+DC were used in the 
context of this dissertation. Lentiviral transduction itself has previously been shown in our 
laboratory not to alter the expression of CD8α+ DC specific markers CD11c, CD11b, CD8a, CD205, 
CD24 or Clec9a. In contrast, lentiviral infection of the dendritic cell line was shown to slightly 
increase expression levels of MHC class II as well as co-stimulatory molecules CD40 and CD80. 
However, the changes were only minor in comparison to TLR ligand activated DC lines (data not 
shown and [128]. Transgene expression was shown before to be stable for at least 20 in vitro 
passages [130]. Nevertheless, the production of the respective transgenic product was assayed 
before each experiment  
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Figure 7 MuTu dendritic cell lines 
expressing tolerogenic molecules: A 
number of MuTu DCs were lentivirally 
transduced in order to express molecules 
with well-described tolerogenic properties. 
IL-10, TGF-β and IL-35 expressing lines 
exhibited most potent suppression of T cells 
in vitro and were therefore further 
investigated. 
 
 
4.2 Effect of Interleukin 10 or TGF-β expression on the DC line 
 
As indicated before, the DC lines expressing either the latent or active form of TGF-β as well as IL-
10 have been previously generated and described by A. Duval [130]. For the sake of 
comprehensibility, the main characteristics of the transgenic DC lines will be summarized below. 
 
4.2.1 Interleukin-10 expressing DC lines 
IL-10 transduced DC line secreted substantial amounts of IL-10 cytokine as assayed by ELISA. 
Surprisingly we also found a robust production of TGF-β by IL-10+DCs (Fig.8a). Previous work 
showed that IL-10+DCs exhibited a reduced ability to upregulate MHC-II and costimulatory 
receptors CD80 and CD86 upon stimulation with the TLR ligands CpG, pI:C and IFN-γ. Expression 
of IL-10 furthermore inhibited the release of pro-inflammatory cytokines such as IL-12 or IL-6 
upon activation, thus interfering with a functional maturation of the DCs. Ovalbumin peptide 
pulsed wild-type DCs induced antigen specific proliferation of CD4+ and CD8+ T cells as well as 
Th1 commitment. In contrast, IL-10+DCs were shown to rather induce Th17 responses as 
indicated by the reduced IFN-γ and increased IL-17 expression by CD4+ T cells (Fig.8b). However, 
the proliferative response was comparable to wild-type MuTu DC (wtDC) primed CD4+ T cells. 
Similarly, ovalbumin peptide pulsed IL-10+DCs did not have an impact on antigen-specific CD8+T 
cell proliferation but it impaired the secretion of IFN-γ by these cells. The expression of cytotoxic 
effector molecules granzyme B or perforin was not affected (data not shown).  
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Figure 8 IL-10 expressing DC line impair Th1 commitment of antigen-specific activated CD4+ T cells: A) 
The expression of the immunosuppressive molecule IL-10 was verified by ELISA on culture supernatants 
collected after 72 hours incubation of the respective DC line. Data represents 1 out of at least 2 independent 
experiments. n.d. = not detectable. B) OT-II CD4+ T cells were cultured for 3 days with the OVA323-339 pulsed 
active TGF-β expressing DC lines. IL-10+DCs slightly reduced IFNγ production while increasing the expression 
of IL-17 by OT-II cells. Data generated by A.Duval. 
 
4.2.2 TGF-β expressing DC lines 
As described in the introduction, TGF-β is produced as a latent, biologically not active, protein 
complex. Separation of the cytokine complex has been shown to be necessary to activate TGFβ, 
thereby imposing a tight regulation of TGF-β function. In order to avoid these restrictions, we 
generated a DC line expressing a mutated TGF-β sequence (Cys223Ser; Cys225Ser) that is not 
able to bind the LAP proteins and thus cannot form the latent complex. Transduction of the wild-
type DCs resulted in the stable production of the active form of TGF-β as assayed by ELISA (Fig9a). 
While TGF-β expression did not affect DC maturation itself, ovalbumin-specific CD4+ T cells 
cultured in the presence of OVA peptide pulsed DCs expressing active TGF-β produced 
significantly less IFN-γ than T cells primed by wtDCs. Moreover, the constitutive expression of 
active TGF-β induced a CD25+ Foxp3+regulatory phenotype on the CD4+ T cells (Fig.9b). However, 
these in vitro induced Tregs were not stable as they completely lost Foxp3 and CD25 expression 
within six days even after restimulation in the presence of TGFβ. Furthermore, the expression of 
the active form of TGF-β by the DCs had no effect on the proliferative response of antigen specific 
CD8+ T cells in vitro but potently inhibited the expression of IFN-γ as well as of the cytotoxic 
effector molecules perforin and granzyme B (data not shown).  
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Figure 9 active TGF-β expressing DCs 
impair Th1 commitment but induce 
Foxp3+ CD25+ expression upon the 
antigen-specific activation of CD4+ T cells: 
A) The expression of the immunosuppressive 
molecule TGF-β was verified by ELISA on 
culture supernatants collected after 72 hours 
incubation of the respective DC line. Data 
represents 1 out of at least 2 independent 
experiments. n.d. = not detectable. B) Only a 
marginal proportion of OT-II cells cultured in 
the presence of DCs expressing the active but 
not the latent form of TGF-β produced IFNγ. 
actTGFβ+DC induced a regulatory phenotype 
on the CD4+ T cells as indicated by the 
increase of CD25 and Foxp3. Data generated 
by A.Duval. 
 
 
4.3 Characterization of the Interleukin-35 expressing dendritic cell line 
 
4.3.1 Generation of a constitutively Interleukin-35 expressing DC line 
A murine dendritic cell line constitutively expressing a biologically functional, single chain IL-35 
construct (Fig.10a) was generated by linking the two IL-35 chains Ebi3 and p35 with a flexible 
(Glycine4Serine)3 linker. The short polypeptide linker allows the expression of both cytokine 
subunits under control of the same promoter while retaining its biologic activity [131]. The native 
CD8α+ MuTu DC line was subsequently transduced using a second generation lentiviral system 
[132]. Transgene expression was confirmed by real-time PCR detection of IL-12p35 and Ebi3 
transcripts (Fig.10c). The single chain protein product was immunoprecipitated and could be 
detected by western blot in the supernatant and the cell lysate of cultured IL-35+DCs (Fig.10b). 
This transgenic DC line is thereafter referred to as “IL-35+DC”. 
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Figure 10 Generation of a constitutively IL-35 expressing CD8α+DC line: A) schematic overview of IL-35 
expression cassette: The two subunits p35 and ebi3 were amplified from T cell cDNA and introduced into a 2nd 
generation lentiviral expression vector. A (Gly4Ser)3 linkerallows the expression as a single-chain construct. Stable 
expression of the transgene in the CD8α+ dendritic cell line was achieved by lentiviral transduction. B) IL-35 subunits 
p35 and Ebi3 but not IL-12p40 or IL-27p28 were detected in the IL-35 transduced DC line by reverse transcription 
rtPCR using primers specific for indicated transcript. C) IL-35 protein was precipitated from supernatant of IL-
35+DCs as well as transfected 293T HEK cells using p35 specific antibody and detected by Western blot using Ebi3 
specific antibodies. 
 
4.3.2 In vitro characterization of the Interleukin-35 expressing MuTu DC line  
IL-35 has recently been described to affect not only T lymphocytes but also a variety of other cell 
types: IL-35 was shown to induce regulatory B cells [34]. Furthermore, EBI3 and IL-12p35 have 
been shown to be expressed in some human cancers [133]. IL-35 expression by murine B16 
melanoma and J558 B myeloma have been shown to increase accumulation of myeloid cells and 
induce angiogenesis in the tumor microenvironment [133]. We therefore investigated whether 
IL-35 can act on an autocrine manner on the transduced dendritic cells itself. 
The IL-35+ dendritic cell line was assessed for the expression of a panel of surface markers 
commonly used to characterize CD8α+ DCs by direct comparison to empty vector transduced DCs 
(mockDC). Flow cytometric analysis revealed significantly reduced expression of CD11c, CD8α 
and CD205 on IL-35 transduced DC line. The expression of CD11b was drastically increased when 
compared to empty vector transduced DC lines (Fig.11a). Furthermore, the IL-35 expressing DC 
line exhibited markedly lower expression of MHC-I and MHC-II as well as co-stimulatory 
molecules like CD40 and CD86 under steady-state conditions. Activation via TLR 3 ligand 
(polyI:C), TLR 9 ligand (CpG) and interferon-γ (IFN-γ) led to a markedly increased surface 
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expression of MHC-II as well as co-stimulatory receptors CD40, CD80 and CD86 on empty vector 
transduced control DC lines (mockDC). In contrast, the IL-35 secreting DCs were unresponsive to 
TLR3/9 and IFN-γ stimulation as indicated by the failure to up-regulate any of the analyzed (co-) 
stimulatory molecules (Fig.11b). Finally, the ability to secrete the pro-inflammatory cytokines IL-
12 and IL-6 by the transduced DC lines was assayed. None or basal levels of the two cytokines 
could be detected in the supernatant of resting cells, activation with the TLR ligands pI:C, CpG as 
well as IFN-γ upregulated the production of both cytokines. While the levels of IL-6 were 
comparable to control and IL-35 transduced dendritic cells, IL-12 secretion by IL-35+DCs was 
markedly reduced when comparing to mockDCs (Fig.11c). 
 
Figure 11 IL35+ DCs upregulate CD11b and do not respond to activation stimuli: IL-35 and mock transduced 
DCs were cultured under same conditions and analyzed by flow cytometry for expression of A) DC specific markers 
or B) activation markers upon 12h stimulation with 5µg/ml CpG and 1µM pI:C. a) IL-35+ DC exhibited a markedly 
increased expression of CD11b whereas the expression of the CD8α+DC specific markers CD11c, CD8α and CD205 
was reduced. B) In comparison to mock transduced DCs, IL-35+ DCs showed lower expression of MHC-II, MHC-I and 
CD40 under resting conditions (filled lines). Upon activation (empty lines), IL-35+ DCs did not respond to activation 
stimuli and were not able to up-regulate MHC as well as costimulatory receptors. Data representative of 4 
independent experiments. C) IL-35 or control transduced DCs were seeded and incubated for 3 days. The cells were 
stimulated for the last 18 hours or not and the secretion of the pro-inflammatory cytokines was quantified by ELISA. 
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4.3.3 Interleukin-35 reduces the upregulation of MHC class II and costimulatory 
molecules and induces IDO transcription by CD8α+ DCs upon activation  
As shown above, IL-35 but not mock transduced dendritic cells exhibited markedly altered 
phenotypical and functional characteristics (Fig.11). Given the IL-35 induced effects observed on 
cells of non-lymphoid origin, we wondered whether IL-35 cytokine might directly skew CD8α+ 
DCs towards a rather tolerogenic phenotype. Wild-type MuTu dendritic cells were cultured for 
four days in the presence of supernatant collected from IL-35 or control transfected 293T cells. 
Similar to IL-35+ DCs, wild -type DCs incubated in the presence of IL-35 conditioned medium 
expressed higher levels of CD11b, while CD11c expression was down-regulated in comparison 
(Fig.12a). However, the effect was less pronounced as compared with IL-35 transduced dendritic 
cells. Upon activation with TLR3 and TLR9 ligands, the up-regulation of MHC-II and co-
stimulatory receptors CD40 and CD80 was significantly impaired when wtDC were cultured in IL-
35 containing medium whereas we could not see an effect on the expression levels of MHC class 
I (Fig.12b). 
Indolamin-2,3-Dioxygenase (IDO) production by DCs has been shown to efficiently inhibit clonal 
expansion of T cells depleting the amino acid tryptophan and inducing regulatory phenotype on 
T cells [134], [135]. CD11b+ IDO secreting dendritic cells have recently been proposed to induce 
systemic immune tolerance [90]. We therefore wondered whether IL-35 induced up-regulation 
of CD11b on CD8α+ DCs is accompanied by IDO expression. As expected, only basal expression 
levels of Ido1 mRNA were detectable by real-time PCR in wild-type DCs (Fig.12c). IFN-γ 
stimulation of wild type and mockDCs led to a considerable increase of Ido1 expression that was 
comparable to Ido1 transduced DCs. Cells that were cultured for 3 days in the presence of IL-35 
conditioned medium exhibited a significantly higher Ido1 transcription than cells cultured in the 
presence of control medium even in the absence of IFN-γ stimulation. 
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Figure 12 IL-35 alters phenotype of MuTu dendritic cells and induces transcription of Indolamin-2,3-
Dioxygenase (Ido1): Wild-type dendritic cell line was cultured for 4 days in presence of filtered and concentrated 
supernatant of IL-35 or empty vector transfected 293T HEK cells. DCs were analyzed by flow cytometry for 
expression of A) DC specific markers or B) activation markers upon 6h stimulation with 5µg/ml CpG and 1µM pI:C. 
Wild-type CD8α+DCs cultured with IL-35 conditioned supernatant but not control supernatant exhibited reduced 
expression of CD11c as well as CD205 and an increased expression of CD11b. However, the differences were not as 
distinct as in the IL-35 transduced DC line. B) Activation of wtDCs cultured in IL-35 conditioned medium led to a 
significant weaker up-regulation of MHC class II as well as co-stimulatory receptors CD40, CD80 and CD86 than in 
control supernatant cultured dendritic cells. Data shown is representative for 5 independent experiments. 
Experiments were conducted in triplicates and results are shown as the mean of the ratio of geometric mean 
activated cells/geometric mean resting cells ±SEM. C) Induction of Indolamin-2,3-Dioxygenase (Ido1) transcription 
by IL-35 conditioned wtDCs could be detected by reverse transcriptase rtPCR analysis. Graph is representative for 
two independent experiments. Data was obtained in triplicates and is depicted as mean relative expression ± SD. 
 
 
A putative heterodimeric receptor for IL-35, composed of the IL-6 receptor family member gp130 
and the β-chain of the IL-12 receptor (Il12rb2) has been described for T cells [37]. More recently, 
B cells were found to express a functional receptor complex comprised of IL-12Rβ2 and IL-27Rα 
that was able to bind IL-35 [34]. Engagement of IL-35 to the receptor induces downstream 
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signaling involving formation of STAT1/4 or STAT1/3 heterodimers in T-, respectively B cells 
[34]. While gp130 is ubiquitously expressed and can consistently be detected on the DC line, we 
were not able to detected constitutive or induced Il12rβ2 expression by IL-35+ or wild-type DC 
lines by real time PCR (data not shown). 
 
4.3.4 Interleukin-35+DC inhibit CD4+ and CD8+ T cell proliferation and function in vitro 
We have previously shown that the MuTu DC line efficiently induces T cell proliferation in MHC-
I and MHC-II restricted systems [128]. IL-35 on the other hand, was originally described to inhibit 
CD4+ T cell proliferation [32], [39]. We therefore tested whether the production of IL-35 by the 
DC line is capable to affect T cell activation and function. An allogeneic mixed leukocyte reaction 
(MLR) was performed using variable amounts of mock transduced or IL-35 expressing, C57BL/6 
derived DCs as stimulators. Co-culture with mock transduced DCs resulted in a robust 
proliferation of BALB/c derived CD4+ responder T cells, which was dependent on stimulator cell 
number. The proliferation of the T cells was accompanied by an increased percentage of activated 
CD44+CD62l- T cells and the production of IFN-γ. Target cell proliferation and activation could be 
severely reduced when IL-35+ DCs were used as activator cells (Fig.13a). In addition to its effect 
on proliferation, IL-35 is described to induce IL-35 expression in the target T cells. We therefore 
investigated the transcription of IL-35 related genes in co-cultured CD4+T cells. Analysis of T cell 
RNA revealed a significant upregulation of p35 and ebi3 but not IL-12p40 or IL-27p28 
transcription when cultured with IL-35+DCs but not mockDCs (Fig.13b).  
Much less is known about if and how IL-35 can affect proliferation and/or effector functions of 
CD8+ T lymphocytes. In fact, only one article describes that CD3/CD28 stimulation of human CD8+ 
T cells can induce IL-35 expression [136]. Another publication described that the presence of IL-
35 in an MLR can attenuate the proliferation of CD8+ T cells [137]. In accordance to the latter 
publication, we found that IL-35+DCs were also able to inhibit proliferation and activation when 
a MLR was performed using mock transduced or IL-35 expressing, C57BL/6 derived DCs as 
stimulators and BALB/c CD8+ T lymphocytes as responder cells (Fig 13c). Although IL-35+DCs 
induced the transcription of significant higher levels of ebi3 and p35 in CD8+ T cells than mock 
transduced DC, the transcription levels were substantially lower than in CD4+ T cells (Fig.13d). 
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Figure 13 Allogeneic stimulation of BALB/c T cells with C57BL/6 IL-35+ DCs: Naive CD4+ T (A and B) or CD8+ T 
(C, D) cells were isolated and purified from BALB/c mice and cultured at different ratios with C57Bl/6 derived wild-
type or IL-35+ DCs. Proliferation, activation status and transcription of IL-12 cytokine family genes of the T cells 
were analyzed after 3 days. A) CD4+ T cells proliferated significantly less and exhibited less CD62l- CD44+ activated 
phenotype when cultured together with IL-35 expressing DCs than with wtDC. Only a slight impairment of CD4+ T 
cell function as assayed by IFN-γ production could be observed. B) Analysis of T cell cDNA by real-time PCR showed 
a robust upregulation of IL-35 subunits p35 and Ebi3 but not of IL-12p40 or IL-27p28 transcription. C) CD8+ T cells 
cocultured with IL-35+ but not wild-type DCs were virtually unable to respond to allogeneic stimulation as indicated 
by drastically reduced proliferation, activation and IFN-γ production. D) Significant higher p35 and ebi3 
transcription were observable in CD8+ T cells. However relative expression levels were considerably lower than in 
CD4+ T cells. Results representative of 3 (CD4+) respectively 2 (CD8+) independent experiments. Data is depicted as 
mean ± SD.  
  
40 Induction of immune tolerance by DC lines secreting tolerogenic molecules 
In order to exclude the possibility of a contamination of the analyzed T cell RNA by IL-35+DCs, we 
performed PCR reactions on the cDNA samples applying primers that amplify only IL-35+DC 
derived single-chain IL-35 but not the induced endogenous cytokine consisting of two 
independent protein chains (Fig.14a). While amplification of IL-35+DC derived cDNA yielded clear 
bands of the expected size only a faint PCR product could be detected in one CD8+T cell derived 
cDNA (Fig.14b). 
 
As demonstrated above, IL-35+DC as well as wild-type DCs cultured in IL-35 conditioned medium 
exhibited a drastically altered phenotype, including a reduced co-stimulatory potential and the 
induction of IDO transcription. We therefore considered the possibility that the effects on T cells 
were not only directly caused by the secreted IL-35, but indirectly through the modulation of the 
immunogenic potential of the DCs. In order to test this hypothesis we performed an allogeneic 
MLR as described above and IL-35 cytokine was depleted using an ebi3-specific antibody. Due to 
the limited availability of the antibodies we could so far only perform a single pilot experiment. 
As observed in Fig.13, the culture of C57BL/6 IL-35+DCs did significantly reduce proliferation 
(Fig.15a) and IFN-γ expression (Fig.15b) by BALB/c derived CD4+ T cells. The addition of anti-
p35 or anti-ebi3 antibody did not reverse the inhibitory effect of IL-35 on proliferation or IFN-γ 
expression by the T lymphocytes. However, although the antibodies are described to neutralize 
the cytokine, we did not assay the actual efficacy of the neutralization.  
 
Figure 14 IL-35p35 and ebi3 transcription detected in the MLRs did not stem from single-chain IL-35 as 
expressed by the transgenic IL-35+DC line. A) Schematic overview over the single-chain IL-35 construct as it is 
expressed by the transgenic IL-35+DC line. The two arrows indicate the primer used in the following PCR reaction. 
B) PCR reaction using single-chain IL-35 specific primers was performed on the same CD4+ and CD8+ T cell derived 
cDNA that was applied for rtPCR in Fig.13. Only one of the MLR samples tested exhibited some minor contamination 
with DC derived IL-35. 
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In a next step, we investigated the effect of IL-35+DC on CD4+ T cells proliferation upon in vitro 
stimulation in an antigen-specific manner. Naïve CD4+OT-II T cells were cultured for 4 days with 
IL-35 or wild-type DCs that were pulsed with different concentrations of OT-II specific OVA323-339 
peptide. OT-II cells primed by wtDCs proliferated consistently and upregulated the activation 
markers CD25 and CD69 in an OVA323-339 peptide concentration dependent manner. Similar to the 
MLR experiments, the IL-35+DCs exhibited a lower immunogenic capacity resulting in a 
significantly reduced proliferative response and a lower percentage of activated OT-II cells. The 
IL-35+DC induced suppression of OT-II cell proliferation and activation could not be overcome 
even when high concentrations of OVA323-339 peptide were applied. A similar, but slightly weaker 
effect on OT-II cell proliferation and activation could be observed when the OT-II lymphocytes 
were cultured with wild-type DCs in IL-35 containing supernatant. High concentrations of OVA323-
339 peptide could induce some proliferation even in the absence of MuTu DC but did not lead to T 
cell activation (Fig.16a). Analysis of the OT-II cell derived mRNA revealed a significant 
upregulation of p35 and ebi3 expression but not IL-12p40, when co-cultured with IL-35+DCs. The 
expression of IL-35 subunits by OT-II cells was comparable to the transcription levels found in 
IL-35+DC. The priming with wtDC induced transcription of the IL-12Rβ2, the receptor chain 
shared by IL-12 and IL-35 receptors, as well as IFN-γ in an OVA323-339 peptide concentration 
dependent manner. Surprisingly, incubation with IL-35+DCs also induced strong IFN-γ expression 
even in the absence of OVA323-339 peptide. In contrast, IL-35+DC or the addition of IL-35 containing 
medium led only to a weak upregulation of IL-12Rβ2 transcription (Fig.16b). As described above, 
we could not detect any DC derived single-chain IL-35 in the T cell cDNA samples (data not 
shown). 
 
 
Figure 15 Neutralization of IL-35 cytokine does not restore CD4+ T cell proliferation and IFN-γ expression: 
Allogeneic MLR was performed as described in Fig.13. IL-35 cytokine was neutralized using anti-ebi3 or anti-p35 
antibodies. However, the neutralization did not restore CD4+ T cell proliferation (A) or (B) IFN-γ expression. The 
data represents the mean±SD of biological triplicates of one experiment. 
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Figure 16 IL-35+DCs suppress proliferation and function of OVA peptide specific CD4+ T cells in vitro. 5x103 
IL-35 transduced or not transduced DCs were seeded in 96-well plate and pulsed for at least 4 hours with the 
indicated concentrations of OVA323-339 peptide before adding 5x104 purified, naive CD4+ OT-II T cells. The OT-II cells 
were harvested after 4 days and analyzed by A) flow cytometry or B) rtPCR. A) Whereas the incubation with wtDC 
resulted in OVA323-339 peptide concentration dependent proliferation and activation of the OT-II cells, the culture 
with IL-35+DC or in the presence of IL-35 containing medium drastically reduced T cell response. B) real-time PCR 
analysis of the cDNA generated from the harvested OT-II cells revealed induction of IL-35 subunits p35 and ebi3 
only when the T cells were cocultured with IL-35+DCs. While wtDC primed OT-II cells upregulated IL-12Rβ2, the 
subunit shared by the IL-12 and the IL-35 receptors, only very weak induction of the receptor chain expression was 
found when cultured in the presence of IL-35. 
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4.3.5 Interleukin-35+DC convert naïve CD4+ T cells into a suppressive population 
Collison et al. proposed IL-35 cytokine to mediate infectious tolerance by inducing a regulatory 
phenotype on naïve CD4+ T cells [32]. We therefore tested whether CD4+ T cells co-cultured with 
IL-35 expressing DCs or IL-35 containing supernatant acquired a regulatory phenotype. Purified 
naïve wild-type CD4+ T cells were co-cultured for 4 days with IL-35+ DC or wtDCs. The suppressive 
capacity of the primed T cells was then assayed by culturing them at different ratios with naïve 
CD4+ responder T cells that were stimulated with anti-CD3 and anti-CD28 antibodies. 
Proliferation of the responder T cells was analyzed after 3 days by measuring the dilution of the 
ef670 dye. We could measure a significantly reduced responder cell proliferation when cultured 
with T cells that were primed in the presence of IL-35+DC or wtDC supplemented with IL-2 and 
TGFβ. Inhibition of the responder T cell proliferation was dependent on the amount of suppressor 
T cells applied and a maximal suppressive effect was found at low T responder to iTreg ratios. 
Interestingly, we found the IL-35+DC induced Tregs to be more potent suppressors than wtDC+IL-
2/TGF-β induced Tregs, both in terms of maximal suppressive capability as well as the minimal 
ratio of suppressor T cells needed to observe an inhibitory effect. T cells primed in the presence 
of wild-type dendritic cells did not inhibit responder T cell proliferation at high responder to 
suppressor ratios. However, at lower ratios a slight suppressive effect could also be observed with 
wtDC primed T cells. In accordance to literature, IL-35 induced regulatory cells did not express 
the classical regulatory T cell marker Foxp3, as do Tregs induced in the presence of IL-2 and TGF-
β (Fig. 17 and data not shown). 
 
 
Figure 17 IL-35+DC conditioned 
CD4+ T cells acquire regulatory 
properties: Naïve CD4+T cells 
were primed in the presence of IL-
35+DCs or wild-type DCs and IL-
2/recombinant TGF-β for 4 days. 
The suppressive capability of the 
conditioned medium was assayed 
by measuring the proliferation of 
naïve target CD4+ T cells in the 
presence of anti-CD3/CD28 
stimulation. Results are indicated 
as mean percent of suppression ± 
SD. Data representative of 4 
independent experiments. 
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4.3.6 Interleukin-35+DC impair CD4+ and CD8+ T cell responses in vivo 
In a next step we assayed the potential of IL-35+ DC to interfere with T cell proliferation and 
function in vivo. CD4+ T lymphocytes were purified from CD45.1+ OT-II mice. T cells were co- 
injected with the respective ovalbumin peptide pulsed, mock transduced or IL-35+DCs into 
CD45.2+ C57BL/6 mice. The spleens of the injected mice were harvested 4 days later and the 
lymphocytes isolated by mechanical disruption of the organ. Flow cytometric analysis revealed 
that the majority of the CD45.1+ OT-II cells did undergo proliferation and exhibited a 
considerable IFN-γ expression when co-transferred with OVA323-339 peptide pulsed mockDCs. Co-
transfer of pulsed IL-35+DCs led only to a moderate decrease in the percentage of proliferated 
cells but the total cell number of retrieved OT-II cells was significantly reduced. In addition, the 
percentage of IFN-γ expressing OT-II cells was also markedly reduced when co-injected with IL-
35+DCs (Fig.18a). 
The incubation of IL-35+DC cells with CD8+T affected their function in vitro. We therefore used 
the same experimental approach as described above to investigate possible effects of IL-35+DC 
on the function of CD8+ T cells in vivo. Mock transduced or IL-35+DC were loaded in vitro with the 
ovalbumin derived SIINFEKL peptide at different concentrations and co-injected with purified 
CD45.1+ CD8+ OT-I T cells. Co-injection of IL-35+DCs led to a drastic reduction of OT-I CD8+ T cells 
that could be retrieved form the spleen of the respective animals. However, the few remaining 
OT-I T cells were found to proliferate comparably to OT-I cells isolated from wtDC co-injected 
animals. The percentage of IFN-γ producing OT-I cells was even significantly higher compared to 
when wtDCs were co-injected (Fig.18b). Host derived CD45.2+ CD8+ T cell count and IFN-γ 
expression was found to be similar in all three experimental groups (Fig.18c). 
Taken together, the inhibitory effect on T cell proliferation and function in vitro and in vivo as well 
as the induction of iTr35 demonstrated that the IL-35 transgenic DC line efficiently interferes 
with proliferation and impairs the inflammatory functions of CD4+ T cells. The induction of IL-35 
subunit transcription and the regulatory potential of co-cultured CD4+ T cells go along with the 
work published by Collison et al. [32]. Surprisingly, the expression of IL-35 by the MuTu DC line 
also inhibits proliferation and IFN-γ production by CD8+ T lymphocytes in vitro as well as in vivo.  
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Figure 18 Il-35 expressing dendritic cell line impairs antigen-specific T cell proliferation and function in 
vivo: 2x105 OT-II restricted CD45.1+CD4+ T cells (A) or OT-I restricted CD45.1+CD8+ T cells were co-transferred 
with 2.5x106 wild-type or IL-35 expressing, peptide pulsed DCs into wild-type C57BL/6 mice (n=3 per experimental 
group) by intra-venous injection. After 4 days, spleen cells were isolated and T lymphocytes analyzed by flow 
cytometry. A) Significantly reduced numbers of CD45.1+ CD4+ OT-II T cells could be detected in animals co-injected 
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with IL-35 secreting DCs when compared to wtDC injected animals. Decreased OT-II count in IL-35+DC co-injected 
mice was accompanied with a significant reduction in the ability to produce IFN-γ. B) Co-injection of IL-35+DC almost 
completely abrogated the proliferation of CD45.1+ CD8+ OT-I T cells. However, the few OT-I cells that could be 
isolated exhibited a significantly increased IFN-γ production. Data shown is representative for 3 independent 
experiments each. 
 
 
4.4 In vivo effects of the interleukin-35 expressing DC line 
 
4.4.1 Vaccination with Interleukin-35+DC line induces tolerance towards tumor growth 
In order to determine whether IL-35 secretion by dendritic cells can restrain anti-tumor immune 
responses and promote tumor growth in vivo, we deployed a dendritic cell cancer based 
vaccination approach. In short, C57BL/6 mice were vaccinated a total of three times with tumor 
cell lysate pulsed, IFN-γ stimulated, mock transduced or IL-35+ dendritic cells. 5 days after the 
first vaccination, CMT93 carcinoma cells were transferred subcutaneously into the flank of the 
mice (Fig. 19a). Non-vaccinated as well as IL-35+ DC vaccinated mice developed palpable tumors 
within 5 days. Carcinoma growth was characterized by a slow, linear increase in volume until 
around 10-12 days weeks after tumor inoculation. While the tumors in IL-35+DC vaccinated mice 
continued to increase in size, the tumor volume in control vaccinated mice decreased and were 
completely rejected in the majority of animals at the end of the experiment (day 40). Animals that 
received tumor lysate pulsed mockDC developed palpable tumors within 7 days. However, the 
tumors failed to grow out but remained stable throughout the course of the experiment or 
showed even complete remission. Animals vaccinated with IL-35+ DCs showed a progressive 
growth and tumor volume was significantly higher than tumors of control animals (Fig.19b). Flow 
cytometric analysis of tumor infiltrating leukocytes 10 days after transfer of tumor cells revealed 
a markedly decreased accumulation of CD3+ T lymphocytes in IL-35+DC treated mice. While the 
ratio between CD4+ and CD8+ T cells was comparable in all experimental groups, both CD4+ and 
CD8+ T cells exhibited a significantly reduced capability to secrete IFN-γ. The production of IFN-
γ is associated with anti-tumor immunity promoting Th1 responses. Furthermore, vaccination 
with IL-35+ dendritic cells furthermore was accompanied with a minor increase of tumor 
infiltration by CD11b+ cells. Within the CD11b+ cell population, a significantly elevated proportion 
of Gr1+ myeloid derived suppressor cells MDSCs could be detected when compared to mockDC 
vaccinated or control animals (Fig.19c). 
Similarly, the transfer of 2x105 B16.F0 melanoma cells into non-vaccinated mice led to the 
development of palpable tumors within 5 days. B16.F0 tumors progressively increased in size to 
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a volume requiring euthanization in median within 20 days in control mice but only 15 days for 
mice vaccinated with IL-35+DCs. Mice that received vaccinations with tumor cell lysate pulsed, 
mock transduced DC exhibited a slight, but not significant delay in tumor growth when compared 
to control animals. IL-35+ DC vaccinated experimental group exhibited progressive tumor growth 
and bore significant bigger tumors within 13 days after tumor cell transfer (Fig. 19d). Flow 
cytometric analysis of tumor tissue 12 days after tumor inoculation showed a drastic reduction 
of tumor infiltration by CD3+ T cells in mice that were vaccinated with IL-35+DC. In addition to 
the reduction of total T cells, infiltrating CD4+ and CD8+ T cells exhibited a significant reduction 
in IFN-γ production. Vaccination with control or IL-35+DCs however, did not affect CD11b+ 
myeloid cell infiltration. Within the CD11b+ cell population, a tendency towards an increased 
proportion of Ly6ghi SSCint granulocytic MDSC could be observed (Fig.19e).  
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Figure 19 IL-35 expressing DCs induce tolerance towards tumor growth: A) C57BL/6 mice were 
subcutaneously vaccinated a total of 3 times with tumor cell lysate pulsed, IFNγ activated 2.5x106 IL-35+DCs, mock 
transduced DCs or PBS. 1x106 CMT93 carcinoma (B+C) or 2x105 B16.F0 melanoma (D+E) cells were transferred 
subcutaneously in the same flank as the dendritic cells. B) Mice developed palpable CMT93 tumors within 5 days of 
transfer. Whereas IL-35+ DC vaccinated mice showed constant tumor growth, tumors in control mice started to 
shrink between days 10-14 and were rejected in a majority of animals at the end of the experiment. Vaccination with 
mock transduced DC led to progressive tumor growth within 10 days after tumor cell injection. Results are 
expressed as the mean of tumor volumes ± SD from 2 pooled experiments (n=4 / experimental group) C) Flow 
cytometric analysis of tumor infiltrating cells 10 day after tumor inoculation, revealed a reduced infiltration of total 
CD3+ T cells, and IFN-γ production of both, CD4+ and CD8+ T cells upon vaccination with IL-35+DCs. Reduced T 
lymphocyte infiltration was accompanied by a significant elevation of CD11b+ Gr1+ myeloid derived suppressor cell 
infiltration of the tumor. The data shows representative results from one of five independent experiments (n=4/ 
experimental group). D) Injection of B16.F0 melanoma cells resulted in the development progressively growing 
tumors that required euthanization in average after in median 20 days in mockDC vaccinated control animals. Mice 
that received IL-35+DC vaccination, exhibited notably faster tumor growth which required euthanization of the 
animals in median after 15 days. Results are expressed as the mean of tumor volumes ± SD from one three 
independent experiments (n=5 / experimental group). E) Analysis of tumor infiltrating cells 12 days after transfer 
of melanoma cells showed a strong reduction of tumor infiltration by CD3+ lymphocytes. Both, CD4+ and CD8+ T cells 
were found to produce less IFN-γ. Infiltration by CD11b+ myeloid cells was not altered by vaccination with IL-35+ or 
mock DCs. However a tendency towards an increased proportion of CD11b+ Ly6ghi SSCint granulocytic MDSC was 
observable in mice that received IL-35+DC vaccination. The data shows representative results from one of three 
independent experiments (n=5/ experimental group). 
 
4.4.2 Interleukin-35+ DCs accelerates tumor growth also in the absence of T cells 
Recent studies on the function of interleukin-35, as well as our own findings indicate that not only 
T cells might be able to respond to IL-35 mediated effects. We therefore sought to determine to 
which extent the accelerated tumor growth in IL-35+ DCs vaccinated mice was dependent on 
adaptive immune responses. We vaccinated Rag1-/- C57BL/6 mice with IL-35+DC or mockDC and 
challenged them with CMT93 carcinoma cells as described above. In the absence of B and T 
lymphocytes, mockDC vaccinated mice developed palpable tumors within the same time frame 
as in wild type animals (7 days). Further tumor growth was noticeably faster in mockDC 
vaccinated RAG1-/- than in wild type mice. However, the injection of IL-35 expressing DCs 
accelerated tumor growth even more, leading to a reduced median survival when compared to 
mockDC vaccinated Rag1-/- animals (Fig.20a). The injection of transformed MuTu DCs has 
previously been shown to generate DC tumors within about 4 weeks only in the SV40:CD11c 
Mushi transgenic or in Rag deficient background [138]. 21 days after the transfer of tumor cells, 
all IL-35+DC vaccinated but only about 20% of mockDC vaccinated animals mice exhibited a 
markedly increased spleen and liver size with visible DC tumor nodules (data not shown). Flow 
cytometric analysis of CMT93 tumor invading cells showed an increased accumulation of CD11b+ 
myeloid cells and a drastic elevated percentage of Ly6g+ SSCint granulocytic myeloid derived 
suppressor cells (MDSCs). No overt changes could be detected for Ly6chi SSClo monocytic MDSCs 
or Ly6clo Ly6glo SSClo macrophage populations. A reduced proportion of total CD11b+ myeloid 
cells was found in the spleen of IL-35+DC vaccinated mice when compared to control animals. 
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However, the composition of the different CD11b+ populations was not altered (Fig.20b). CD11c 
GFP+ MuTu DC could be detected at similar percentages in all spleens macroscopically showing 
DC tumor nodules but not in unaffected organs (data not shown). 
 
 
Figure 20 IL-35+DC induce tolerance towards tumor growth also in the absence of T and B cells: A) T- and B 
lymphocyte deficient Rag1-/- mice were vaccinated a total of 3 times with 2.5x106 tumor cell lysate pulsed IL-
35+DCs or mock transduced DCs. Subcutaneous injection of 2x106 CMT93 cells gave rise to palpable tumors within 
7 days. IL-35+DC vaccinated mice exhibited a noticeable fester tumor growth, resulting in a significant increased 
tumor volume within 14 days when compared to control mice. B) Flow cytometric analysis of tumor infiltrating 
innate cells 21 days after tumor cell transfer revealed a significant increase of total CD11b+ leukocytes and the 
accumulation of CD11b+Ly6g+SSCint neutrophils in tumors of IL-35+DC vaccinated animals when compared to 
mockDC vaccination. However, no changes were found for CD11b+ Ly6chi monocyte or CD11b+ Ly6c- Ly6g- 
macrophage populations. A significant lower percentage of CD11b+ cells was found in the spleens of IL-35+DC 
vaccinated animals, however the relative proportions of populations within CD11b+ cells was similar in both 
experimental groups. Results show representative data from one of three independent results, n=4 animals per 
experimental group. Results are represents as the mean ± SEM. 
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4.5 Investigation of Interleukin-35+DC induced effects on cells of non-
lymphoid origin 
 
4.5.1 Interleukin-35+DC supports neutrophil but not macrophage survival in vitro 
To further investigate whether and how IL-35 may affect cells of the innate immune system, we 
harvested spleen from wild-type C57BL/6 mice. The isolated splenocytes were magnetically 
depleted from CD3+ cells in order to minimize the possibility for T cells to act as a sink for IL-35 
and minimize possible indirect effects. The cells were cultured in the presence of supernatant 
obtained from IL-35 or mock transduced 293T cells for 15 hours. Some of the samples were 
stimulated for additional 4 hours with the protein kinase C activator PMA and all samples were 
subsequently analyzed by flow cytometry. (Fig.21a). Addition of mock or IL-35 conditioned 
supernatant itself seemed to affect activation and survival of the cultured cells. Especially without 
additional stimulation, the proportions of both Ly6C+ and Ly6G+ CD11b+ myeloid populations 
were increased. However, the absolute number and proportion of CD11b+ Ly6G+ neutrophilic 
granulocytes remaining after overnight incubation was significantly higher in IL-35 containing 
medium even when compared to mock supernatant treated cells. Furthermore, the addition of IL-
35 supernatant led to a reduced expression of CD62L in Ly6G+ CD11b+ cells which is associated 
with an activated phenotype in neutrophils. The expression level of CD11b, another marker for 
neutrophil activation, was comparable within the three experimental groups (data not shown). 
In contrast, no differences in proportion or cell number for CD11b+ Ly6C+ monocytes were found. 
Stimulation of the CD3 depleted splenocytes with PMA, resulted in a noticeable expansion of the 
total live CD11b+ population irrespectively of the medium the cells were incubate with (data not 
shown). The addition of mock and IL-35 supernatant affected the CD11b+ Ly6C+ monocytic 
population similarly. However, the proportion as well as the total cell number of CD11b+ Ly6G+ 
neutrophils was augmented only upon incubation with IL-35 containing supernatant. 
Surprisingly, PMA stimulation slightly increased the expression of CD62L, that is, they exhibited 
a reduced activation status in the presence of both conditioned media. Nevertheless, the addition 
of IL-35 activated neutrophils more than mock supernatant, as indicated by a significantly lower 
expression of CD62L. 
 
Since the previous experiments indicated that IL-35 can influence neutrophils, we sought to 
investigate the effects of IL-35 on neutrophils during inflammatory conditions in vivo. We injected 
mock transduced or IL-35+DCs together with the inflammatory agent thioglycollate into the 
peritoneal cavity of wild-type C57BL/6 mice. 18h after the second injection we assayed the 
recruitment of myeloid cells to the site of inflammation as well as for their potential to survive ex 
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vivo. Flow cytometric analysis directly after cell isolation showed the peritoneal exudate cells to 
consist predominantly of CD11b+ Ly6g+ SSCint neutrophils (Fig.21b). The percentage of 
neutrophils was marginally higher in mice injected with IL-35+DCs when compared to mockDC 
injected animals. The total cell number of neutrophils within the peritoneal exudate was 
comparable in all three experimental groups. Similarly, the injection of mock or IL-35+DCs did not 
alter the expression levels of the activation marker CD11b on the CD11b+ Ly6G+ neutrophil 
population. Compared to control animals, the transfer of DC led to a reduced proportion of 
neutrophils that stained positive for the dead cell maker efluor506. The transfer of IL-35+DCs 
further increased the viability of the recovered CD11b+ Ly6G+ cells when compared to mockDC 
injection. A part of the peritoneal exudate cells that were cultured for 18h hours in vitro in order 
to address a potential effect on neutrophil survival by IL-35. Neutrophils constituted an 
insignificant but reproducible higher relative as well as total proportion of the analyzed cells 
when IL-35+DC were injected. The transfer of both, IL-35+ and mockDCs increased the expression 
of CD11b respectively reduced the percentage of dead cell marker positive neutrophils. However 
neutrophils retrieved from IL-35+DC injected mice were significantly brighter for CD11b 
expression and reproducibly exhibited a higher proportion of viable cells. The same approach 
was used to investigate the effect of IL-35+DC on inflammatory macrophages. 4 days after 
thioglycollate injection, peritoneal exudate cells consisted predominantly of CD11b+ Ly6c- Ly6g- 
SSClo macrophages. As seen before, both the mock or IL-35 transduced DCs slightly altered 
macrophage frequency and activation when compared to the not injected control group. However, 
no overt effect on the frequency of the population, expression levels of MHC-II and co-stimulatory 
molecules or survival could be observed when comparing IL-35+DC to mockDC injected animals 
(Fig.21c).  
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Figure 21 IL-35 supports neutrophil but not macrophage activation and survival: A) Peritoneal exudate cells 
and spleen were harvested from C57BL/6 mice. Splenic cells were isolated digestion and CD3+ cells were depleted. 
Peritoneal exudate cells and splenocytes were cultured in the presence of Il-35 conditioned or control medium. After 
2 days the cells were harvested and analyzed by flow cytometry. An increased amount of total and activated 
neutrophils but not monocytes could be detected exhibited when cultured in the presence of IL-35 containing 
medium. B) 2.5x106 mock transduced or IL-35+ DCs and 1ml of 4% thioglycollate were intraperitoneal injected into 
wild-type C57BL/6 mice (n=3 per experimental group).Injections were repeated after 18h and 21h after the first 
injection peritoneal exudate cells were isolated. The cells were analyzed by flow cytometry either directly or after 
18h in vitro culture and were found to consist predominantly of CD11b+ Ly6g+ SSCint neutrophils. IL-35+DC injected 
animals exhibited a small but significant increase in neutrophil accumulation and higher viability when compared 
to control DC injected mice. After 18h of in vitro cultivation, neutrophils derived from IL-35+DC injected animals 
exhibited a higher viability and upregulate CD11b, which is described to correlate with neutrophil activation. C) 
Peritoneal exudate cell isolated 5d after thioglycollate injection consisted predominantly of inflammatory 
macrophages. The injection of IL-35+DCs did not affect number or activation state of the isolated macrophages. 
Results are representative of 3 respectively 2 independent experiments. Data shown as mean±SD.  
 
4.5.2 Interleukin-35 increases the proliferation of endothelial cells in vitro 
As demonstrated chapter 4.4.2, the vaccination with IL-35 expressing dendritic cells accelerated 
tumor growth even in RAG deficient mice lacking T and B lymphocytes. Analysis of the tumor 
infiltrating myeloid cells as well as the in vitro/ex vivo experiments described above indicated 
neutrophils to be a target for IL-35. In two recent publications it was observed that tumor cell 
derived IL-35 can augment angiogenesis in the tumor environment and thereby promotes tumor 
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growth [133], [139]. For this reason we were interested whether IL-35 production by DCs does 
affect proliferation or survival of endothelial cells. In contrast to the aforementioned studies, we 
decided to address this question in an in vitro wound healing assay. HUVEC endothelial cells were 
plated and once they formed a continuous cell layer, a scratch was inflicted using the tip of a 
pipette. The endothelial cells were incubated with either supernatant obtained from IL-35 or 
mock transduced 293T cells. In order to examine whether continuous cytokine production is 
required, endothelial cells were cultured together with IL-35+DC or mock transduced MuTu DCs 
plated on transwell inserts. The membrane separating the two chambers had a pore size of 0.4μm 
avoiding the migration of the DCs into the lower chamber while allowing the diffusion of secreted 
factors (Fig.22a). The endothelial cells were harvested 12 and 24 hours after the addition of the 
conditioned supernatant respectively the dendritic cells. The ability to close the injury inflicted 
by the scratch was assayed by measuring the area not covered by the endothelial cells after the 
indicated time points (Fig.22b). After 12 hours of co-culture with IL-35+DCs, the endothelial cells 
did not exhibit any differences in the ability to close the gap when compared with mockDCs 
incubated cells. The addition of IL-35 conditioned medium on the contrary, led to a markedly 
reduced average scratch area when compared to control medium. 24 hours after inflicting the 
scratch, the scratch was mostly closed when IL-35+DCs or IL-35 containing supernatant was 
added to the endothelial cells. Incubation with control DCs or supernatant exhibited a 
significantly larger average area not covered by the endothelial cells (Fig.22c).  
Immunostaining of the cleaved caspase3 molecule and Ki-67 allowed the detection of apoptotic 
respectively proliferating cells. 12 hours after the addition of the conditioned medium or the DCs, 
respectively, the proportion of Ki-67+ endothelial cells tended to be higher when cultured in the 
presence of IL-35+DCs as compared to those cultured with mockDCs. The addition of IL-35 
conditioned supernatant did not enlarge the proportion of proliferating endothelial cells but we 
could rather observe a substantial increase in the percentage of cleaved caspase3+ apoptotic cells. 
However, after 24 hours of incubation in the presence of IL-35 conditioned supernatant or IL-
35+DCs, the proportion of proliferating endothelial cells was significantly increased when 
compared to the respective controls. Although capsase-3 expression was quite variable within 
the different samples, the production of IL-35 by the dendritic cells tended to reduce the fraction 
of apoptotic endothelial cells when compared to mockDCs (Fig.22d+e).  
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Figure 22 Regulation of proliferation and migration of endothelial cells by IL-35. A) A HUVEC endothelial cell 
monolayer was scraped using a pipette tip, forming a straight scratch and cultured in the presence of conditioned 
medium or the respective DC lines plated on the upper chamber of a transwell insert. Endothelial cells were fixed 
after 12 and 24 hours and histologically analyzed for cell migration, proliferation and apoptosis. B) Representative 
microscopic views 24 hours after scraping are shown. The white lines indicate the remaining, non-covered scratch 
area. C) The scratch area was quantified by calculating the mean ± SD of the scratch area of 4 non overlapping 
sectors. Data indicate improved cell migration after 12 hours when cultured with IL-35 conditioned medium. After 
24 hours the remaining scratch area was significantly reduced in both, IL-35+DC and IL-35 conditioned medium 
cultured endothelial cells. D) Representative microscopic views 24 hours after scraping are shown. Proliferating 
cells was stained green using the Ki67 specific antibody. The apoptosis-related cleaved caspase 3 was stained in red. 
E) Proliferation and apoptosis of endothelial cells was quantified by calculating the mean percentage ±SD of Ki67 
respectively caspase3 positive cells within 5 randomly selected sectors of the sample. 
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5 In vivo tolerance induction by dendritic cells expressing 
tolerogenic molecules  
 
5.1 Previous findings on IL-10 and TGF-β expressing DC lines 
 
A total of eight different, well-documented immune suppressive molecules have originally been 
introduced into the MuTu dendritic cell line and were investigated for their potential to suppress 
T cell proliferation and effector functions in vitro. Some of them, especially the Arginase-1 and 
Ido1 transduced DC lines, were difficult to maintain under in vitro culture conditions. The 
constitutive catabolic activity of the expressed molecules probably imposed an inhibitory effect 
on the DCs itself. Other DC lines did not exert any detectable immunosuppressive effect on T 
lymphocytes. They were therefore excluded from further investigation. The IL-10+DC line and the 
DC line constitutively expressing the active form of TGF-β were identified as the most promising 
candidate DC lines in terms of immune suppressive potential. IL-10 expression by the DCs was 
shown to impair their capability to respond to activation by TLR-ligands. IL-10+ DCs induced 
comparable antigen specific CD4+ or CD8+ T cell proliferation but skewed CD4+ T cells towards an 
IL-17 secreting phenotype. Secretion of active TGF-β by the DC line on the other hand did not 
influence the expression of MHC and costimulatory molecules by the dendritic cell itself but 
inhibited Th1 commitment and induced Foxp3+ regulatory T cells.  
 
5.2 Prevention of Experimental Autoimmune Encephalitis by tolerogenic 
DC lines 
 
Experimental Autoimmune Encephalitis (EAE) is a commonly used murine model for human 
multiple sclerosis (MS) which is a chronic inflammatory autoimmune disease of the central 
nervous system (CNS). MS is characterized by the infiltration of the CNS by auto-reactive Th1 and 
Th17 cells which in turn attract and instruct mature myeloid cells to destroy the CNS parenchyma 
in a GM-CSF dependent manner (reviewed by [140]). The destruction of myelin producing 
oligodendrocytes causes demyelation of neuronal axons which results in an impaired 
transmission of nerve impulses and typically manifests in impaired sensory and motoric 
functions [141]. While the exact etiology of MS is unknown, the disease susceptibility is associated 
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with genetic, environmental as well as geographical factors. In one of several proposed models, a 
so far unknown infectious or environmental trigger causes oligodendrocyte death, which in turn 
leads to immune dysregulation. While myelin-specific T cells could even be detected in healthy 
humans, Tregs retrieved from MS patients exhibited a reduced capability to suppress myelin 
specific effector T cell proliferation [142], [143]. These findings indicate that rather defective 
immune regulation than de novo priming of auto-reactive T cells is related to MS pathogenesis. 
In accord, adoptive transfer of myelin specific CD4+ CD25+ regulatory T cells into mice has been 
shown to protect from EAE development [144]. 
EAE can be divided into an induction and an effector phase. Immunization with myelin peptides 
or proteins in complete Freud’s adjuvant (CFA) triggers the priming of myelin-specific CD4+ T 
cells. These T cells cross the blood-brain barrier and generate a pro-inflammatory environment 
attracting and activating myeloid cells. The resulting demyelation manifests in an impaired 
neuronal signaling and a progressive but reversible paralysis of the hind limbs. The inflammatory 
nature of EAE development and the involvement of auto reactive CD4+ T cells make the disease 
an excellent model for the investigation of immunomodulatory treatment approaches.  
 
5.2.1 Role of DC in EAE development and regulation 
DCs are present in the CNS draining cervical lymph nodes and upon inflammation also within the 
CNS where they efficiently present myelin-derived peptides and provide inflammatory cytokines. 
The importance of DCs for EAE was shown by the finding that presentation of myelin antigens on 
MHC-II molecules expressed by non-CNS resident CD11c+ DCs alone is permissive for the 
initiation of the disease [145]. Furthermore, the depletion of mature DCs by the inhibition of FLT3 
signaling correlated with an improved disease progression [146]. Dendritic cells are not only 
involved in the induction and propagation of EAE but also participated in the regulation. 
Desphande et al. could demonstrate that at the peak of disease, the CNS residing DCs exhibit an 
immature phenotype expressing lower levels of MHC class II and costimulatory molecules [147]. 
 
5.2.2 Regulation of EAE pathology by TGF-β and IL-10 
Both IL-10 and TGF-β have been shown to modulate EAE induction and progression on different 
levels. TGF-β treated mice exhibited a reduced EAE severity while the neutralization of the 
cytokine exacerbated the disease [148]. Various mechanisms by which TGF-β ameliorates EAE 
have been described. Inactivation of TGF-β receptor signaling in CD11c+ DCs caused an increase 
of EAE severity which was linked to an increase of IFN-γ and IL-17 expressing T cells [149]. The 
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administration of TGF-β or IL-27 can induce IL-10 secretion by Th1 cells, thereby reducing their 
encephalitogenic potential [150]. Furthermore, TGF-β induced regulatory T cells have been 
shown to suppress the induction of EAE [151]. Paradoxically, TGFβRII deficient CD4+ T cells 
cannot acquire a Th17 phenotype and are not able to initiate EAE, further stressing the 
multifaceted characteristics of the cytokine [152] 
Mice deficient for IL-10 develop more severe EAE, while the over-expression of the cytokine in T 
or antigen presenting cells protects from the disease [153]. In fact, an increased IL-10 production 
by several cell types, including astrocytes, NKT, Th1 and Tr1 cells has been shown to correlate 
with disease remission in human and mice. These findings demonstrate that IL-10 plays a pivotal 
role in the regulation of autoimmune encephalitis. Therapeutic treatment of EAE by the 
intracranial injection of IL-10 was shown to downregulate the production of an array of pro-
inflammatory cytokines including IL-6, IL-12, GM-CSF, IFN-γ or TNFα. However, depending on the 
delivery route, timing and the disease model applied, systemic IL-10 delivery has yielded 
contradictory findings. It is assumed that a continuous delivery of the cytokine in the CNS during 
the effector phase of EAE is needed to affect EAE pathogenesis. [154]. 
 
5.2.3 Active TGF-β expressing DCs completely abrogate induction of EAE symptoms 
In order to assess the potential of dendritic cell mediated tolerance induction in vivo, we 
compared the potential of IL-10, active TGF-β or IL-35 expressing DC lines to suppress the 
induction of EAE. While the experiment applying IL-10+ or TGFβ+DCs was repeated several times 
with comparable results, only one experiment using the IL-35+DCs was performed so far. The 
results involving IL-35+DCs have therefore be regarded as preliminary. Due to technical problems 
inducing EAE using the widely used active induction of EAE and other considerations, we decided 
to use an adoptive transfer EAE model as it was described by [155]. Briefly, autoreactive T cells 
were primed in wild-type C57BL/6 mice using the myelin oligodendrocyte glycoprotein (MOG35-
55) peptide emulsified in complete Freud’s Adjuvant. Two injections of Pertussis toxin boost T cell 
priming and are required to induce reliable disease. In order to study the effect of tolerogenic 
molecules, the mice received two injections of MOG35-55 peptide-pulsed transgenic or control 
MuTu DCs. 12 days post immunization, lymph node cells of the immunized animals were 
expanded in vitro for 4 days in the presence of the respective MOG35-55 peptide pulsed DCs and 
recombinant IL-12p70. After in vitro restimulation the cells were transferred to C57BL/6 
recipient mice, which received an additional injection of the respective MOG35-55 peptide pulsed 
DCs (Fig.23a). The adoptive transfer EAE has been described to lead to more severe but also 
homogenous and reproducible induction of autoimmune CNS inflammation than the generally 
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used direct induction of EAE. In addition, the ex vivo restimulation and expansion of myelin 
specific T cells allowed to interact with the respective tolerogenic DC line for a prolonged time. 
Flow cytometric analysis of the ex vivo restimulated lymphocytes revealed no significant 
differences in regard to Th1/Th17 or Treg differentiation, irrespective of the DC line used for 
restimulation (Fig.23b). Restimulation of the lymph node cells markedly reduced the frequency 
of CD25+Foxp3+ regulatory T cells in comparison to not restimulated cells, independently of the 
experimental group. T cells primed and restimulated in the presence of active TGFβ+DCs tended 
to increase the proportion of Tregs when compared to mock or wild type DC restimulated cells. 
The presence of IL-10+DCs or IL-35+DCs on the other hand did not affect Th1/Th17 respectively 
Treg skewing of the T lymphocytes (data not shown). However, we could observe that the 
formation of proliferative blasts was considerably reduced and fewer cells could be recovered 
from the respective wells upon restimulation with IL-35+DC but not any other of the DC lines 
(data not shown). 
Mice that received MOG reactive T cells primed in the presence of wild type or mock transduced 
dendritic cells reproducibly exhibited EAE related disease symptoms within 9 days after T cell 
transfer. A maximum disease score of 3, corresponding to a paralysis of the hind limbs, could be 
observed between 12 to 14 days after T cell transfer. The animals subsequently recovered and no 
disease symptoms could be observed in average 22 days after the transfer of immunogenic T cells. 
The adoptive transfer of IL-10 expressing DCs led to a disease course that was identical to the 
control groups (Fig.23c and data not shown). In contrast, none of the mice that received T cells 
primed and restimulated in the presence of active TGFβ+DCs did show any EAE associated disease 
symptoms. An intermediate disease progression could be observed in mice that received DCs 
expressing latent TGF-β or interleukin-35. Animals that were injected with latent TGF-β 
expressing DCs also exhibited EAE associated symptoms 8 days after T cell transfer but the 
disease course was less pronounced, reaching a maximal disease score of 1 (reduced tail tonus) 
and completely recovered within 14 days. Similarly, the presence of IL-35+DCs drastically 
reduced maximum disease severity to a maximal score of 1 (Fig.23f). Table 3 summarizes the 
observed clinical scores for all of the investigated tolerogenic DC lines. 
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Figure 23 Active and latent TGF-β and IL-35 expressing DCs diminish the development of EAE: A) passive induces 
adoptive transfer EAE priming of MOG specific T cells in the presence of the respective DC lines in donor mice. Lymph node 
cells were restimulated in vitro in the presence of the respective DC line and IL-12. The cells were then transferred into 
recipient mice and the development of EAE associated symptoms was observed. B) Analysis of in vitro restimulated lymph 
node cells showed only marginal differences between the different experimental groups with a tendency towards increased 
Foxp3+ Tregs when the cells were cultured with actTGFβ+ DCs C) The development of EAE associated symptoms was 
observed in control animals but not in actTGFβ+ DC primed animals. D) Analysis of the draining lymph node resident cells 
12 days after T cell transfer exhibited significantly increased numbers of Tregs in the actTGFβ+ DC primed group. Data 
representative for 4 independent experiments. n=4 animals per experimental group Data denoted as mean ± SD. E) 
Representative microscopic views of the brains of recipient mice 12 days after T cell transfer revealed focal T cell infiltration 
only in control groups. Indicated are isolated CD3+ cells within the cerebrum. F) Pilot experiment applying IL-35+ DCs 
resulted in reduced disease severity and yield.  
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Next we wanted to investigate whether the observed differences in the course of the disease is 
associated with a phenotypical change of the CD4+ T lymphocytes. We therefore analyzed the 
infiltration of T cells into the brain as well as of the CNS draining, cervical lymph nodes on day 12 
after T cell transfer. At this time point maximal disease severity was generally observed in control 
animals. Flow cytometric analysis exhibited comparable proportions of CD4+ CD3+ cells in all 
experimental groups. When looking at total cell numbers, significantly more CD4+ T lymphocytes 
could be detected in the draining lymph nodes of mice that received actTGF-β expressing 
dendritic cells when compared to control animals. Interestingly, the transfer of latTGFβ+DCs led 
to a substantial reduction of IFN-γ expressing CD4+ T cells when compared to mock or 
actTGFβ+DCs. Although not statistically significant, a similar reduction of IFN-γ expression could 
be observed upon transfer of IL-35+DCs. The expression of IL-17 by CD4+ T cells was shown to be 
uniform in all experimental groups. While the transfer of latTGFβ+or IL-35+DC did not affect the 
Foxp3+ CD25+ CD4+ regulatory T cell population in the draining lymph node, we found that active 
TGF-β expressing DCs notably augmented Treg percentage as well as total cell number (Fig.23d). 
DC line Incidence Mean maximal EAE score 
wild-type 10/13 2.7 
mock 8/16 2.6 
active TGFβ 0/13 0 
latent TGFβ 4/10 0.6 
IL-10 4/5 2.5 
IL-35 3/5 0.5 
Table 3 Summary EAE scores: The table specifies the pooled mean maximal EAE score and incidence for 
each of the tolerogenic DC lines investigated. 
 
 
Histological analysis of the brain revealed the typical focal inflammatory lesions within the myelin 
rich regions with a preferential perivascular accumulation of CD3+ cells in diseased control 
animals. No formation of such lesions but only few, isolated T cells could be observed in the 
actTGF-β as well as in the IL-35 experimental groups (Fig.23e). Due to technical problems we 
were unfortunately not able to determine the exact phenotype of these infiltrating cells. 
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6 Induction of tolerance towards allogeneic skin transplants 
 
6.1 Introduction to organ transplantation 
Transplantation is the most effective way to replace dysfunctional or failing organs respectively 
tissues. Autologous transplantation in order to replace, for example burned skin, is widely used 
and does not impose major difficulties. Allogeneic transplantation on the other hand, requires 
permanent suppression of the host immune system in order to ensure functional survival of the 
graft over a maximal period of time. These treatment regimens usually consist of nonspecific 
immunosuppressive drugs that, besides other secondary effects, increase the risk for life-
threatening infections and cancer. In addition, nonspecific immunosuppression is generally not 
able to ensure graft survival, leading to a gradual loss of its function. Induction of graft specific 
tolerance, with a minimal impact on the recipients’ immune system has therefore long been an 
aim of transplantation research. T cells were shown to be the major mediators of acute as well as 
chronic graft rejection [156]. Considering their critical role in the regulation of the adaptive 
immune response, the application of tolerogenic dendritic cells has been thought to be a feasible 
approach to specifically delay or even prevent graft rejection and to reduce the dependence on 
immunosuppressive drugs. The preventive transfer of donor derived immature or semi-mature 
DCs has been shown to prolong allograft survival, while the transfer of mature DCs lead to acute 
graft rejection [109]. Various different mechanisms have been evaluated for their potential to 
generate and retain the tolerogenic phenotype of the applied dendritic cells: Inhibition of the 
functional maturation of DCs using specific cytokines or drugs. Generation of costimulatory 
molecules deficient DCs or blockade of the costimulatory receptors using antibodies or small 
chemical compounds interfering with functional costimulation. Another approach is the 
generation of DCs expressing immunoregulatory cytokines or molecules inducing apoptosis on 
the target T cells by genetic modification. Various studies are aiming to induce antigen-specific 
hyporesponsive T cell responses and/or regulatory T cells (reviewed by [157]).  
 
6.2 Transfer of tolerogenic dendritic cell lines lead to the prolongation of 
graft survival 
The prophylactic transfer of tolerogenic DCs can probably not be directly translated into a 
clinically relevant treatment approach, for example for autoimmune diseases like multiple 
sclerosis. We therefore sought to investigate the tolerogenic potential of DCs in a clinically more 
relevant setting. Tolerogenic DCs have been proposed as a practicable strategy to promote 
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tolerance towards grafted organs and tissues. Thus, we applied IL-10, IL-35 or activeTGF-β 
producing DC lines in two different settings of skin allotransplantation. Recipient mice were given 
intravenous injections of 2.5x106 of the respective tolerogenic or control DC lines two days before 
and one day after transplantation. Allografting of skin derived from the tail of the respective 
donor animal was performed as previously described by [158]. 
 
6.2.1 Major & multiple minor mismatched 
Skin grafts derived from F1 (C57BL/6 x BALB/c) mice (MHC haplotype b/d) that were grafted 
onto C56BL/6 mice rapidly developed focal necrosis and were completely rejected within an 
average of 14 days. Transfer of mock transduced or a mixture of IL-10 and active TGF-β 
expressing dendritic cells did only marginally affect graft survival (median graft survival for 
mockDC=15 days, for actTGFβ+/IL-10+DC=16 days) (Fig. 24a). Due to these results we decided to 
continue only in the multiple minor mismatched system. 
 
6.2.2 Multiple minor antigen mismatch 
In a second transplantation model we used mouse strains that are only multiple minor 
histocompatibility mismatched, while MHC class I and II haplotypes are matched. Thus, 129/Sv 
(MHC haplotype b) animals received allogeneic skin derived from C57BL/6 (MHC haplotype b) 
animals. We expected the allograft reaction in this setting to be less aggressive, allowing a 
possible tolerogenic effect of the transferred dendritic cells to be better observable. As described 
before, the respective DC lines were transferred one day before and two days after grafting of the 
skin. Mice that received no or mock transduced DCs completely rejected the grafted skin in 
median after 15.5 respectively 15 days. The adoptive transfer of DCs expressing IL-10 or active 
TGF-β did not delay graft rejection. In contrast, the injection of a 1:1 mixture of actTGF-β and IL-
10 expressing DCs surprisingly delayed graft rejection drastically to a median graft survival of 20 
days. Furthermore, IL-35+DCs alone were also found to significantly delay the rejection of the 
grafted skin. No long-term survival of the grafted skin could be observed for any of the tested 
combinations (Fig. 24b).  
In a next step we tried to shed light on the cellular mechanisms driving the observed delay in graft 
rejection. Due to the limited capacity to perform graft experiments, the following experiment has 
only been performed once and the results have to be considered as preliminary. Mice were bled 
one day before and seven days after skin transplantation and the peripheral lymphocyte 
populations were analyzed by flow cytometry. Unfortunately we were not able to establish a clear 
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connection between the observed differences in graft rejection and the frequency of 
inflammatory, respectively of regulatory T cells in the peripheral blood of recipient mice. Transfer 
of a single DC line alone resulted in the reduction of the total CD3+ T cells proportion when 
compared to the mice that were injected with a mixture of IL-10+ and actTGFβ+DCs. This 
reduction was most pronounced in mice that received IL-35+DCs. The relative ratios of CD8+ and 
CD4+ T cells remained comparable in all experimental groups. Surprisingly, the transfer of any of 
the transgenic DC lines led to a noticeable increase of IFN-γ expressing CD4+ T cells, especially 
upon the transfer of IL-35+ or IL-10+ DCs. actTGFβ+DCs alone but not in combination with IL-10 
expressing DCs were found to significantly impair with the acquisition of a CD44+ CD62l- activated 
phenotype on CD4+ T cells. In CD8+ T cells on the other side, the injection of any of the transgenic 
DC lines was shown to strikingly decrease the expression IFN-γ. Injection of IL-10+ or actTGFβ+ 
alone or in combination reduced the proportion of activated CD8+ T cells similarly when 
compared to naïve or IL-35+ treated mice. Finally, the transfer of actTGFβ+DC alone but not in 
combination with IL-10+ DC significantly increased the fraction of CD25+ Foxp3+ CD4+ regulatory 
T cells found in peripheral blood (Fig. 24c). 
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Figure 24 The combination of IL-10 and actTGF-β expressing DCs as well as IL-35+DCs delay allogeneic skin 
graft rejection: A) No differences in major & multiple minor mismatched allogeneic skin graft survival could be 
observed with any if the injected DC lines. B) The transfer of IL-35+ or a combination of IL-10+/actTGFβ+DCs 
prolonged the rejection of the transplanted multiple minor mismatched skin. C) Flow cytometric analysis of 
peripheral blood lymphocytes 1 day before respectively 7 days after skin transplantation. Data representative of 3 
independent experiments. Statistical analysis of the survival curves was performed using Log-Rank test. 
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7 Augmentation of anti-tumor immunity applying semi-
allogeneic DC vaccination 
 
For this second project, we took advantage of the availability of the CD8+ MuTu dendritic cell line 
and tested its potential as antigen delivery vehicle for cancer vaccination. A vast number of 
studies applying dendritic cells to induce, respectively reconstitute anti-tumor immunity have 
been performed. While some of them showed the generation of immunological responses in 
murine models, only limited clinical impact was observed in most cases [159], [160]. Most of the 
current DC-based vaccine trials have employed ex-vivo maturated, autologous monocyte or CD34+ 
hematopoietic precursor-derived DC. Depending on the cytokine combinations used for 
monocyte differentiation, the resulting DC subsets form a diverse population exhibiting a high 
degree of plasticity and triggering functionally distinct types of immune responses. Kissenpfennig 
et al. for example demonstrated that different peripheral DC subsets migrate to distinct, 
contiguous areas within draining LN [161]. Thus, the immune response elicited by current DC 
vaccination approaches might not be of the quality needed to allow tumor rejection. It is therefore 
of eminent importance to control the DC subtype(s) applied in cancer vaccines. Cytotoxic 
lymphocytes are CD8+ effector T cells specialized to eliminate infected or aberrant cells in an 
antigen specific manner. As CD8+ T cell invasion is correlated with tumor regression and better 
prognosis in different cancer (models), these cells are regarded potent anti-tumor effectors. 
Stimulation of naïve CD8+ T cell is dependent on antigen presentation by MHC class I molecules. 
Cross-presentation provides a direct way for exogenous proteins to be processed and presented 
on MHC-I molecules on cells not directly infected by microbial pathogens [162]. CD8α+ dendritic 
cells possess the ability to selectively phagocyte dead cells and efficiently cross-present 
exogenous antigens on MHC class I receptors. This ability makes them effective activators of CD8+ 
T cells. CD8+ DCs are furthermore able to produce large amounts of biological active Il-12p70 and 
therefore promote Th1 type as well as cytotoxic CD8 T-cell responses [85]. 
Besides the choice of an adequate DC subtype, one of the central challenges of any antitumor DC 
vaccination is to provide enough costimulation in absence of an acute inflammation. In lack of 
danger signals, DCs are shown to regulate and maintain peripheral tolerance; they are able to 
secrete immune-regulatory cytokines as well as they can induce a regulatory phenotype in T 
lymphocytes. The proper choice of antigen and activation of the cells is therefore of imminent 
importance to elicit tumor specific immunity. 
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In order to improve the immunogenicity of the cancer vaccination, a “semi-allogeneic” system 
was used. Antigen presentation in the absence of sufficient co-stimulation and adequate cytokine 
signals can even lead to the induction of tolerance against the specific antigen. The antigen 
presenting cell therefore has to be adequately activated in order to be able to induce pro-
inflammatory immune responses. On the other hand, antigens presented by an MHC mismatched 
cell cannot be recognized by the host T cell receptors due to self-MHC restriction. But it evokes a 
strong inflammatory response against the foreign MHC molecules. By using an allogeneic 
dendritic cell expressing MHC class I molecules of the recipient’s haplotype as antigen delivery 
vector, we anticipated to be able to prime tumor antigen specific adaptive immune responses in 
the context of self-MHC while creating a strong inflammatory environment against the otherwise 
allogeneic cell (Fig.25). By using this so called “semi-allogeneic” concept we hypothesized to 
enhance conventional cancer vaccination that are using autologous dendritic cells in various 
points: 
 Due to the high T cell precursor frequency against allogeneic MHC molecule and the 
possibility of direct recognition of allogeneic MHC class I and II molecules, adaptive 
immune responses against non-self MHC are generally very strong. On the other side, 
tumors often induce an immune-suppressing microenvironment leading to weak or even 
absent CD4+ T-cell help [163]. Thus, by the application of partially allogeneic DCs, an 
inflammatory environment is created. Through direct and indirect CD4+ T cell responses, 
the allogeneic dendritic cell-directed inflammation can be exploited to provide potent 
help for the generation of CTLs against tumor peptides presented on the shared H-2 class 
I Kd molecules. Indeed, a few reports could show allogeneic DC fused with syngeneic 
cancer cells to elicit anti-tumor effects superior to syngeneic DCs [164], [165]. 
Furthermore, it has been shown that CD4 T cell help is as important to mediate and re-
establish innate antitumor effectors for example for activation of macrophages and 
natural killer cells.  
 
 The cell line generated in our lab represents a well-defined, homogenous CD8α+ dendritic 
cell population which can be produced in theoretically infinite numbers. This facilitates 
practical realization of experiments and allows us to apply a more standardized vaccine 
in terms of phenotype and maturation status.  
 
 The cell line is further modifiable, e.g. for overexpression of pro-inflammatory cytokines. 
This may allow to combine the benefits of site-directed local cytokine therapy and 
vaccination leading to a more efficient antitumor effect. Further modification of the DC 
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line enables the local delivery of pro-inflammatory cytokines which might alter the effects 
of antitumor vaccination. 
 
Figure 25 Schematic overview on the “semi-
allogeneic” dendritic cell vaccination approach: 
The C57BL/6 derived MuTu dendritic cell line was 
modified in order to express the MHC class I 
molecule H-2Kd. The transfer of allogeneic DCs into 
BALB/c mice should trigger a strongly inflammatory 
environment while tumor antigens presented by the 
autologous H-2Kd molecules may prime a tumor 
specific cytotoxic response. 
 
7.1 The CT26 colon carcinoma model 
In order to elicit allogeneic responses against the DC line, the tumor, respectively its syngeneic 
host, must not be of C57BL/6 background. For practical reasons a subcutaneously growing tumor 
is preferred as changes in tumor size can easily be monitored in vivo. The tumor cell line that was 
chosen for this project is CT26, a chemically induced murine colon adenocarcinoma. The cell line 
established in the 1970ies by repeated intra rectal injections of the carcinogen N-Methyl-N-
Nitrosurea (NMU) [166]. It is syngeneic on BALB/c background and has since then been widely 
used in animal studies. The tumor is an undifferentiated Grade IV carcinoma, exhibiting 
aggressive growth and spreading. It tends to form metastatic lesions in lung, kidneys, heart, 
mesentery and diaphragm.  
 
7.2 Establishment and verification of H2K-d+Dendritic cell line 
In order to use the dendritic cell line as semi-allogeneic vaccine, the DCs have to express H2-Kd, 
the MHC class I haplotype expressed by the BALB/c mouse strain presenting the 
immunodominant antigens in the CT26 tumor model. A lentiviral transfer vector containing the 
full length MHC-I H2-Kd sequence has previously been created in collaboration with the group of 
Immanuel Luescher, LICR Lausanne. The wild-type C57BL/6 MuTu DC line was lentivirally 
transduced and the transduced cells were sorted for the expression of H2- Kd. Purity of the 
resulting H2-Kd+ population was around 80 percent (Data not shown). The DC line is henceforth 
called “Kd+DC”. The phenotype of the Kd+ dendritic cell line was compared to wild-type MuTu DC 
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line in steady-state and upon activation with TLR ligands and IFN-γ, showing no significant 
differences (data not shown). 
 
7.3 Establishment of pulsing protocol 
An appropriate protocol for the activation of dendritic cell is one of the key requirements for the 
generation of effective CTL responses. We decide to pulse the dendritic cells with necrotic tumor 
cell particles. This approach has the advantage that it may lead to a polyclonal T cell activation 
and a therefore potentially more vigorous anti-tumor immunity. Indeed, strong CTL responses 
could be detected even in poorly immunogenic tumor models upon immunization with tumor 
extract-pulsed DCs [167]. However, the lack of a defined, uniform antigen makes it more difficult 
to standardize the experimental procedure and different batches of tumor cell lysate might vary 
in their immunogenicity. In the absence of an appropriate activation, the dendritic cells might fail 
to induce a beneficial Th1 response or even promote tolerance towards the tumor derived 
antigens. In a first step, we therefore tried to identify ideal conditions for pulsing and activating 
the dendritic cells. 
 
Lysate to DC ratio: CT26 tumor cell lysate used for this project was produced by harvesting cells 
in log phase of their growth curve and lysed by 5 consequent freeze-thaw cycles in liquid nitrogen. 
In order to titer the CT26 tumor lysate ratios that allow optimal activation and antigen 
presentation, Kd+DCs were co-cultured at different proportions of tumor cell lysate or TLR 
agonists for up to 24h. The expression of MHC class II, the transgenic H2-Kd as well as co-
stimulatory molecules CD80, CD86 and CD40 were analyzed by flow cytometry. Activation of DCs 
applying a high lysate to DC ratio tended to induce DC apoptosis, whereas proportions lower than 
1:2 were not efficient in augmenting expression of co-stimulatory molecules (data not shown). A 
1:2 ratio of lysate to DCs was therefore applied in all following experiments. 
 
Time: It was previously observed that prolonged activation of the MuTu cell line (and of 
endogenous CD8α+ DCs) causes induction of apoptosis in a type I interferon dependent manner 
[128] while a too short activation might not be sufficient for the optimal presentation of antigen 
and expression of co-stimulatory signals. A time laps experiment was therefore performed to 
compare the activation status of DCs activated by tumor cell lysate with or without the addition 
of IFN-γ to DCs activated using the TLR9 agonist CpG and IFN-γ. The addition of CpG tended to 
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lead to a faster up-regulation of co-stimulatory molecules. However, after 24 hours of activation 
the tumor lysate activated DCs exhibited elevated levels of MHC class II as well as co-stimulatory 
molecules that were comparable to CpG induced activation. The addition of IFN-γ resulted in a 
further up-regulation of surface activation markers, especially MHC-II and CD40 in both, CpG as 
well as CT26 lysate activated cells. (fig.26a). 
In order to provide secondary and tertiary activation stimuli to T lymphocytes, additional 
inflammatory mediators are normally required. We therefore compared the production of pro-
inflammatory cytokines by the KD+DCs upon stimulation with either TLR ligand or tumor cell 
lysate. IL-12p40 secretion was found to be increased upon addition of CpG or CT26 cell lysate. 
Again, the kinetics were different with considerable amounts of IL-12p40 produced by CpG 
stimulated DCs already after 6 hours while cytokine secretion by lysate stimulated DCs could only 
be detected after 12 hours. Secretion of biological active Il-12p70 heterodimer however could 
only be detected when the dendritic cells were also supplemented with IFN-γ (fig. 26b).  
The preparation of tumor cell lysate is difficult to standardize and different batches of CT26 lysate 
might vary in their ability to activate DCs. So far, possible differences in tumor lysate efficiency 
have not been compared. Taken together the results indicate that tumor cell lysate alone seems 
to be capable to induce DC activation. However, an additional inflammatory stimulus, here 
provided by IFN-γ, was needed for the full activation of the DC line. More than 12 hours of 
activation was required to observe a distinctive expression of MHC-II, costimulatory receptors 
and inflammatory cytokines while activation for more than 24h hours drastically reduces the 
viability of the DCs. We therefore decided to pulse the Kd+DCs for 18 hours in the following 
experiments.  
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Figure 26 Establishment of a pulsing protocol: In order to determine optimal pulsing and activation conditions, 
different parameters were examined. A) The expression of MHC class II and co stimulatory molecules and B) the 
expression of the Th1 associated cytokine IL-12 was measured at different time points after the activation of DCs 
with CT26 cell lysate +/- IFNγ was compared to CpG and IFNγ activated DCs. Data representative of 2 independent 
experiments. 
 
7.4 H2-Kd+ DC induce CD4+ and CD8+ T cell proliferation  
In the next step we tested whether activated Kd+DCs were able to elicit CD8+ T cell responses in 
an in vitro assay. Kd+DCs were pulsed with CT26 lysate and IFN-γ, CpG and IFN-γ or PBS and 
irradiated to inhibit their proliferation. BALB/c derived splenocytes were isolated, and co-
cultured with the pulsed DCs at different ratios. Proliferation of T lymphocytes was assayed by 
eFluor670 dilution after 5 days. An increasing proportion of eFluor670low, CD4+ and CD8+ T cells 
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could be observed, depending on the DC ratio applied (Fig.27a). Interestingly, the CT26 cell lysate 
pulsed or CpG activated Kd+DC reproducibly led to a noticeable higher percentage of proliferating 
CD8+ T cells at low DC to splenocyte ratios. For CD4+ T cells this effect was much more pronounced 
when the splenocytes were cultured in presence of C26 lysate pulsed DCs.  
Analogous to T cell proliferation, an enhanced IFN-γ secretion was measured with increasing 
Kd+DC to splenocytes ratio. Similarly to T cell proliferation, IFN-γ production was found to be 
considerably higher when the Kd+DCs were previously activated with CT26 lysate and IFN-γ. 
Although only basal amounts of IL-17a could be detected in culture supernatant, IL-17a secretion 
tended to correlate negatively with DC to splenocytes ratio (Fig. 27b). Moreover, no significant 
amounts of IL-4 or IL-10 could be measured in culture supernatant (data not shown). 
 
 
Figure 27 CT26 lysate pulsed Kd+ DC induce T cell proliferation and Th1 skewing: A) BALB/c derived CD4+ or 
CD8+ T cells were cultured at different ratios with CT26 lysate / IFNγ pulsed or CpG/IFNγ stimulated Kd+DCs. 
Whereas the proliferation of CD8+ T cells was comparable, CT26 pulsed Kd+DCs induced CD4+ T cell proliferation 
already at lower DC to T cell ratios. B) Cytokine secretion of the cocultured cells was detected by ELISA. CT26 pulsed 
Kd+DCs tended to induce more IFNγ production while reducing IL-17 secretion. No Il-4 and only basal levels of Il-10 
could be detected (data not shown). Data representative of 3 independent experiments. 
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7.5 Vaccination of BALB/c mice with H2-Kd expressing C57BL/6 DC line 
delays tumor growth 
The immunogenic potential of the semi-allogeneic dendritic cell vaccination was assayed in a 
therapeutic vaccination setting. 5x104 CT26 tumor cells were subcutaneously transferred in the 
flank of wild-type BALB/c or F1 (BALB/c x C57BL/6) mice. Three and ten days after tumor 
inoculation, the mice were vaccinated with 2x106 tumor cell lysate pulsed, activated Kd+ or wild-
type DCs. The development of tumor size was measured regularly. The mice of all experimental 
groups developed palpable tumors within 8 days. This initial tumor growth was often followed 
by a short period of contraction that was followed by an anew increase in volume. PBS injected 
controls mice exhibited a progressive tumor growth leading to a tumor volume that required 
euthanasia in median 30.5 days after inoculation. A comparable increase of tumor volume was 
measured for animals that were vaccinated with wtDCs or resting Kd+DCs. However, the overall 
better health status of the mice in these experimental groups increased the median survival 
noticeably (act wtDC: 35 days, resting Kd+DC: 37.5 days). Vaccination of the mice with CT26 lysate 
pulsed Kd+DC led to a markedly slower increase of tumor size when compared to control animals 
and further increased the median survival to 43 days. Although the observed differences were 
highly reproducible, they were, especially at later stages, barely statistically significant. This was 
caused by the considerable variation of tumor volumes within the experimental groups. 
Surprisingly, we noticed that autologous vaccination of (BALB/c x C57BL/6) F1 mice with 
activated Kd+DCs drastically accelerated tumor growth in a highly reproducible way and reduced 
the median survival of this experimental group to 27 days (Fig.28a+b).  
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Figure 28 Vaccination of BALB/c mice with H2-Kd expressing C57BL/6 DC line delays tumor growth: CT26 
tumor cells were subcutaneously injected into wild-type BALB/c mice. Mice were vaccinated 3 and 10 days later and 
A) tumor growth and B) survival was followed. Semi-allogeneic vaccination with tumor lysate pulsed, IFNγ activated 
Kd+DCs reproducibly delayed whereas the autologous transfer into (C57BL/6 x BALB/c) F1 mice surprisingly 
accelerated tumor growth. Data depicted as mean tumor volume ± SEM. B) Mice were euthanized when the met 
abort criteria as described in the Material & Methods part. Again, semi-allogeneic vaccination prolonged median 
survival. Survival curves were compared using Log-Rank test. The graphs are showing pooled results of 2 
experiments. A total 6 independent experiments were conducted. 
 
7.6 Semi-allogeneic vaccination did not affect tumor infiltration by CD4+ 
and CD8+ T cells 
As described above, BALB/c or BALB/c x C57BL/6F1 mice were vaccinated with activated, tumor 
cell lysate pulsed Kd+ or wtDCs. 14 days after tumor cell inoculation, when tumor growth was 
observable in all experimental groups. The mice were sacrificed and leukocytes were isolated 
from tumor, tumor draining inguinal lymph nodes, and spleen by collagenase digestion and 
mechanical disruption. Single cell suspensions were analyzed by flow cytometry for the presence 
of T lymphocytes as well of a palette of innate myeloid leukocytes. Unfortunately the flow 
cytometric analysis of the cells yielded partially contradicting results and high inter-experimental 
discrepancies. The results shown in Fig.29 were chosen from one experiment that was successful 
from a technical point of view and represents best the observations from the different 
experiments. When looking at tumor infiltration by total CD45+ hematopoietic cells, we could 
observe a drastic reduction upon transfer of Kd+DC or wtDC into BALB/c animals. This effect was 
especially pronounced when C26 lysate pulsed, activated dendritic cells were injected (Fig.29a). 
 77 Augmentation of anti-tumor immunity applying semi-allogeneic DC vaccination 
Regarding adaptive infiltration, the vaccination seemed to reduce the recruitment of CD3+ T cells 
independently of activation status of the DCs and the genotype of the animal. We could further 
observe a tendency towards a reduced proportion of CD25+ Foxp3+ regulatory T cells and, 
biologically more relevant, a decreased Treg to CD8+ T cell ratio in the tumors of BALB/c mice 
that received vaccination. However, the effect was similar when using wild-type or tumor cell 
lysate pulsed, semi-allogeneic Kd+DCs. Vaccination of F1 mice resulted in an infiltration of total 
CD4+ as well as regulatory T cells that was comparable to not vaccinated control animals. But 
again, the differences were not statistically significant. Similarly to tumor infiltration, DC injection 
led to a decrease of total T cell proportion within the tumor draining inguinal lymph node 
regardless of the genotype of the mice. Semi-allogeneic vaccination but not autologous 
vaccination did significantly increase the percentage of CD4+ T cells found in the lymph nodes 
resulting in an increase of the Treg to CD8+ T cell ratio (Fig 29b). When analyzing tumor 
infiltration by cells of the innate immune compartment, we could not detect any differences in the 
proportions of NK1.1+ natural killer or CD11b+ cells. However, vaccination with pulsed Kd+DCs 
seemed to shift the high Ly6G+ granulocytic infiltration found in control vaccinated animals rather 
towards an increased invasion by Ly6C+ monocytes or Ly6G-Ly6C- cells (Fig 29c). Semi-allogenic 
or control but not autologous vaccination did significantly reduce the percentage of CD45+ 
hematopoietic cells found in the spleen of the respective animals. In addition, the transfer of Kd+ 
and wild-type DC into BALB/c mice was associated with some minor but statistically significant 
shifts within the different CD11b+ populations: While the Ly6G+ as well as the Ly6C-Ly6G- 
populations tended to augment, we could detect significantly fewer Ly6C+ monocytes when 
compared to not vaccinated animals (Fig.29d).  
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Figure 29 Semi-allogeneic vaccination did not affect tumor infiltration by CD4+ and CD8+ T cells: CT26 tumor 
was inoculated and mice were vaccinated as described above. The animals were sacrificed 12 days after CT26 cell 
injection, when tumor growth was observable in all experimental groups. A+C) Tumor infiltrating, B) tumor draining 
lymph node or D) spleen resident leukocytes were analyzed by flow cytometry. A+B) No major differences in T cell 
infiltration and function was observed between the experimental groups. C) An increased infiltration of total CD45+ 
leukocytes could be observed upon autologous vaccination. D) Only minor differences of spleen resident innate cells 
could be measured between the experimental groups. Results show representative data from 4 independent results, 
n=4 animals per experimental group. Results are represented as the mean ± SD. 
 
7.7 Enhancing semi-allogeneic vaccination by the application of pro-
inflammatory cytokines expressing H2-Kd+ dendritic cell lines  
The application of immunologically defined molecules, in our case pro-inflammatory cytokines, 
as “adjuvants” has been proposed since the 1990’s (reviewed by [168]). Various cytokines have 
been described to improve anti-tumor immunity in murine tumor models and clinical studies. 
Many of the classical candidate cytokines like, IFN-α, IL-2 or IL-12 have been described to 
promote anti-cancer immune responses (reviewed by [117]). Their pro-inflammatory 
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characteristics may therefore be combined and exploited to improve the efficacy of cancer 
vaccination and help to overcome immune suppressive tumor environment.  
Three cytokines that have caught special attention for cancer immunotherapy have been selected 
for this project: 
Interleukin-2: Secreted mainly by CD4+ T cells, IL-2 promotes growth, survival and 
differentiation of antigen-activated T lymphocytes. Responsiveness to this cytokine is controlled 
by tight regulation of the cognate receptor; functional, high-avidity IL-2Rαβγc is found only on 
activated T cells. Regulatory T cells express IL-2R constantly, even without overt antigen or IL-2 
stimulation. It is therefore assumed that the IL-2 has an important role in Treg survival and 
function in vivo. In addition to the effects on T cells, high levels of IL-2 also promote proliferation 
and differentiation of natural killer cells. 
Interleukin-15 shares receptor components of IL-2 and has similar structural characteristics. 
Thus, the biological activities of the two cytokines overlap. But in contrast to IL-2, IL-15 is 
expressed only by nonlymphoid cells, including activated monocytes and DCs. A unique 
characteristic of IL-15 and IL-15Rα is the ability to stimulate neighbor cells via a mechanism 
known as trans-presentation, i.e. the IL-15Rα on the surface of DC or monocytes forms a complex 
with IL-15 and then presents it in trans to neighboring cells. IL-15 induces proliferation of naive 
and memory CD8+ T cells, promotes primary CTL responses and makes both CD4+ and CD8+ T 
cells resistant to suppression by Tregs. It is able to maintain central memory CD8+ T cell 
homeostasis. In addition IL-15 promotes activation of NKs, DCs, monocytes and macrophages 
[169]. 
Interleukin-12 acts as a master regulator of the innate and adaptive immune system: The 
probably most important and characteristic activity is its ability to promote Th1 immune 
responses: IL-12 stimulates the development of naïve CD4+ T cells as well as resting memory CD4+ 
T cells into Th1 cells capable of producing large amounts of IFN-γ. It can also act directly by 
enhancing the lytic activity of NK and cytotoxic CD8+ T lymphocytes [170]. IL-12, together with 
IFN-γ, inhibits the proliferation of Th2 polarization and therefore regulates the balance between 
Th1 and Th2 mediated immune responses. There is further evidence that IL-12 is also capable of 
inhibiting pro-angiogenic factors like vascular endothelial growth factor (VEGF). 
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7.7.1 Generation of CD8α+ DC lines constitutively expressing pro-inflammatory 
cytokines 
IL-2 and IL-15 were amplified from activated T cell, respectively DC cDNA and cloned into a 
lentiviral expression vector. For IL-12, a single-chain construct was cloned in the laboratory of 
Burkhard Becher, Zürich. The two subunits forming IL-12, p35 and p40 are linked by a (Gly4Ser)3 
sequence. In addition, a murine IgG3 Fc tag was added to the single-chain construct in order to 
increase stability and solubility of the protein product. The H-2Kd+ MuTu DC line was transduced 
with the respective lentiviral vectors and the expression of the transgene was controlled by rtPCR 
and ELISA (Fig.30a + b).  
In order to assay whether the generated DC lines affect proliferation or function of T cells, OVA 
peptide specific CD8+ OT-I or CD4+ OT-II cells were stimulated in vitro in the presence of the 
transgenic DCs pulsed with the respective peptide. After 4 days of incubation the T cells were 
harvested and proliferation as well as activation was analyzed by flow cytometry. As expected, 
peptide pulsed DCs induced a strong proliferation as well as the CD44+ CD62L- activated 
phenotype of both OT-I and T-II T cells when compared to T cells cultured with resting DCs. 
However, both the percentage of proliferated as well as of activated T cells was similar when any 
of the cytokine transduced DC or the Kd+DC control line was used for T cell simulation (Fig.30c). 
The secretion of IFN-γ protein by the T cells was measured by ELISA. Incubation with IL-2 
expressing DCs reproducibly induced IFN-γ production even in the absence of OVA peptide and 
led to a further increase of IFN-γ expression by OT-I and OT-II cells when compared to control 
DCs. IL-12Fc+DC augmented IFN-γ secretion only by CD4+ OT-II cells (Fig30d). 
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Figure 30: Characterization of proinflammatory cytokine expressing DC lines: The expression of the 
inflammatory cytokines was verified by A) rtPCR and B) ELISA on supernatants collected after 72 hours incubation 
of the respective DC line. C) Comparable proliferation and activation of CD4+ OT-II or CD8+ OT-I T cells was measured 
upon culture with the different DC lines pulsed with the respective peptides. D) Cytokines secretion by the T cell 
was measured by ELISA on the culture supernatants. The incubation with IL-2 expressing DCs resulted in an increase 
of IFNγ production by OT-II but not OT-I cells.  
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7.7.2 Expression of pro-inflammatory cytokines did not improve the efficacy of semi-
allogeneic DC cancer vaccination 
In a next step we tested whether the expression of proinflammtory cytokines by the DCs might 
improve inflammatory response towards the tumor in the context of the semi-allogenic 
vaccination approach. As described before, BALB/c mice were subcutaneously challenged with 
CT26 tumor cells and were vaccinated two times with the respective activated and CT26 lysate 
pulsed DC line. Vaccination of the tumor bearing mice with any of the Kd+ dendritic cell lines 
delayed tumor growth when compared to not vaccinated control animals. However none of the 
Kd+DCs expressing pro-inflammatory cytokines was able to further significantly delay tumor 
growth. Only in animals vaccinated with IL-12 expressing Kd+DCs a tendency towards a slower 
tumor growth and a marginally increased median survival could be observed (Fig.31a+b). Due to 
the discouraging results using these cytokine transduced DC lines and the contradictory data 
obtained from the analysis of tumor infiltrating immune cells shown above, we refrained to 
pursue this part of the project. 
 
 
Figure 31 Expression of pro-inflammatory cytokines did not improve the tumor specific response of the 
semi-allogeneic vaccination CT26 tumor was inoculated and mice were vaccinated with the cytokine expressing 
Kd+DC lines as described above. No differences in A) tumor growth and B) survival of the mice was measurable when 
compared to vaccination with control Kd+DC. 
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III. Discussion 
8 Expression of tolerogenic cytokines by the MuTu Dc line 
The failure to mount appropriate immune responses against infectious agents or aberrant cells 
can lead to life-threatening pathologic conditions. On the other side, uncontrolled or chronic 
immunity against (self-) antigens is associated with the development of a variety of (auto-) 
immune diseases and can lead to the development of cancer. A high level of organization and 
regulation is therefore needed to ensure effective functioning of the immune system. Dendritic 
cells are the most efficient antigen presenting cells, they provide costimulatory, respectively 
coinhibitory and cytokine signals in order to promote and regulate T cell responses. Due to their 
central role in determining the outcome and quality of adaptive immune responses, DCs have 
caught major interest as potential therapeutic tools for the immunotherapy of (auto-) 
inflammatory disease or cancer.  
 
8.1 Generation of transgenic DC lines 
Research on dendritic cells is traditionally limited by the scarcity of the cells in vivo and the 
resulting work and cost intensive isolation. Classical derivation of DCs from bone marrow or 
monocytic precursor cells is time intensive and results in a less homogenous, at least partially 
activated DC population. For this study we have taken advantage of the MuTu CD8α+ dendritic 
cell line that was established and characterized in the laboratory of Prof. Acha-Orbea. The MuTu 
DC line constitutes a homogenous cell population that corresponds phenotypically as well as 
functionally to CD8α+ DCs. The DC line can easily be cultured and provides an infinite source for 
manipulation in vitro and in vivo. Lentiviral infection of the cells was found to yield high 
transduction rate and stable expression of the desired transgene without severely affecting DC 
phenotype [127], [128]. However, the MuTu DC lines were derived from mice expressing the SV40 
largeT oncogene and GFP under the control of the CD11c promoter. In retrospect, the use of GFP 
as marker on the lentiviral expression vectors was therefore not an advantageous decision. While 
A. Duval was able to sort transduced dendritic cells according to the shift in GFP expression upon 
lentiviral transduction, we could not detect such an increase of GFP signal when compared to the 
wild-type DC line (Fig.32). Accordingly we were neither capable to assay efficacy of transduction 
nor could we sort transgene expressing cells. Although the same amount of lentiviral particles 
was used to transduce the DCs, we observed variable transgene expression which might explain 
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some of the variation in the results obtained with IL-35 expressing DCs. As a consequence, a RFP 
expressing lentiviral transfer vector has currently being used in our laboratory. 
 
 
Nevertheless, the CD8α+ MuTu DC line has proven to be an invaluable tool for the investigation of 
various aspects of dendritic cell biology. The field of applications ranges from basic immunologic 
questions as addressed in this thesis to more molecular questions. For example decipher the 
molecular mechanisms that regulate cytokine production in response to different TLR and 
cytokine stimuli (Gupta et al, in preparation).  
 
9 Interleukin 35 expressing dendritic cell line reveals novel 
functions for IL-35 
Analogous to the other members of the IL-12 cytokine family, interleukin 35 is an important 
regulator of pro- respectively anti-inflammatory immune responses. IL-35 was shown to be a key 
mediator of Treg function by the suppression of CD4+ T cell proliferation and induction of a 
regulatory phenotype on naïve CD4+ T cells [39]. Decreased levels of IL-35 have recently been 
found to be associated with various human (auto-)inflammatory pathologies like systemic lupus 
erythematosus, COPD or Hepatitis B [171]–[173], On the other hand, IL-35 production by 
different human tumors has been found and was shown to correlate with a poor prognosis [139]. 
These findings suggest IL-35 to be a promising target for the treatment of autoimmune diseases 
 
Figure 32 Lentiviral transduction of MuTu Dendritic Cell line does not lead to a significantly 
higher GFP expression: Wild-type MuTu dendritic cells were transduced using different lentiviral 
particles that allow the stable expression of the gene of interest as well as a GFP marker. The efficacy of 
the transduction was controlled by measuring the shift in GFP expression since the DC line itself already 
expresses GFP. In contrast to previous findings we were not able to detect a significant increase in mean 
fluorescence in any of the lentiviral transduced DCs when compared to not transduced DCs. 
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and its inhibition may be beneficial in cancer treatment. However, the biological functions of the 
cytokine are still poorly understood.  
 
 
9.1 Interleukin-35 promotes a tolerogenic phenotype on CD8α+ DCs 
 
The flow cytometric analysis of the interleukin 35 expressing MuTu DC line revealed remarkably 
differences in their phenotype when compared to control virus transfected DCs: While the 
expression of the CD8α+ dendritic cell markers CD11c, CD8α and DEC205 was down regulated, 
IL-35+DC prominently upregulated CD11b expression. Activation of the DC lines with TLR ligands 
led to a marked upregulation of MHC class II as well of co-stimulatory receptors CD40 and 
CD80/86 by control DCs. In contrast, IL-35 expressing DCs did express lower expression levels of 
MCH class I and II as well as CD40 already in unstimulated conditions. Activation of the cell line 
did not cause the upregulation of any of the analyzed molecules. A comparable but less 
pronounced effect could be observed when wild-type DCs were cultured for 4 days in IL-35 
conditioned medium. Considering that neither mock transduced DCs nor DCs cultured in control 
supernatant exhibited a markedly altered phenotype, we assume it very unlikely that the 
observed effects were provoked by the lentiviral transduction. Besides the observed immature 
phenotype, we measured the transcription of the immunosuppressive molecule Ido1 by IL-35 
containing supernatant cultured wtDCs. As described, Ido transcription could also be detected in 
wtDCs activated by IFN-γ and Ido transduced DCs but not in mock supernatant treated DCs. 
Together, these observations imply a possible direct effect of IL-35 cytokine on the dendritic cells 
itself. While a large array of mediators have been reported to induce a tolerogenic phenotype on 
DCs, no such effect has been described for IL-35. In agreement with our observations, tolerogenic 
dendritic cell populations are generally thought to express low levels of MHC-II and costimulatory 
molecules. The cells are therefore largely ineffective in activating T cells trough the classical TCR 
signaling pathways. In addition, tolerogenic, respectively Th2 inducing DCs are described by 
several studies to have a rather macrophage-like phenotype, including the expression of CD11b 
[64], [174], [175]. Especially interesting is the finding that a distinct subset of CD11b+ dendritic 
cells that expresses Ido can mediate systemic immune regulation in a model of oral tolerance 
induction [90]. 
Taken together, our findings indicate that IL-35 cytokine produced by the transduced DCs or 
supplemented in the medium directly affects the phenotype of the CD8α+ DC line. The inability to 
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adequately upregulate the expression of MHC II and costimulatory molecules in response to TLR 
ligand stimulation indicate a possible interference with the immunogenic capabilities of the DC 
lines. In addition, the production of the regulatory molecule Ido might further contribute to the 
regulatory functions of IL-35 conditioned DCs. Regarding the drastic effect of IL-35 on phenotype 
and function of the MuTu DC line, we can hypothesize that IL-35 does not only directly regulate T 
cell responses but also indirectly via the induction of a tolerogenic phenotype on DCs. 
Nevertheless, such a direct effect of IL-35 on dendritic cells has yet to be verified. In a pilot 
experiment we attempted to test the ability of IL-35+DCs to promote T cell proliferation while 
depleting secreted IL-35 cytokine using an ati-ebi3 antibody. We thereby hoped to be able to 
distinguish between the direct effects of IL-35 on the T cells and the induced tolerogenic 
phenotype of the DCs. Unfortunately the experimental setup did not function and has to be 
improved. In order to be able to response to IL-35 signaling, dendritic cells need to express an IL-
35 receptor. Although the exact composition of the receptor is still disputed, there is agreement 
that IL12rb2 is indispensable for IL-35 signaling. Although IL-12rβ2 transcription was detected 
in our DC line and is, according to the immgen.org microarray database, moderately expressed in 
most conventional DC subtypes. We did not address whether the MuTu DCs express a functional 
IL-35 receptor on protein level. Engagement of IL-35 receptor in B or T cells has been shown to 
trigger intracellular signaling mediated by the phosphorylation of Stat1/Stat3 respectively 
Stat1/Stat4 heterodimers [34], [37]. It would therefore be crucial to investigate whether the 
conditioning of DCs with IL-35 cytokine actually induces Stat signaling. The identification of the 
target genes induced by IL-35 signaling could give further insight in the effector mechanisms 
deployed by the cytokine. Lastly, the experiments discussed here were performed on MuTu DC 
line only. In order to confirm the findings we will repeat the experiment using endogenous CD8α+ 
but also other DCs populations. This will allow us to determine whether the observed effects on 
MuTu DCs are restricted to the CD8α+ DC subtypes or whether it represents a more general 
mechanism to induce tolerogenic DCs.  
 
9.2 Interleukin-35 expressing DCs mediate T cell tolerance 
Studies on IL-35 have been hindered because the stability of commercial available, recombinant 
IL-35 is rather short. The constitutive expression of IL-35 cytokine by the MuTu dendritic cell 
lines allowed us to circumvent this problem and to investigate how the cytokine might influence 
the outcome of DC-T cell interactions. In a first step we therefore sought to assay whether the 
transgenic expression of the IL-35 construct by DCs can limit the expansion and effector functions 
of T lymphocytes as it was described by others. 
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9.2.1 Interleukin-35+ DC inhibit CD4+ and CD8+ T cell proliferation in vitro and in vivo 
and induce a regulatory phenotype on CD4+ T cells. 
The contribution of IL-35 to the functions of regulatory T cells was the first attribute of the IL-35 
cytokine described in the literature. Its effect on CD4+ T lymphocyte function is by now best 
investigated function. First, the expression of a functional transgene product was verified by in 
vitro culture of IL-35+DCs with CD4+ T cells. As expected, IL-35+DCs were found to impair 
expansion of the lymphocytes upon both, polyclonal as well as antigen-specific stimulation. In 
contrast control DCs induced a robust proliferation. Furthermore, a lower proportion of CD4+ T 
cells exhibited an activated phenotype and tended to produce less IFN-γ when they were primed 
by IL35+DCs. The application of IL-35 expressing DCs in the mixed lymphocyte reaction as well in 
the OVA peptide specific stimulation setting prompted the transcription of the IL-35 subunits p35 
and ebi3 but not the IL-12 related protein p40. Interestingly we found that the addition of IL-35 
containing medium to OVA323-339 pulsed, wild type DC also led to the inhibition of OT-II CD4+ T 
cells but these cells did not transcribe p35 or ebi3. Furthermore, the expression of IL-35 by DCs 
converted naïve CD4+ T cells into a regulatory population, able to suppress proliferation of other 
naïve CD4+ T cells. The transfer of OVA323-339 specific OT-II cells together with peptide pulsed IL-
35+ DCs reduced the total number of OT-II that could be retrieved when compared to control DCs 
injected mice. IFN-γ secretion by OT-II was found to be reduced but surprisingly the proportion 
of proliferating cells within the retrieved OT-II cells was only marginally reduced. 
In contrast to the better described responses of CD4+ T cells to IL-35, only two studies so far have 
addressed its effect on CD8+ T cells. Guo et al. observed that the expansion of CD8+ T cells was 
significantly inhibited when IL-35 conditioned supernatant was added in a mixed lymphocyte 
reaction [137]. Moreover, in another study it was shown that anti-CD3/CD28 stimulated CD8+ T 
cells produced comparable amounts of IL-35 cytokine as CD4+ T cells[136]. In our hands the 
polyclonal activation of CD8+ T cells by allogeneic IL-35+ DCs did lead to a significantly reduced 
proliferation, activation and IFN-γ production when compared with control DCs cultured cells. 
We were able to detect transcription of IL-35 subunits p35 and ebi3 when the primed CD8+ T cells 
were primed by IL-35+DC but not with control DCs. However the relative expression of the two 
subunits was markedly lower than in CD4+ T cell primed by IL-35+DCs. Comparably, the transfer 
of OVA specific OT-I CD8+ T cells together with peptide pulsed IL-35+DC but not control DCs in to 
C57BL/6 mice almost completely abrogated the expansion of OT-I cells. The remaining OT-I 
proliferated to the same extend and expressed similar levels of IFN-γ as mockDC injected mice. 
The endogenous CD8+ T cells populations were not affected by the transfer of IL-35+DCs. Besides 
IFN-γ we did not assay a possible effect on other (cytotoxic) effector molecules like perforin or 
granzyme B nor did we measure the lytic capability of these cells. A suppression of effector 
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functions by IL-35+DCs can therefore not yet be definitively clarified. Curiously, when similar 
experiments were conducted by A. Duval using active TGF-β expressing DCs, no suppressive effect 
on CD8+ T cell responses could be detected. She and other showed that the priming of CD8+ 
effector responses by DC based vaccines is dependent on endogenous CD11c+ DCs that cross-
present the vaccine derived antigen to CD8+ T cells [130], [176]. This was thought to interfere 
with a possible tolerogenic effect by TGF expressing DCs. based on the available data the 
discrepancy to the results presented here are difficult to explain. One can speculate that either 
the production of IL-35 directly imposes suppressive signal that is potent enough to override the 
activating stimuli by the endogenous APCs. Another possibility is that the IL-35+ DCs might, for 
some reason, not be able to transfer antigen to the endogenous DCs. 
Thus, our data indicate that the IL-35 expressing dendritic cell line is able to exert immune 
modulation functions on T cells and demonstrate that the expressed transgene is indeed 
biologically functional. Our results support previous findings that IL-35 does not only impair 
proliferation and effector functions of CD4+ T cells, but can similarly affect CD8+ T lymphocytes. 
In contrast to the data published by Guttek and Reinhold, the activation of CD4+ and CD8+ T cells 
in absence of IL-35 cytokine was not sufficient to induce transcription of the IL-35 related 
subunits ebi3 and p35. However, CD4+ and CD8+ T cells cultured in the presence of IL-35+DCs or 
IL-35 containing supernatant did express p35 and ebi3 at least on mRNA level. By now there are 
also commercial IL-35 ELISA kits available that would allow to assays whether the induction of 
transcription is translated to protein secretion. The expression of the cytokine by CD4+ T 
lymphocytes mediates infectious tolerance by suppressing proliferation and inducing a 
regulatory phenotype on naïve CD4+ T cells termed iTr35 [32]. Our observation that IL-35+DC but 
not IL-35 containing medium led to the transcription of IL-35 subunits by CD4+ T cells suggest 
that the engagement of IL-35 alone is not sufficient to generate iTr35 cells. In accordance with 
the above mentioned Collison paper where T cells were activated with anti-CD3/CD28 in order 
to acquire suppressive ability. In addition, Guttek and Reinhold showed that 
immunosuppressants like rapamycin or dexamethasone abrogate the anti-CD3/CD28 activation 
induced IL-35 production by T cells [136]. Together these findings suggest that IL-35 alone is 
sufficient to regulate T cell proliferation. But the induction of IL-35 expression by T cells depends 
on additional activating stimuli. Collison and colleagues described that the addition of IL-10 
enhances the conversion of naïve CD4+ T cells into iTr35. While we did find only low IL-10 
production by IL-35+DC, the question whether the addition of recombinant IL-10 or the 
combination with IL-10 expressing DCs would further increase suppressive capability by iTr35 
remains open. It might represent a possibility to augment the tolerogenic potential of the IL-35+ 
DC line. Another aspect of the IL-35+DC induced effects on T cells we did not address is the 
stability of the induced regulatory phenotype. In the experiments we performed the suppressive 
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capability of iTr35 cells was assayed directly after 4 days of conditioning by IL-35+DCs. Again, an 
elegant experiment by Collison et al. showed that in a long-term experiment the transfer of TGF-
β induced iTregs was less efficient in delaying disease development of Foxp3-/- mice than iTr35 
[32]. Thus, these observations indicate that IL-35 induced regulatory T cells can maintain their 
suppressive phenotype over a long period.  
The observed effects on CD8+T cell raises new questions whether iTr35 can also regulate CD8+ T 
cell responses and whether CD8+ T lymphocytes can acquire an IL-35 induced regulatory 
phenotype. TGF-β induced CD8+regulatory T cells have been described but the mechanisms of 
suppression by these cells are not well defined. According to the literature, the regulatory 
capability of TGF-β induced CD8+ Tregs seems to be independent from IL-10 and TGF-β (reviewed 
by [177]). Also in regard to the increasing number of reports indicating a role for IL-35 in the 
immune evasion by tumors, it would be highly interesting to further investigate the effects of IL-
35 cytokine, respectively IL-35+DCs on CD8+T cells. 
 
9.2.2 Interleukin-35+ DC induce tolerance to tumor growth 
We further investigated whether the observed suppression of T cell proliferation and function by 
IL-35+DCs can affect anti-tumor immunity. C57BL/6 mice were vaccinated before and after 
subcutaneous tumor inoculation with either tumor cell lysate pulsed, IL-35 or mock transduced 
DCs. In both cancer models we tested, the moderately immunogenic CMT93 colon carcinoma as 
well as the poorly immunogenic, aggressive B16.F0 melanoma, we observed a significantly 
increased tumorigenesis upon the transfer of IL-35+DCs when compared to the control groups. 
Surprisingly, the vaccination by tumor lysate pulsed mockDC did not lead to a delay in tumor 
growth when compared to not vaccinated mice, which indicates that the vaccination protocol 
itself might not have promoted anti-tumor immunity. However, IL-35+DCs promoted tumor 
growth was accompanied by a markedly reduced tumor infiltration by CD3+ T lymphocytes and 
an impaired IFN-γ production by CD4+ and CD8+ T cells. Interestingly we could observe an 
accumulation of CD11b+ Gr1+ in both tumor models. When the same experiment was performed 
using T and B lymphocyte deficient RAG-/- mice, we surprisingly could still observe an accelerated 
tumor growth upon vaccination with IL-35+DCs. The analysis of tumor infiltrating cells revealed 
a significantly increased proportion of CD11b+ Ly6G+ SSChi neutrophilic respectively granulocytic 
MDSC. 
These findings further confirmed the tolerogenic potential of the IL-35 expressing DC line to 
regulate T cell proliferation and effector function. To our surprise, the induction of tolerance 
against the malignancy was not only mediated through the regulation of the adaptive anti-tumor 
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response but also by affecting innate cells. While these tumor experiments were performed, a 
study was published demonstrating that tumor cells that were genetically modified to express IL-
35 enhanced the accumulation of CD11b+ Gr1+ myeloid cells in their environment and led to an 
increased vascularization [133]. These findings correspond nicely to our results and further 
reinforce the hypothesis that IL-35 mediated effects are not restricted to T lymphocytes. However, 
the study by Wang et al. raised a series of new questions. Especially the precise identity of the 
CD11b+ myeloid cell accumulating in the tumor environment and the mechanisms facilitating 
tumor growth are of interest. Our data point towards Ly6G+ neutrophils as the IL-35 responding 
myeloid population, as it is discussed further below in more detail. The depletion of MDSCs using 
anti-Gr1 antibody or the functional characterization would help to verify the contributions of to 
the accelerated tumor growth. The use of NOD-SCID mice would further allow to exclude NK cells 
as IL-35 responder cells. Another open question is whether tumor derived IL-35 acts as an 
attractant for MDSCs or whether it affects the function or survival of the myeloid cells was. In our 
experimental system the cytokine was not delivered locally at the site of the lesion, which makes 
it unlikely that IL-35 exerts direct chemoattractant functions on myeloid cells.  
 
Although the ectopic expression of IL-35 by tumor cell lines was employed in the study by Wang 
et al., they and several other recent studies have shown that a variety of human tumors express 
the IL-35 subunits p35 as well as ebi3. In addition, elevated plasma levels of the cytokine can 
indeed be detected in patients with, for example, non-small lung cancer [178]. The exact 
mechanism how tumor derived IL-35 supports tumor development is still unclear. Using a human 
epithelial derived pancreas cancer model, Nicholl et al. demonstrated that tumor-derived IL-35 
can act in an autocrine manner and promotes tumor cell proliferation through an increased 
expression of cyclins B and D while it reduces apoptosis through the expression of anti-apoptotic 
molecules like Bcl-2 [139]. In contrast, Long et al 2013 claimed that IL-35 expression by several 
human tumors leads to an induction of cell cycle arrest and increase sensitivity to TNFα induced 
apoptosis [179]. However, while we did not control for a direct effect of IL-35 expression on 
tumor growth, none of the just mentioned studies addressed possible effects on tumor associated 
myeloid cells. 
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9.3 Interleukin-35 mediates effects on non-lymphoid cells 
Over the last 2 years several studies on the effects of IL-35 on tumor cells and B lymphocytes cells 
were published, demonstrating that the cytokine is not only involved in the regulation of CD4+ T 
cells responses. However, the possible biological functions of IL-35 on responder cells other than 
T lymphocytes remains poorly investigated. Only a few studies have addressed the question 
whether cells of non-lymphoid origin are capable to response to IL-35. The observed induction of 
a tolerogenic phenotype on CD8α+ MuTu DCs as well as the acceleration of tumor growth upon 
vaccination with tumor lysate pulsed IL-35+DCs in T and B cell deficient mice indicated an 
involvement of cells other than B and T lymphocytes. We therefore expanded our investigations 
and looked whether IL-35 can affect other cell types. 
 
9.3.1 Interleukin-35 increases neutrophil survival and proliferation 
The only indication so far that IL-35 may impose an effect on myeloid cells comes from the already 
mentioned study by Wang et al. who showed an increased accumulation of CD11b+ Gr1+ myeloid 
cells in the environment of IL-35 transfected tumors. Since the vaccination with IL-35+DC in our 
hands pointed in the same direction, we investigated the effects of IL-35 on myeloid cells in vitro 
under steady-state as well as under inflammatory conditions. The observed accumulation of 
myeloid cells may have been caused directly by the expression of IL-35 or indirectly through 
other tumor derived factors. We therefore sought for experimental approaches that exclude such 
effects. 
An increased relative as well as absolute number of CD11b+ Ly6G+ neutrophils could be detected 
after in vitro culture of T cell depleted splenocytes in the presence of IL-35 containing but not 
control supernatant. Moreover, a higher proportion of the neutrophils exhibited an activated 
phenotype. On the contrary, CD11b+ Ly6C+ monocytes were not found to be affected by the 
presence of IL-35. Intraperitoneal injection of the inflammatory agent thioglycollate, together 
with IL-35+DCs augmented the number of neutrophils that could be isolated from the peritoneal 
lavage. A higher percentage of those cells were found to be viable and seemed to be more 
activated.  
Thus, the addition of IL-35 containing culture medium as well as the presence of IL-35+DCs 
affected the expression of activation markers and survival of CD11b+ Ly6G+ SSCint neutrophils but 
not of monocytes or macrophages. These results indicate that the observed accumulation of 
myeloid cells (respectively neutrophils in our experiments) in the tumor environment indeed be 
a direct effect of IL-35 causing an improved survival of the cells. Depletion of neutrophils for 
example using Gr-1 antibody should at least partially reverse the tumor supporting effect of IL-
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35+DC in our model. Neutrophils are characterized by a short half-live time of only about a few 
hours (in mice) resulting in a high turnover rate. The life-span of neutrophils can markedly be 
prolonged by the activation of neutrophils under inflammatory conditions. Especially cytokines 
as IFN-γ and GM-CSF but also bacterial products and direct interactions with other cells have been 
shown to activate and prolonging the survival of neutrophils in inflamed tissue. This assures an 
optimal adaption and to the inflammatory conditions [180]. Another possibility for the increased 
accumulation of neutrophils would be an enhanced recruitment of the cells. We assume it unlikely 
that IL-35 directly mediates neutrophil attraction since no such effect has been described for any 
of the IL-12 family cytokines. It is conceivable that IL-35 might induce the expression of the 
chemokines CXCL1, CXCL2 or CXCL8, which are the main mediators of neutrophil 
chemoattraction. However, we did not yet investigate the expression of chemokines by the DCs 
or the stromal cells that come into question. 
Neutrophils are well recognized as critical players during acute infection. They are quickly 
recruited to an inflammatory site and can eliminate pathogens by various mechanisms. More 
recently, it has been reported that neutrophils express a variety of molecules as for example the 
matrix metalloprotease 9 (MMP9) indicating their involvement also in resolving inflammation 
and promoting tissue repair. Mediate regulation of adaptive immune responses by the production 
of ROS, arginase 1 or IL-10 which suppress T cell activation and function (reviewed by [181]). In 
addition, it was shown that Tregs can induce a regulatory phenotype on neutrophils in acute as 
well as in chronic inflammation [182], [183]. In regard to these finding it can be hypothesized that 
Treg derived IL-35 might expand neutrophils with anti-inflammatory properties. These 
neutrophils in turn can contribute to the resolution of inflammation by promoting tissue 
remodeling and by regulating adaptive immune responses. In the context of malignant disease, 
tumor cell derived IL-35 might serve to operate the same mechanisms in order to improve the 
survival and function of tumor associated neutrophils respectively MDSCs. Further investigation 
is needed to elucidate the effector functions of IL-35 activated neutrophils and to support this 
hypothesis. 
We are aware that more elegant and maybe less ambiguous experimental approaches exist to 
address the effects of cytokines on different myeloid cell types. Especially neutrophils are 
described to be not very resistant to manipulations ex vivo [184]. We accordingly tried to 
separate myeloid populations using different techniques including magnetic separation and 
density gradient centrifugation. However, these attempts either yielded very low purity, activated 
the cells or induced death of a large proportion of the isolated cells.  
 
  
94 Interleukin 35 expressing dendritic cell line reveals novel functions for IL-35 
9.3.2 Interleukin-35 increases endothelial cell proliferation 
The study by Wang et al. demonstrated that the expression of IL-35 by tumor cells results in the 
accumulation of CD11b+ Gr1+ myeloid cells in the tumor environment and leads to increased 
angiogenesis. This could be directly mediated by the IL-35 cytokine or indirectly through the 
factors secreted by the attracted leukocytes. In order to investigate possible direct effects of the 
cytokine, we incubated HUVEC endothelial cells either in the presence of IL-35 containing 
medium or in a transwell assay with IL-35+DCs. In comparison to control medium respectively 
control DCs, the addition of IL-35 led to a significantly faster closure of the inflicted scratch. This 
effect was accompanied by a markedly increased proportion of proliferating cells, especially but 
not exclusively at the margins of the scratch, as well as a reduction of apoptosis. 
These findings indicate that IL-35 might indeed positively affect the proliferation and survival of 
endothelial cells. We can at this point not discriminate whether the positive effect on endothelial 
cell growth is directly caused by IL-35 or whether IL-35 induces the expression of endothelial 
growth factors such as VEGF, which in turn could mediate the observed effects. A recent study by 
Nicholl et al demonstrated that IL-35 promotes the growth and reduces apoptosis of epithelial 
derived pancreas cancer cells. IL-35 induced proliferation was shown to be associated with an 
increase of cyclins B and D as well as the anti-apoptotic molecule Bcl-2 [139]. These results can 
certainly not directly be translated to non-tumorigenic, endothelial cells. Nevertheless, it 
demonstrates that IL-35 can exert effects comparable to our observations on cells of non-
hematopoietic origin. We are well aware that HUVEC cells are derived from human umbilical cord 
vein and might therefore not represent an optimal system for our purposes. However, they were 
the only endothelial cell line that was available to us at that time. In addition, murine and human 
IL-35 are well conserved from mouse to humans and other murine cytokines of the IL-12 family 
have been shown to be functional on human cells (personal communication with J. vom Berg, 
Zürich and according to the company R&D systems). In a next step we want to verify our findings 
in vitro by performing similar scratch assays using the murine endothelial line C166 respectively 
primary murine endothelial cells. Whether the enhanced endothelial growth translates in vivo 
into an improved vessel formation can be assayed by looking at the vascularization of tumors 
upon vaccination with IL-35+DCs as it was performed above. In order to better understand the 
molecular mechanisms involved in the response to IL-35, it would be interesting to analyze the 
signaling pathways and target genes targeted in endothelial cells upon IL-35 engagement. 
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10 Application of tolerogenic DC lines for the of the treatment and 
prevention of unwanted inflammation  
 
10.1 Induction of tolerance to autoimmune encephalitis 
Experimental autoimmune encephalitis, is caused by the infiltration of myelin-specific Th1/Th17 
cells that in turn attract and instruct mature myeloid cells to destroy the CNS parenchyma. DCs 
were shown to be involved in the priming and activation of myelin specific T cells. The modulation 
of DC function by the expression tolerogenic molecules might therefore represent a promising 
approach to limit or even prevent EAE.  
Since we had some difficulties to elicit robust and reproducible disease course we decided to use 
an adoptive transfer EAE model as it was described [155] instead of the widely used active 
induction of EAE. Besides the more reliable EAE induction, the use of the adaptive transfer EAE 
allowed us to prolong the time the (auto-reactive) T cells can interact with the dendritic cell lines 
expressing tolerogenic molecules.  
10.1.1 Active TGF-β expressing DCs prevent EAE through the induction of Foxp3+ 
regulatory T cells: 
Transfer of actTGF-β DCs alone was sufficient to completely suppress the development of EAE 
associated symptoms. No reduction of IFN-γ or IL-17 expressing CD4+ T cells could be observed 
in the CNS draining cervical lymph nodes, while the number of Foxp3+ CD4+ regulatory T cells was 
significantly increased. Interestingly, only minimal, scattered CNS infiltration by CD3+ T cells was 
observable in any of the mice. We can therefore assume that the induction of tolerance towards 
EAE by actTGFβ+DCs was caused by the induction or expansion of Foxp3+ regulatory T. The lack 
of any CNS T cell infiltration indicates that the regulatory T cells did not suppress effector T cells 
in situ but rather prevented the migration from peripheral lymphoid tissue to the CNS. Since an 
increased proportion of Foxp3+ Tregs was already detectable during the in vitro restimulation of 
donor mouse derived lymph node cells, we suppose that the protective Tregs were generated in 
vivo during the priming of CD4+ T cells in the donor mice. Whether the Foxp3+ Tregs were 
generated by the expansion of nTregs, their elevated survival or the induction of regulatory T 
cells from naïve CD4+ T cells can only be speculated and would need further investigation. The 
protective role of regulatory T cells in the prevention of EAE has already been described by 
different studies: While the depletion of Tregs exacerbates EAE disease, the adaptive transfer of 
Tregs suppresses CNS infiltration by effector T cells and ameliorates disease. Interestingly, the 
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injected Tregs did not traffic into the CNS but rather accumulated in spleen and lymph nodes 
[185], [186]. 
Mice that were treated with DCs expressing the latent form of TGF-β exhibited an intermediate 
disease course. The latent complex has to be cleaved in order to become biologically active. Since 
the in vitro restimulation of donor mice derived lymph node cells did not show major differences 
in the proportions of IFN-γ or IL-17 expressing effector cells nor of Tregs, it appears that latent 
TGF-β does exert any regulatory functions during the priming phase of adaptive transfer EAE and 
thus might be cleaved only during the effector phase in the recipient mice.  
10.1.2 Interleukin-35 expressing DCs reduce EAE severity 
We performed only one experiment applying IL-35+DCs in the adaptive transfer EAE model. The 
results have therefore to be considered as preliminary. Nevertheless, the significant reduction of 
disease incidence and severity when compared to the control groups suggest IL-35 to be a 
promising candidate molecule. This result is in agreement with previous findings by Shen et al 
who could demonstrate that IL-35 expression by B cells contributes to the recovery from EAE. In 
their hands B cell-derived IL-35 limited disease by reducing the functional properties of the 
pathogenic Th1 and Th17 cells [38]. In our hands, Flow cytometric analysis of the ex-vivo 
restimulated lymph node cells from the immunized donor mice did not affect effector function of 
the T cells. However, in vitro restimulation in the presence of MOG pulsed IL-35+DC seemed to 
inhibit the proliferative response of the donor mice derived T cells.  Histological analysis revealed 
a drastically reduced CNS infiltration of CD3+ T cells. Although IL-35 expressing DCs seem to 
partially inhibit EAE pathogenesis in our model, the preliminary results do not allow to draw 
conclusions on the cellular mechanisms explaining the observations. The experiment will be 
repeated in order to verify our findings paying particular attention on the B cell phenotype as 
suggested by the study mentioned above.  
 
10.1.3 Interleukin-10 expressing DC do not affect EAE development 
IL-10 expressing DCs did not affect EAE development in our hands (A. Duval, data not shown). 
This findings are in discrepancy to the literature showing that IL-10 limits EAE progression by 
different means. For example have draining lymph node resident, regulatory plasma cells been 
proposed to be required to limit EAE development in a IL-10 dependent manner [187]. 
Interestingly, the secretion of IL-10 by regulatory B cells has been shown to be associated with 
IL-35 expression [38]. In addition, the repetitive stimulation of effector Th1 cells in the presence 
of TGF-β was found to induce IL-10 production by IFN-γ+ Th1 effector cells. An increased 
frequency of these double producers was associated with a reduced CNS infiltration and less 
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severe EAE [150]. Although these observations underline the importance of IL-10 for controlling 
EAE disease, the expression of IL-10 by MuTu DCs was not sufficient to reduce EAE severity in 
our hands. 
 
10.2 A combination of IL-10 and activeTGF-β expressing DC lines prolong 
skin graft survival 
Allotransplantation of tissues or organs evokes strong inflammatory responses leading to the 
rejection of the graft over time. Current treatment mainly consists of broad-range 
immunosusspression which is non-specific and increases the risk to develop infection and 
malignancy. The need for new strategies that allow a specific suppression of transplant-directed 
immunity is therefore obvious. T cells are the main mediators of graft rejection whereas DCs are 
considered responsible for the induction of graft-directed adaptive immunity [156]. In contrast 
to autoimmune diseases, transplantation in many cases allows a preventive transfer of (donor-
derived) dendritic cells. It therefore can be hypothesized that by the modulation of dendritic cells 
we may be able to suppress donor-reactive T cells or induce Tregs. Indeed, a recently published 
meta study showed that the transfer of tolerogenic DC generally prolongs skin allograft survival 
[157] demonstrating the general feasibility of this approach. The molecular mechanisms 
underlying DCs for induction of allograft tolerance largely remained poorly understood. 
For practical reasons we chose a skin graft model to test our hypothesis. Transplanted skin is 
generally acutely rejected despite intensive immunosuppressive therapy and thereby represents 
one of the most immunogenic tissues in allotransplantation. Any observed change in graft 
survival therefore can be assumed to be the result of a strong modulatory effect. In a full MHC 
mismatched setting the transfer of a combination of donor derived IL-10 and active TGF-β 
expressing DCs was not sufficient to delay graft rejection in. It can be assumed that the elicited 
transplant-directed immune response was too potent to be overcome respectively that a possible 
tolerogenic effect did not translate into an observable change in graft rejection. 
When multiple minor mismatched skin was grafted, the transfer of IL-10 together with activeTGF-
β expressing DCs reproducibly delayed rejection of C57BL/6 skin allografts. Surprisingly no effect 
on graft survival could be observed upon the transfer of only one of the respective DC lines. These 
results indicate complementary mechanisms that lead to a synergistic tolerogenic effect. In 
addition, we found that the transfer of IL-35 expressing DCs alone has a minor but statistically 
significant positive effect on graft survival. In a preliminary experiment, the analysis of peripheral 
blood lymphocytes harvested 7 days after skin transplantation did not reveal a consistent 
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mechanism responsible for the synergistic effect. Besides some technical issues it might be 
possible that blood leukocytes do not reflect the tolerogenic DC induced effects at the site of 
engraftment. We are planning to repeat the experiment and will analyze lymphocytes infiltrating 
the graft, within the draining lymph node and the spleen 7-10 days after transplantation.  
As opposed to our observations, different studies have shown that the in vivo administration or 
transfection of TGF-β alone can delay allograft rejection [188], [189]. Experiments by Daley and 
colleagues have shown that TGF-β signaling is not required for the suppression of graft-reactive 
effector T cell function but it mainly act through the induction or expansion of Foxp3+ Tregs [190]. 
IL-10 seems to play a dual role in the context of transplantation: On one side IL-10 inhibits the 
stimulatory activity of dendritic cells and contributes to graft tolerance in a dose-dependent 
manner. While high doses of recombinant IL-10 have been shown to reduce allograft survival in 
rats by the attraction of neutrophils, low doses prolonged graft rejection [191]. Another study 
showed that the transfer of DCs expressing viral IL-10 does not prolong skin graft survival. In 
their hands the secreted vIL-10 seemed to inhibit Th2 responses while promoting IFNy 
production by neutrophils or NK cells [192]. In concordance with our results, a potent synergistic 
effect was described when combining IL-10 and TGFβ. Several studies have demonstrated that 
IL-10 and TGF-β can cooperate in order to maximize the potential of each cytokine to induce 
hyporesponsive T cells respectively Tregs [193], [194]. The mechanisms underlying this 
synergistic effect are not completely understood. However, it was for example shown that IL-10 
upregulates TGF-β receptor expression on effector and memory T cells rendering them 
susceptible to TGF-β mediated Treg induction [195]. Less is known about the role of IL-35 in 
transplantation. In fact only two published studies investigated the role of IL-35 in the context of 
transplantation. Both suggest IL-35 to be important for the expansion of Foxp3+ regulatory T 
cells: Antibody mediated depletion of IL-35 has been shown to reduce skin graft survival and led 
to a reduced transplant infiltration by Foxp3+ Tregs [196]. In vivo transfection with an IL-35 
expression vector delayed cardiac graft rejection associated with a systemic increase of Treg 
[137].  
So far we have acquired only very limited data record on T cell function and phenotype. We 
therefore cannot speculate yet why the transfer of IL-10+ or actTGFβ+DC alone did not improve 
graft viability or why the combination of both DC lines did. Nevertheless, the results indicate that 
our tolerogenic DC lines represent a useful platform for further improvement of DC-based 
therapy. In a next step we will therefore investigate whether other combinations of tolerogenic 
DC lines, for example IL-35+DC together with actTGF-β expressing DCs might also exhibit 
synergistic effects. We intentionally refrained from using immunosuppressive drugs in the 
experiments presented here in order to maintain the experimental system as simple and clean as 
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possible. The combination with initial administration of immunosuppressive drugs might further 
enhance graft survival by dampening the initial inflammatory response inflicted by the procedure. 
Finally, we will try to decipher the cellular mechanisms underlying the observed (synergistic) 
effects as described above. 
 
11 Augmentation of antitumor immunity applying a semi-
allogeneic DC line 
 
The application of dendritic cells for cancer immunotherapy has been studied with a great 
interest. Nevertheless, current DC vaccination strategies are still limited by the low affinity of 
tumor antigens, not optimal DC maturation and activation protocols and other difficulties. 
Current vaccination approaches induce tumor specific adaptive immunity in vitro an in rodent 
models. But they generally fail to translate into a robust, therapeutically relevant response in 
(pre-) clinical trials. The application of gene-modified DCs, expressing immunostimulatory 
molecules are therefore thought to enhance the efficacy of DC vaccination by directing antigen 
delivery and overcoming the immune suppressive environment of the tumor  
For this second project we took advantage of the access to the MuTu dendritic cell line. We sought 
to apply the cell line as a tool to investigate how to improve the immunogenicity of DC based 
cancer vaccines. The DC line allowed us to investigate in a standardized fashion in terms of DC 
phenotype and activation status and provided availability infinitive numbers of cells for 
experimentation.  
 
11.1.1 Semi-allogeneic DC vaccination interferes with CT26 tumor growth 
In a first approach to augment immunogenicity of DC cancer vaccines we tested a so called “semi-
allogenic” vaccination. The C57BL/ derived MuTu DC line was transduced in order to express the 
MHC class I molecule H2-K of the BALB/c haplotype H2-d. Tumor bearing BALB/c mice were then 
vaccinated using this DC line and the effect on tumor growth was observed. We proposed that 
semi-allogeneic DC-based vaccines may induce an even stronger vaccine-specific immune 
response than autologous DCs for two reasons: Since an estimated 1–10% of the circulating T cell 
repertoire is directed against allo-antigens, allogeneic DCs may trigger a broadly reactive T cell 
response providing CD4+ T cell help for an optimal activation of cytotoxic T lymphocytes. The 
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expression of the autologous H2-K molecule allows the presentation of tumor antigens in the 
context of self-MHC, thereby priming a specific cytotoxic T lymphocyte response. 
Various parameters like adequate activation and delivery route of the DCs influence the efficacy 
of a DC based vaccine. By varying dendritic cell to CT26 tumor lysate ratio, duration of activation 
or the supplementation with stimulatory molecules the conditions that lead to a maximal 
activation of the Kd+DCs were determined. Using these conditions for the activation of Kd+DC, we 
could observe similar or even more proliferation by cocultured BALB/c derived CD4+ and CD8+ T 
cells when compared to CpG and IFN-γ activated DCs. The production of IFN-γ but only basal 
levels of IL-17a upon coculture indicated that the T lymphocytes were probably polarized 
towards a Th1 phenotype. Due to lack of an adequate H-2Kd-restricted tetramer we were 
unfortunately not able to assay CT26 specific cytotoxic responses elicited by Kd+DCs primed CD8+ 
T cells. 
Next, the impact of vaccination on tumor growth was assayed by transferring CT26 lysate pulsed 
Kd+DC (semi-allogeneic) or wtDC (fully allogeneic) into tumor bearing mice. As expected, semi-
allogeneic vaccination reproducibly and statistically significant delayed tumor growth and 
prolonged survival when compared to not vaccinated or full allogeneic DC vaccinated mice. 
Surprisingly the autologous vaccination of (BALB/c x C57BL/6) F1 mice with Kd+DCs did 
significantly accelerate tumor growth. We expected the DC vaccination to predominately affect 
the frequency and possibly also the function of CD8+ lymphocytes. However, Flow cytometric 
analysis of tumor infiltrating, draining Lymph node and spleen resident leukocytes did not allow 
to correlate the observed slowed tumor growth to a cellular mechanism causing this effect. 
Whereas in the tumor the frequency of total CD3+ T cells did not significantly change only a minor 
reduction of the Treg to CD8+ T cell ratio was measured upon transfer of KD+ DCs into BALB/c 
animals. Kd+DC vaccinated F1 mice exhibited a remarkably increased total CD45+ leukocyte 
infiltration together with an slight increase in Tregs and CD11b+ myeloid cells, which might at 
least partially explain the accelerated tumor growth. It should be mentioned that the all the 
organs were harvested at the same time point after tumor inoculation. The observed differences 
especially of tumor infiltrating cells might therefore rather be caused by the different size and 
developmental level of the tumor than really representing an effect of the DC vaccination. In 
addition, some of the variation might has been caused by practical difficulties during the isolation 
tumor infiltrating cells.  
Although we were not able to reveal the cellular mechanisms involved, the observed delay in 
tumor growth confirmed the applicability of the “semi-allogeneic” DC vaccination approach. Due 
to its availability and the convenience of genetic modifications, the MuTu DC line a convenient 
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tool to further investigate how DC based tumor vaccines can be improved. Especially in regard to 
clinical application, the use of partially mismatched or semi-allogeneic DCs has some major 
advantages: It can be used as an “off the shelf” treatment, thereby bypassing the need for 
individually prepared vaccines. This represents a considerable logistic advantage and allows the 
preparation of large clinical-grade batches of a more standardized DC vaccine in terms of 
phenotype and maturation status. (Pre) clinical studies applying allogeneic DCs / autologous 
tumor hybrid cells or partially HLA-matched allogeneic DCs are currently being conducted [197]. 
11.1.2 Generation of DC lines expressing proinflammatory cytokines 
As a second approach to increase the immunogenicity of DC based cancer vaccinations, we 
generated MuTu dendritic cell lines constitutively expressing the cytokines IL-2, IL-12 or IL-15. 
We hypothesized that the local delivery of these T cell stimulating cytokines, combined with the 
semi-allogeneic vaccination, might further promote tumor specific adaptive responses. Although 
we could clearly detect the expression of the respective transgene by the DCs, in vitro 
proliferation assays did not result in improved CD4+ or CD8+ T cell proliferation or function. 
Maybe the concentrations of the respective OVA peptides used in the experiments was already 
sufficient to induce maximal proliferation and activation of T cells covering a potential effect of 
transgene expression. In order to assay a possible beneficial effect of cytokine delivery, tumor 
bearing mice were vaccinated with tumor cell lysate pulsed Kd+DCs expressing any of the 
cytokines. Unfortunately we could not observe a more potent response on tumor growth or 
survival of the animals. 
The observed results are somewhat surprising, as the proinflammatory properties IL-12 and IL-
15 are well documented. Several studies have shown regression of established tumors applying 
transfected dendritic cells (reviewed by [198]). We can only speculate why the combination of 
semi-allogeneic vaccination with the delivery of the cytokines did not lead to further delay of 
tumor growth. On reason might base on the finding that MuTu Dc injected into immunocompetent, 
autologous hosts has been shown to be rejected within 8 to 13 days [130]. In an allogenic context 
the DCs are probably rejected even quicker. Thus the timeframe the DCs have to migrate to the 
tumor draining lymph nodes and can provide interacting T cells with the cytokines may not be 
sufficient. It might have been better to test a potential beneficial effect first in an autologous 
vaccination setting. Another possibility is that the intravenous injection route might not allow an 
adequate delivery of the cytokines. The inflammatory stimulus provided by the cytokine might 
not be required in the lymphoid organs but rather in the tumor environment in order to support 
anti-tumor immunity. Indeed, the local, subcutaneous or intratumoral administration of IL-12 or 
IL-15 expressing DCs has been shown to delay or even prevent tumor development [199], [200]. 
Only the concomitant, systemic delivery of IL-2 has been shown to enhance the anti-tumor effects 
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of DC vaccination [201]. It might therefore be interesting to compare different delivery routes of 
the cytokine expressing DCs.  
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12 Conclusion & Outlook 
 
In this study we demonstrated the MuTu dendritic cell line represent an excellent tool to 
investigate how dendritic cells modulate immune responses and how this regulation can be 
altered according to our requirements. In contrast to endogenous or bone marrow derived DCs, 
the MuTu cell lines represents a homogenous population that is easily genetically modifiable and 
is available in infinite amounts without the need for large quantities of mice. These features allow 
us to define and characterize optimal DC based treatment approaches before applying ex vivo 
derived dendritic cells. 
The results presented here constitute a rather broad overview of how dendritic cells modified to 
express tolerogenic molecules can influence the outcome of inflammatory responses. The study 
therefore may be more descriptive than it explains the observations. The cellular and molecular 
mechanisms underlying several of the observed tolerogenic responses remain unidentified or 
have been only superficially analyzed. However, the findings raise many new questions. For 
example on the effector mechanisms of IL-35, on the failure of cytokine expressing DCs for cancer 
vaccination or the persistence of DC induced tolerance in vivo. Some of these open questions are 
mentioned in the discussion part of the thesis and should to be addressed experimentally. 
 
12.1 Conclusions tolerogenic DCs  
As summarized in table 4, we could demonstrate the tolerogenic potential for several of the 
investigated molecules. Our result indicate that different mechanisms, such as autocrine effects 
on the DCs itself, direct inhibition of T cell proliferation or the induction of different Treg 
populations, are involved in tolerance induction by the DC lines. This finding suggests that the 
combination of different tolerogenic effector molecules might evoke synergistic effects, 
multiplying the tolerogenic potential, as it was for example shown in the skin transplantation 
model.  
Active TGF-β as well as IL-35 expressing MuTu DCs have shown to induce immunologic tolerance 
in both autoimmune encephalitis as well as skin transplantation models. Although the results 
obtained in this study can certainly not directly be adapted for the clinical applications, they 
demonstrate the feasibility and potential of the tolerogenic DCs for immunotherapeutic 
approaches for autoimmune disorders, organ transplantation or in cancerous disease. 
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Table 4 Overview on the DC lines expressing tolerogenic molecules created in our lab  
 
12.2 Novel cellular targets for IL-35 
The results we generated show that IL-35 does not only regulate inflammatory responses of B 
and T lymphocytes but it can furthermore affect myeloid as well as non-hematopoietic cells. We 
are, to our knowledge, the first to describe dendritic and stromal endothelial cells as IL-35 targets. 
Our work therefore adds new insights in the functions of this poorly investigated cytokine. It 
furthermore underlines the importance for the regulation of inflammatory responses and makes 
IL-35 a promising target for the therapeutic modulation of immunity. As depicted in Fig.33 we 
Transgene  Effect on T cells 
 DC maturation state in vitro in vivo 
CTLA-4 
Lower CD80/86 in steady state 
and upon activation, less IL-12, IL-
6 
Generation of 
hyporesponsive T cells 
induction of tumor 
tolerance 
IL-10 
Lower CD80/86 &CD40 upon 
activation, less IL-12, IL-6 
reduced IFN-γ 
secretion by T cells 
delays skin graft 
rejection with 
actTGFβ+DCs 
Latent TGFβ No change of activation markers 
induction of Tregs and 
prevention of CTL 
development 
limits EAE, ?  
Active TGFβ No change of activation markers 
induction of Tregs and 
prevention of CTL 
development 
induction of tumor 
tolerance 
prevention of EAE 
development, 
delays skin graft 
rejection with IL-
10+DCs  
IL-35 
  
Lower MHC-II and costimulatory 
molecules, upregulation of CD11b,  
generation of iTr35 
cells, moderate 
inhibition of CTL 
responses 
Seems to limit EAE 
, delays graft 
rejection, induces 
tolerance towards 
tumor growth, 
ongoing 
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propose an extended model for the function of IL-35 that takes into consideration our 
observations. As already mentioned, the functional consequences of IL-35  
 
Figure 33 Indirect mediation of immune suppression and propagation of infectious tolerance by IL-35: In 
addition to the already described effects on T cells, our findings show that non-lymphoid cells can be targets of IL-
35.  
 
remain poorly understood and it would be very interesting to elucidate how IL-35 instructed 
endothelial or granulocytic cells exactly contribute to the regulation of inflammation and to what 
extend these mechanisms are relevant in vivo.  
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13 Materials 
 
13.1 Chemicals 
Chemical Supplier Comment 
2-Mercaptoethanol 50mM Gibco No. 31350-010 
Agarose Eurogentec 500g, No.83018A 
Ammonium Persulfate BioRad 161-0700 
Ampicillin (Amp) Sigma 5g, No.A9518 
Bovine Serum Albumin (BSA)   
Blotto, non-fat dry milk Santa Cruz Biotech No. sc-2325 
Brefeldin A Sigma B7651-5MG 
DNase & RNase free ddH2O Gibco 10977-035 
eFluor 670 cell cell proliferation dye eBioscience 65-0840 
Ethanol 100% (V/V) Fluka Analytical 02860-2.5L 
Fetal calf serum (FCS) Pan Biotech P40-37100M 
GelRed Biotium No.41003 
 HEPES 1M Gibco 15630-080 
15630-080 
 
Isopropanol Fluka Analytical 59310-2.5L-F 
Ionomycin Calbiochem 407950 
Methanol Reactolab 99046 
Mitomycin C Sigma No.M-0503 
Percoll GE Healthcare No.17-0891-01 
Phosphat Buffered Saline solution (PBS) MagBil  
phorbol 12-myristate 13-acetate (PMA) Sigma P8139 
Sodium Pyruvate Gibco 11360-039 
SYBR Safe DNA Stain Life Technologies S33102 
TEMED Sigma T-8133 
Thioglycollate Broth Fluka Analytical 70157-100G 
TransIT 293 transfection reagent Mirus MIR 2700 
TRIzol Ambion 15596026 
Table 5 Chemicals 
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13.2 Buffers and Solutions 
Buffer/Solution Content/Application Comment 
0.25% Trypsin with EDTA  Gibco, 25200-056 
ProtoGel Stacking Buffer  0.5M Tris HCl 0.4% SDS, pH6.8 National Diagnostics, 
EC-893 
1.5M Tris HCl Buffer pH 8.8 PAGE separation buffer BioRad 161-0798 
ProtoGel 
30% Acrylamide: 0.8% Bis-
Acrylamide Stock solution 
(37.5:1) 
National Diagnostics 
EC-890 
40% Acrylamide/Bis Solution, 
19:1 
For PAGE BioRad, 161-0144 
Dulbecco’s Modified Eagles 
Medium(DMEM) + GlutaMAX 
 Gibco, 31966-021 
ELISA Assay Diluent 10% FCS in PBS  
ELISA Coating buffer 
1l dH20, 8.4g NaHCO3, 3.56g 
Na2CO3, pH 7.0 
 
ELISA wash buffer 1x PBS, 0.05% Tween20  
Erythrocyte lysis buffer  
155mM NH4Cl, 10mM KHCO3 
,1mM EDTA at pH 7.3, sterile 
filtered 
 
FACS buffer 1x PBS, 2% FCS, 5mM EDTA  
Iscove’s Modified Dulbecco’s 
Medium (IMDM) + GlutaMAX 
 Gibco, Nr. 31980-022 
   
LB powder  AppliChem 
Lenee Buffer  
20ml Glycerol, 25ml 0.5M Tris 
pH6.9, 0.02g Bromophenol Blue, 
6g SDS, 5ml DTT 
 
PFA 4% Paraformaldehyde in PBS  
RIPA Buffer  SIGMA, R0278 
Roswell Park Memorial 
Institute Medium 1640 (RPMI) 
 Gibco, 21875-034 
Saponin Cell Permeabilization 
Buffer 
PBS, 3% FCS, 0.5% Saponin 
Filtered, stored at 
4°C 
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SDS electrophoresis buffer 
15,1mg/ml Tris Base, 72mg/ml 
Glycine, 5 mg/ml SDS in H2O) 
 
SOC medium 
2% w/v tryptone (20g), 0.5% w/v 
bacto-yeast extract (5g), 10mM 
NaCl (0.584g),2.5mM KCl, 
(0.186g), 10mM MgCl2 (0.952g), 
10mM MgSO4, 20mM glucose 
(3.603g), ddH2O to 1000mL, pH7 
Invitrogen, 
No.15544-034 
Spleen digestion buffer 
RPMI1640+Glutamax, 10% 1M 
Hepes, 3% FCS, 1/500 
Gentamycin, 1/1000 Collagenase 
D, 1/25 DNase A at1mg/ml 
Always add 
collagenase and 
DNase fresh 
Tris-acetate-EDTA (TAE) 
electrophoresis buffer 
40mM Tris-acetate, 1mM EDTA  
TE buffer 10mMTris pH7.5, 1mM EDTA  
TENS solution 0.1M NaOH, 0.5% SDS in TE 
buffer 
 
WB Transfer Buffer  
10% ethanol, 10% 10x 
Tris/Glycine (30mg/ml Tris, 44 
mg/ml Glycine), 80% H2O 
 
WB Separating gel 10% 
5ml 30% Acrylamide/0.8% Bis 
Acrylamid, 3.75ml TRIS HCL/SDS 
pH 8.8, 6.25ml dH2O, 50µl 
10%APS, 10 µl TEMED 
Enough for two 8-
pocket gels 
WB Stacking Gel 
0.65ml 30% Acrylamide/0.8% Bis 
Acrylamid, 1.25ml TRIS HCL/SDS 
pH 6.8, 3.05 ml dH2O, 25µl 
10%APS, 5µl TEMED 
Enough for two 8-
pocket gels 
Table 6 Buffers and Solutions 
 
 
 
 109 Materials 
13.3 Kits and Consumables 
Kits/ Consumable Supplier Comment 
100bp DNA ladder Invitrogen No.15628-019 
1kb DNA ladder Invitrogen No.15615-016 
2-Log DNA ladder NEB N3200 
Cell Strainer 40µm BD Falcon No.352350 
96 deep well plate 
 
Nunc No.278743 
dNTP Mix Promega No.U1515 
ECL Prime WB detection reagent GE Healthcare RPN2232 
Foxp3 staining  buffer set eBioscience No.00-5523-00 
OptEIA Mouse Il-12(p40) ELISA BD Bioscience No. 555171 
QIAquick PCR Purification Kit  
 
Qiagen No.28106 
QIAprep Spin Maxprep kit Qiagen No. 27106 
QIAprep Spin Miniprep kit Qiagen No. 12163 
Wizard SV Gel and PCR Clean-up 
Promega 
Promega A2982 
Protein A/G PLUS Agarose Santa Cruz 
Biotech 
Sc-2003 
Rapid DNA ligation Kit Roche No. 11 635 379 001 
RNeasy RNA extraction Kit Qiagen  
SYBR FAST qPCR Kit (optimized for 
use with Roche LightCycler 480) 
Kapa 
Biosystems 
KK4610 
Table 7 Kits and consumables 
 
13.4 Antibodies 
For flow cytometry the antibodies against following molecules were used:  
Antibody Clone Colors used Manufacturer 
CD11b M1/70 APC, PE eBioscience 
CD11c HL3 APC Biolegend 
CD45.1 30-F11 Pe eBioscience 
CD45.2 104 Fitc eBioscience 
CD4 RM4-5 APC, efluor450 eBioscience 
CD8α 53-6.7 
FITC, APC-Cy7, Pacific 
Blue 
eBioscience 
Foxp3 FJK-16a Pe-Cy5 eBioscience 
IFNγ XMG1.2 Pe eBioscience 
MHC-I (H-2Kb) AF6-88.5.5.3 APC eBioscience 
MHC-II M5/114.15.2 PerCp  BioLegend 
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Pan NK cells (CD49b) DX5 Fitc eBioscience 
DEC205 205yekta PerCp-ef710 eBioscience 
Clec9A 42D2 PE eBioscience 
GR-1 RB6-8C5 
Pe 
PerCP-PeCy5.5 
BioLegend 
eBioscience 
CD40 1C10 APC, Pe eBioscience 
CD80 16-10A1 Brillian Violet 421 BioLegend 
CD86 GL1  PeCy7 BioLegend 
Ly6C HK1.4 APC eBioscience 
Ly6G 18A PerCp-Cy5.5 BioLegend 
Table 8 Antibodies for flowcytometric analysis 
For immunohistochemistry the following antibodies were used: 
Antibody Clone Colors used Manufacturer 
CD3    
Cleaved Caspase3   Cell signaling 
KI67 B56, mouse IgG1κ  BD pharmigen 
VEcadherin 180215, mouse 
IgG2b 
 R&D systems 
Table 9 Antibodies used for immunohistochemistry 
For Immunoprecipitation and Western blot the following antibodies were used:  
Antibody Clone Manufacturer 
Ebi3 V1.4C4.22, V1.4H6.29  Shenondoah Biotech 
p35 45806 R&D systems 
Table 10 Antibodies used for IP and western blot 
 
13.5 Competent cells 
E.coli Top10 (Invitrogen): F- mcrA (mrr-hsdRMS-mcrBC) 80lacZ M15 lacX74 recA1 ara
139 (ara-leu)7697 galU galK rpsL (StrR) endA1 nupG 
E.coli MAX Efficiency DH5α (Life Tecchnologies, 18258-012): F- Φ80lacZΔM15 Δ(lacZYA-argF) 
U169 recA1 endA1 hsdR17 (rk-, mk+) phoA supE44 λ-thi-1 gyrA96 relA1. 
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13.6 Enzymes 
All restriction enzymes utilized were obtained from New England Biolabs (Ipswich MA, USA) and 
used according to manufacturer’s instructions. All other enzymes are described with the methods 
they were used in. 
Enzymes Supplier Comment 
Antarctic phosphatase NEB M0289 
DNase I Roche  
20mg/ml in RPMI 
Cat.No.104159 
Collagenase D Roche 11088866001 
Platinum Taq DNA Polymerase High Fidelity Invitrogen  
RNase A Qiagen Cat. No. 19101 
Superscript reverse transcriptase II Life Technologies 18064-014 
T4 ligase NEB M202 
T4 polymerase NEB M0203 
Taq DNA polymerase 
 
NEB Cat.No.M0273 
Table 11 Enzymes 
 
13.7 Plasmids 
Detailed maps of the vectors are listed in the appendix  
Plasmid Supplier Comment 
pWP-SIN-cPPT-WPRE)-
CMV-IRES-GFP  
Strategene 2nd generation lentiviral expression plasmid. 
≈10350bp, nobody knows where we got it from 
pRRLSIN.cPPT.PGK-
GFP.WPRE 
Trono Lab, EPFL 
Lausanne 
2nd generation lentiviral expression plasmid. 
Addgene plasmid # 12252, 7384bp 
psPAX2 Trono Lab, EPFL 
Lausanne 
2nd generation lentiviral packaging 
plasmid. Addgene plasmid # 12260. 10703bp 
pMD2g Trono Lab, EPFL 
Lausanne 
VSV-G envelope expressing plasmid. 
Addgene plasmid # 12259. 5824bp 
Table 12 Plasmids 
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13.8 Software 
Software Supplier Purpose 
AxioVision Zeiss Image aqcuisition microscopy 
Mendeley Desktop Mendeley Ltd. Paper Organization 
FACSDiva BD Biosciences FACS acquisition /analysis 
FlowJo X Tree Star Inc. Analysis Facs data 
Illustrator CS6 Adobe  
Prism 6 GraphPad Graphics and statistics 
Office 2013 Microsoft  
Photoshop CS6 Adobe  
qBase Biogazelle Analysis rtPCR data 
VectorNTI 10.3.1 Invitrogen In silico cloning 
Table 13 Software  
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14 Methods 
 
14.1 Generation of transgenic DC lines 
 
14.1.1 Cloning strategy 
All primers were designed using the “Primer-BLAST” tool on the NCBI homepage 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?) and ordered from Microsynth, 
Switzerland. 
Oligonucle
otide 
Description Sequence 5’ -> 3’ 
SalIEbi3fw SalI kozak Ebi3 GTCCG GTCGACGCCACCATGTCCAAGCTGCTCTTC 
linkerEbi3r
ev 
ebi3, no stop 
codon! 15bp of 
linker 
CGAGCCACCGCCTCCGGGCTTATGGGGTGC 
linkerfw 26bp linker GGAGGCGGTGGCTCGGGCGGTGGTGG 
SalIp35rev 
SalI, p35incl 
stop codon! 
AGCTCGTCGACtcaGGCGGAGCTCAGATA 
SalIIl12fw IL-12Fc cloning GTCCG GTCGACCTCGCAGCAAAGCAAGAT 
FctagSalIrev  CGCTCGTCGACTGTTCTCATTTACCAGGG 
BamHIIl2fw IL-2 cloning GTCCGGGATCCGCCACCATGTACAGCATGCAGCTC 
SalIIl2rev  GGCTCGTCGACTTATTGAGGGCTTGTTGA 
BamH1IL15
Rafw 
Il15ra forward 
from  
TGATAGATCCGCCACCATGGCCTCGCCGCAGCT 
Sal1IL15Rar
ev 
reverse AGCTCGTCGACTTAGGCTCCTGTGTCTTC 
 rtPCR primers  
p28rtPCRfw  CATGGCATCACCTCTCTGAC 
p28rtPCRre
v 
 AAGGGCCGAAGTGTGGT 
p35RTfw  AAATGAAGCTCTGCATCCTGC 
p35RTrev  TCACCCTGTTGATGGTCACG 
p40RTfw  GGAAGCACGGCAGCAGAATA 
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p40RTrev  AACTTGAGGGAGAAGTAGGAATGG 
ebi3RTfw  ATG TCC AAG CTG CTC TTCCT 
ebi3RTrev  AGA GGA GTC CAG GAG CAG TC 
IL2RTfw  CCT GAG CAG GAT GGA GAA TTA CA 
IL2RTrev  TCC AGA ACA TGC CGC AGA G 
IL-15rtfw  AACTGGATAGATGTAAGATATGACC 
IL-15rtrev  GGACGTGTTGATGAACATTT 
gp130fw  CGTGGGAAAGGAGATGGTTGTG 
gp130rev  AGGGTTGTCAGGAGGAAGGCTAAG 
il12rb2fw  TGTGGGGTGGAGATCTCAGT 
il12rb2rev  TCTCCTTCCTGGACACATGA 
IDO1fw  ACT GTG TCC TGG CAA ACT GGA AG 
IDO1rev  AAG CTG CGA TTT CCA CCA ATA GAG 
Table 14 Primers used for cloning or rtPCR 
 
Genes of interest were amplified by PCR from different templates using the primers indicated in 
table 14 and Hifi Taq polymerase. IL-12Fc and IL-35p35 were obtained from the expression 
vector BBV74, a courtesy of Burkhard Becher, University of Zürich. IL-2 cDNA was amplified from 
cDNA of activated T cells. IL-15 and IL35ebi3 were obtained from cDNA of activated dendritic 
cells. The cloned sequences were ligated into the lentiviral expression vector. Single E.coli 
colonies were picked and integration of the transgene was assayed in a colony screening assay. 
Plasmid DNA was purified using the Plasmid Mega Kit (Qiagen) and sequenced to verify the 
integrity of the cloned gene sequences. The amplification was carried out with 0.2mM dNTP 
(Roche), 1x Expand High Fidelity Buffer (Roche), 0.35 Units Platinum High Fidelity Polymerase, 
0.5 mM specific primers and the template in a final reaction volume of 20 μl. After initial 
denaturation at 94°C for 90’’, 35 cycles of the following program was done: 30’’ at 94°C 
denaturation, 30’’ annealing at the calculated Tm-5°C and extension at 68°C for 1’ per kb. Products 
were finally amplified once at 68°C for 10’. PCR products were loaded in Sea Kem GTG agarose 
(Lonza) gels and revealed with SYBR Safe DNA gel stain (Lifetechnologies) with the use of an 
adequate DNA ladder as scale. The amplified DNA fragments were extracted from the agarose gel 
using the Wizard SV Gel and PCR Clean-up system according to the supplier’s instructions. 
 
The gene of interest was inserted into the BamHI/SalI cloning site of the lentiviral expression 
vector (pWP-SIN-cPPT-WPRE)-CMV-IRES-GFP. For this purpose, BamHI and SalI restrictions 
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sites were added to the 5’ respectively 3’ end of the PCR amplified gene of interest. TGF-β as well 
as IL-35 harbor internal BamH1 restriction sites. This problem was circumvented by adding SalI 
restriction sites at the 5’ and 3’ ends.  
 
14.1.2 Ligation and transformation 
Lentiviral expression vectors were linearized using the BamH1 and SalI or SalI only. In order to 
minimize plasmid self-ligation, the expression vectors were dephosphorylated using Antarctic 
phosphatase and the according buffer (NEB). Reaction was incubated for 15min at 37°C and 
enzyme was afterwards heat-inactivated for 10min at 65°C. Ligations were performed with 1μl 
T4 ligase (NEB) and 2μl of the according buffer. Insert and Vector DNA were added in 3:1 and 5:1 
molar ratio and dH2O was added to a total reaction volume of 20μl. Reaction was incubated for 
30min at 16°C and enzyme was subsequently heat inactivated for 10min at 65°C. Competent 
Escherichia coli MAX Efficiency DH5α where thawed on ice. 10μl of the ligation mix was added to 
50μl bacteria and incubated for 30min on ice. The bacteria were transfected by heat-shocking 
them for 40sec at 42°C. The cells were placed back on ice for 2min and 150μl SOC medium was 
subsequently added to each transfection. After incubating one hour at 37°C in the shaking 
incubator the bacterial suspension was plated on prewarmed agar plates containing the adequate 
antibiotic and put overnight into a 37°C incubator. On the following day, single colonies were 
transferred into reaction tubes containing 4ml LB medium and respective antibiotics and were 
grown over night in the shaking incubator at 37°C. 
 
14.1.3 Isolation of plasmid DNA 
Colonies were picked from an agar plate and transferred in to 96-deep well plate (DWP) filled 
with 200μl LB and adequate antibiotic. The DWP was sealed with punctured Parafilm and 
incubated at 37°C for 3h on a thermo shaker. Afterwards, 20μl from the cultures were transferred 
to a PCR plate and 90μl dH2O was added to each well. Cells were lysed at 95°C for 10 minutes 
using a PCR-cycler and subsequently centrifuged at 3000g for 5 minutes.  5μl of the supernatant 
was then taken for PCR. Primers that allow amplification of an insert fragment were chosen and 
standard PCR was performed. For the detection of correctly ligated clones, presence of PCR 
amplicons was analyzed by agarose gel electrophoresis. Positive clones were sequenced to verify 
integrity of the gene of interest. In order to obtain plasmid DNA of high purity for further cloning 
use, colonies bearing correctly ligated plasmids was extracted using QIAprep Spin Maxiprep Kit 
and following the manufacturers instruction. 
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Figure 34 Schematic overview of the cloning of the IL-35 expression vector: Ebi3 and p35 subunits were amplified 
from T cell cDNA respectively a IL-12 expression plasmid and annealed as indicated. SalI sites were added in order to 
allow cloning into the lentiviral expression vector. 
 
 
14.2 Production of Lentiviral Vectors 
 
The second generation lentiviral transduction system applied here consists of 3 different vectors: 
The expression vectors pWP-SINcPPT-WPRE)-CMV-IRES-GFP or pRRLSIN.cPPT.PGK-GFP.WPRE 
containing the gene of interest. The envelope vector pMD2G and the packaging psPAX2 provide 
the genes required for the assembly of replication deficient lentiviral particles.  
 
14.2.1 Transfection  
Lentiviral particles were generated in 293T HEK cells. The HEK cells were transfected using the 
TransIT-293 transfection reagent, adapting the protocol provided by the manufacturer. Briefly, 
293T cells were seeded on 10cm culture dishes and inubated until they were ~80% confluent. A 
TransIT293 reagent: DNA complex was prepared immediately before transfection by mixing 
2.5μg of the respective plasmid DNA and 21µl of the transfection reagent in serum-free DMEM 
medium. The DNA:Transfection reagent complexes were added drop-wise to the cells and rocked 
gently to distribute the complexes evenly. The cells were incubated overnight and the medium 
was replaced with DC medium. After another 24h the lentivirus containing supernatant was 
 117 Methods 
harvested and filtered using a 0.45µm PVDF filter (Millex). Supernatants were either directly used 
for transduction of DCs or aliquoted and stored at -80°C. 
14.2.2 Transduction 
100’000 MuTu DC line per well of a 6-well plate were plated an incubated overnight. On the 
following day the media was removed and 1mll of the 293T derived supernatant containing the 
viral particles was added onto the culture. The medium was replaced with normal DC medium 
after 24 hours and the efficiency of the transduction was checked by flow cytometry respectively 
rtPCR. 
 
14.3 Quantification of gene and protein expression 
 
14.3.1 RNA Isolation and Reverse Transcription 
RNA isolation for rtPCR was generally performed using the RNeasy Kit (Qiagen) following the 
instructions of the manufacturer. For other applications, the cells were harvested and lysed 
directly on cell culture dish by addition of 500µl Trizol and repeated pipetting and 5’ incubation 
at room temperature. Cell lysate was precipitated by addition of 100µl chloroform. Lysate was 
centrifuged 15’ at 16x104 rcf and 250µl of isopropyl alcohol was added to aqueous phase. 
Precipitate was pelleted by centrifugation for 10’ at 16x104 rcf and washed by addition of 500 µl 
70% ethanol. Ethanol was completely removed after centrifugation and pellet resuspended in 
25µl of RNA secure. RNA was incubated at 60°C for 10’ and stored at -70°C. 2μl (200ng/μl) 
random nonamer primers were added to10μl of RNA and denatured for 5’ at 70°C. Primers were 
allowed to align at 4°C for 10’.4μl of 5x RT buffer, 1μl of 10 μM dNTP, 1μl of 0.5μg/μl BSA, 2μl 
100mM DTT and 0.5 RNASin. Mixture was pre-incubated for 10’ at room temperature. 0.5μl 
Superscript reverse transcriptase was added and the reaction incubated for 50’ at 42°C. The 
Enzyme was inactivated at 70°C for 5’ and the remaining RNA digested with 1μl RNAse H. The 
Reaction was purified using a Qiaquick PCR purification kit following the manufacturer’s 
instructions. The resulting purified cDNA was eluted in 30μl ddH2O and cDNA quantity and purity 
assayed using a Nanodrop 1000 spectrophotometer (Thermo Scientific). cDNA was only used for 
rtPCR when ratio of A260/A280>1.80. 
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14.3.2 Semi-quantitative real-time PCR 
The relative expression of different genes was assayed using the respective specific primers as 
depicted in table 14. For each reaction 2 μl of cDNA (2,5ng/µl) with 0.25μl of each primer (10μM) 
and 2,5μl SYBR Fast Green qPCR Master mix. Reactions were run in technical triplicates on a 
LightCycler480 rtPCR machine (Roche). A standard protocol was used for most of the analyzed 
genes: Initial denaturation for 5’ at 95°C. 45 cycles of amplification: Denaturation for 10’’ at 95°, 
primer annealing for 10’’ at 60°C, expansion at 72°C for 10’’ and signal acquisition at 78°C. 
Followed by acquisition of a melting curve starting at 65°C (60’’) and increasing the temperature 
to 97°C at a rate of 0.11°C/s with 5 signal acquisitioons per second. Relative expression for each 
gene of interest was calculated using the qBase software and represented as expression 
normalized to β-actin. 
 
14.3.3 Enzyme linked immunosorbent assay (ELISA) 
To compare expression levels of the respective cytokines produced by the dendritc cells, standard 
enzyme linked immunosorbent assays were performed. 1.5x106 cells were plated and cultivated 
in fresh medium as described above. Cell supernatant was taken at several time points and 
immediately frozen at -80°C until further processing. Samples were applied in biological 
duplicates. ELISA assay was then performed using the respective Kits, following the 
manufacturer’s instructions. Data read out was performed with a microplate reader 560 (BioRad) 
at 450nm within 30 minutes after stopping of the color reaction.  
 
14.3.4 Immunoprecipitation and western blot 
IL-35 protein was first precipitated from cell lysate or IL-35 conditioned cell supernatant using 
the protein A/G plus beads following the manufacturer’s protocol and 2μg anti-IL12p35 antibody 
per reaction. 
Before loading on the SDS-PAGE, equivalent quantity of protein per sample was denatured by 
incubation in the laemmli buffer (60mM Tris-Cl pH 6.8, 2% SDS, 10% glycerol, 5% β-
mercaptoethanol, 0.01% bromophenol blue) for 10 minutes at 95°C. Samples were loaded onto a 
SDS-10% polyacrylamide gel and electrophoresis was run at 120 volts for about 1h in SDS 
electrophoresis buffer. Gel was blotted onto PVDF membrane (Amersham Pharmacia Biotech) by 
wet sandwich transfer in WB transfer buffer at 120 volts for 1h-1h30, further verified by Ponceau 
red (Fluka) staining of the membrane. Membrane was blocked in 1% BSA (Applichem), 5% Blotto 
(Santa Cruz Biotechnology), 0,1% Tween20-1x PBS (blocking solution) for 1h at RT then 
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incubated with primary antibodies diluted in the blocking solution for overnight at 4°C. After 
washing 3 x 10 minutes in 0.1% TBS-Tween20, membrane was incubated in HRP-conjugated 
secondary antibody for 2h at RT. After washing the membrane 6x for 5minutes, the 
chemiluminescent peroxidase substrate ECL was added and incubated for 5’ in the dark at room 
temperature-Blotted proteins were visualized by exposure of X-ray film (Kodak) to the 
membrane.  
 
14.4 Cell culture  
 
All Cells were handled and prepared on a class 2 laminar flow bench under sterile conditions. 
293T HEK, CT26, CMT38 and B16 cell lines: were kept in DMEM Glutamax with 10% FCS and 1% 
Penicillin/Streptomycin) at 37°C in a 5% CO2 atmosphere. Medium was changed every third day. 
Before cells reached 90% confluency medium was aspirated and cells washed two times with PBS. 
Cells were then detached by addition of 0.25% Trypsin. After 3min incubation at 37°C cells were 
resuspended in 10ml medium and centrifuged for 5 minutes at 360rcf. Cells were split 1:20 into 
fresh medium. 293T cells were detached by pipetting the cells up and down and directly 
centrifuged. 
Dendritic cell lines: Cells were kept in IMDM Glutamax with 10% FCS, 10mM HEPES, 50µM β- 
Mercaptoethanol, 50U/ml penicillin and 10µg/ml streptomycin at 37°C in a 5% CO2 atmosphere. 
When Cells where split when reaching 100% confluency. DCs were harvested by incubation in 
cell dissociation buffer (10mM HEPES and 5mM EDTA in 1x PBS) and centrifuged for 5 minutes 
at 320rcf. Cells were re-seeded according to the table below (table XX). 
 Surface [cm2] Volume [ml] Number of DCs 
96-well 0.32 0.2 20’000 
24 well 1.9 0.5 150’000 
12 well 3.9 1 300’000 
6 well 9.5 2.5 600’000 
Culture flask T25 25 6 1x106 
Culture flask T75 75 20 4x106 
Culture flask T150 150 35 1.2x107 
Table 15 Minimal number of MuTu dendritic cells seeded per indicated area 
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T and Lymph node cells were cultivated in RPMI1640-Glutamax medium supplemented with 10% 
FCS, 12.5 Hepes, 1mM sodium pyruvate, 0.1mM non-essential amino acids (NEAA), 5µM β-
Mercaptoethanol, 50U/ml penicillin and 10µg/ml streptomycin 
Granulocytes and Macrophages were cultured in DMEM medium supplemented with 10% FCS 
and 50U/ml penicillin and 10µg/ml streptomycin. 
 
14.4.1 Cell counting  
Cells were counted using an automatic cell counter (CASYcounter, Innovatis), following the 
manufacturer’s instructions. 
 
14.5 Flow cytometry 
 
For surface staining of cells, the cells where washed once in FACS buffer and centrifuged for 10’ 
at 300g. A maximum of 1x106 cells were then resuspended in staining buffer composed of a 1:1 
of 24G FC blocking antibody and FACS buffer containing the respective fluorochrome coupled 
antibodies. After 30’ incubation at room temperature cells were washed and directly analyzed. 
For intraclllular staining of IFNγ, Foxp3 the lymphocytes were restimulated with 50ng/mL 
phorbol 12-myristate 13-acetate (PMA) and 1μg/mL ionomycin in the presence of 10μg/mL 
brefeldin a for 4 hours at 37°C, 5%CO2 prior to surface staining. Cells were then fixed in 4% 
paraformaldehyde for 30’ (or overnight in1% PFA) and permeabilized with saponin buffer for 30’. 
Cells were washed and stained with the adequate antibodies in a 1:1 mix of 24G and saponin 
buffer for 30’. Foxp3 was stained using the Foxp3 / transcription factor staining set 
(eBiosciences) following the manufacturer’s instructions.  
Data was acquired on LSRII flow cytometers (BD Biosciences) and analyzed with FlowJo X 
software (Treestar). 
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14.6 In vitro experiments 
 
14.6.1 Allogeneic Mixed Leukocyte Reaction (MLR) 
1x104, 2x104 or 5x104 wild-type or Il-35DCs were plated on a U-bottom 96 well plate and 
activated with pI:C, CpG and IFNγ for 4 hours. CD4+ or CD8+ T cells were isolated from wild-type 
BALB/c lymph nodes and magnetically sorted using the respective MACS kit. Purified T cells were 
stained with ef670 proliferation dye according to manufacturer’s instructions and 1x105 cells per 
well were added to DCs. After 3 days of incubation T cells were harvested and proliferation and 
functional phenotype were analyzed by rtPCR and flow cytometry. For depletion of 10μg/ml IL-
35 cytokine, anti-p35 (clone 45806, R&D Systems) or anti-ebi3 (clone V1.aC4.22, Shenandoah 
Biotechnology) were added to the cells at the beginning of the coculture. 
 
14.6.2 Antigen specific OT-I/II proliferation assay  
To assess antigen-specific T cell presentation, untransduced or transduced DC were seeded at 
5x104 DC per well in a 96-well round-bottom plate one day before. DC were pulsed for 3 hours 
with the respective specific OVA-peptides: The MHC-II-restricted OVA(323-339) peptide 
(ISQAVHAAHAEINEAGR) or the MHC-I-restricted OVA(257-264) peptide (SIINFEKL). For MHC-II 
presentation, naive CD4+ CD62L+T cells were magnetically isolated from lymph nodes of OT-II 
mice (MACS, Miltenyi). Similarly, for MHCI presentation, CD8+ T cells were magnetically sorted 
(MACS, Miltenyi) from lymph nodes of OT-I Rag2-/- mice. The T cells were labeled with 5 μM of 
eFluor670 proliferation dye according to manufacturer’s instructions. 1x105 T cells were 
cocultured with the DCs after washing away the peptide in the case of OT-I pulsed DCs.  
4 days later, T cells were nonspecifically restimulated with 10ng/ml of phorbol 12-myristate 13-
acetate (PMA), 500 ng/ml of ionomycin and 10 μg/ml of brefeldin A for 4h at 37°. Activation and 
proliferation was measured by flow cytometry. To analyze cytokine secretion half of the 
harvested T cells was lysed in Trizol. RNA was extracted by phenol extraction and cDNA 
synthesized using superscript reverse transcriptase following the protocol provided by the 
manufacturer. Relative Il12p40, Il12p35, ebi3, Ifng and Il12Rb2 expression was assayed by rtPCR. 
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14.6.3 iTreg suppression assay 
The suppression assay Based on the protocols published by Collison et al. [202]. Shortly, 1x105 
IL-35+DC or wild type DC were plated per well of a24 well plate and incubated overnight. 
Dendritic cells were activated with CpG, polyI:C, (all 1:1000) for 6 h. In the meantime CD4+ T cells 
were magnetically isolated from C57BL/6 mice using the naïve CD4+ T cell isolation kit (Miltenyi) 
and plated at a 10:1 (1x10e6 cells) ratio to wild-type or IL-35+DCs. 2ng/ml recombinant TGF-β 
and 10ng/ml IL-2 were added to some of the wells containing wtDCs for generation of Foxp3+ 
Tregs. Cells were incubate for 4 days. Different amounts of the generated suppressor T cells were 
seeded with 2.5x104 ef670 proliferation dye stained naïve target T cells. Proliferation of the target 
cells was assayed by ef670 dilution after 3 days. Percent suppression was calculated using the 
following formula: 
% 𝑝𝑟𝑜𝑙𝑖𝑓𝑒𝑟𝑎𝑡𝑒𝑑 𝑇𝑐𝑜𝑛𝑣 𝑎𝑙𝑜𝑛𝑒−% 𝑝𝑟𝑜𝑙𝑖𝑓𝑒𝑟𝑎𝑡𝑒𝑑 𝑇𝑐𝑜𝑛𝑣 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝑇𝑟𝑒𝑔
%𝑝𝑟𝑜𝑙𝑖𝑓𝑒𝑟𝑎𝑡𝑒𝑑 𝑇 𝑐𝑜𝑛𝑣 𝑎𝑙𝑜𝑛𝑒
× 100. 
 
14.6.4 IL-35+DC effect on myeloid cells 
Spleen were harvested and splenocytes were isolated by mechanical disruption followed by 
enzymatic digestion in spleen digestion buffer for 20’ at 37°C. Collagenase was blocked by adding 
complete medium. Cellular debris was removed by passing the cell suspension through a 40μm 
cell strainer. CD3+ cells were magnetically depleted (MACS, Miltenyi) and 1x105 cell were seeded 
per well of a 96 well plate. The respective conditioned supernatant was added at a final ratio of 
¼ to culture medium. 18 hours later the medium was replaced and some of the cells were 
stimulated for 3 hours with 10ng/ml PMA. Cells were afterwards harvested and analyzed by flow 
cytometry. 
 
14.6.5 Endothelial cell scratch assay 
1x105 HUVEC endothelial cells were seeded and cultivated for two days on coated cover slips 
covered with 0.2% gelatin in 24-well plate. A “scratch” was inflicted by scraping the endothelial 
cell layer using a 200μl pipette tip. Detached cells were washed away with PBA and fresh 1% FBS 
basal medium was added. The cells were cultured in the presence of either IL-35 conditioned or 
control medium or 2.5x104 of the respective DC lines seeded on the upper chamber of a transwell 
insert. The two chambers of the transwell were separated by a membrane with 4μm pore size 
preventing the transmigration of DCs. After 12, 24 and 36 hours, the HUVEC cells were gently 
washed in PBS and fixed in 4% PFA for 10 minutes at room temperature. Cells were 
permeabilized with 0.1% Triton in PBS and stained for KI67, VEcadherin and caspase3.  
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14.7 In vivo experiments 
 
14.7.1 Mice handling  
All experiments were performed in accordance with Swiss federal legislation and had been 
approved by the Cantonal Veterinary Office. C57BL/6 mice were purchased from Harlan 
Laboratories. BALB/c mice were purchased from Charles River. The CD11c:SV40lgT, OT-I CD45.1, 
OT-II CD45.1 and RAG1-/- deficient animals were bred and kept in house in a specific pathogen 
free (SPF) facility under standardized light, temperature and humidity conditions. Maximal 6 
adult animals were held together in green line individual ventilated cages (IVC) (Tecniplast). 
Males were kept together only when littermates. At least 3 age-matched, female animals per 
experimental group were used for each experiment.  
 
14.7.2 Isolation of spleen, lymph node and tumor cells  
Mice were euthanized by cervical translocation. Organs were harvested and shredded using a 
surgical blade. An adequate amount of lysis buffer was added and incubated for 20’ at 25°C for 
spleen and lymph nodes, or at 37°C for 25’ respectively. Samples were passed through a 40µm 
cell strainer and washed in lysis buffer. For some experiments, erythrocytes were removed by 
incubation in RBC lysis buffer for 3’ at room temperature. 
 
14.7.3 Isolation of peritoneal exudate cells 
Mice received an intraperitoneal injection of 1ml 5% thioglycollate using a 21G needle. For 
neutrophil isolation, the overnight. For macrophage isolation the inflammatory response was 
allowed to develop for 4 days. Mice were carefully sacrificed. 10 ml sterile PBS was injected 
through the peritoneal wall using a 21G needle. The peritoneal fluid was harvested after gently 
massaging the abdomen of the mice. Cells were centrifuged at 200g for 10’ and resuspended in 
neutrophil/macrophage medium. 
 
14.7.4 In vivo antigen-restricted OT-I/II T cell proliferation 
The respective DC line was pulsed for 3 hours with MHC-II restricted with either the MHC-II-
restricted OVA323-339 peptide (ISQAVHAAHAEINEAGR) or the MHC-I-restricted OVA257-264 peptide 
(SIINFEKL). For MHC-II presentation, naive CD4+ CD62L+T cells were magnetically isolated from 
lymph nodes of OT-II mice (MACS, Miltenyi). Similarly, for MHCI presentation, CD8+ T cells were 
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magnetically sorted (MACS, Miltenyi) from lymph nodes of OT-I Rag2-/- mice. The T cells were 
labeled with 5 μM of eFluor670 proliferation dye according to manufacturer’s instructions. 2x105 
and 2.5x106 DCs were mixed and injected intravenously. One day later, the mice received another 
2.5x106 DC pulsed with the respective OVA peptide. The mice were sacrificed 5 days after the first 
injection and the spleen and inguinal and brachial lymph nodes were harvested. Single cell 
suspension of lymphocytes was isolated by mechanical disruption of the organs and passing them 
through a 40μ cell strainer (Falcon). Proliferation and IFNγ expression of the isolated T cells was 
analyzed by flow cytometry upon in vitro restimulation with 10ng/ml PMA 500ng/ml ionomycin 
and 10μg/ml brefeldin A for 4 hours at 37°C. 
 
14.7.5 Induction of adaptive transfer Experimental Autoimmune Encephalitis (EAE) 
Adaptive transfer EAE was induced as described by[155]. Shortly, Myelin oligodendrocyte 
glycoprotein (MOG) reactive T cells were primed in donor C57B/6 mice by two sub-cutaneous 
injections of MOG35-55-peptide emulsified in complete Freud’s Adjuvant (Sigma). Intra peritoneal 
injection of 200ng Pertussis Toxin (Sigma) was used to boost lymphocyte priming. In order to 
study the effect of tolerogenic molecules, MOG35-55 peptide-pulsed control or transduced DCs 
were intravenously injected one day before and one day after the immunization. 12 days post 
immunization, inguinal, brachial and axillary lymph nodes were isolated and by digestion in 
1mg/ml Collagenase D (Roche) for 20min at 37°C. Single cells suspension was prepared using a 
40µm cell strainer (Falcon). LNC were expanded in vitro for 3 days in the presence of MOG35-55 
pulsed DCs and 0.5ng/ml recombinant IL-12 (eBiosciences). T cells were then transferred to 
C57B/6 recipient mice by i.p. injection. Mice were boosted by intra venous injection with MOG35-
55 pulsed DCs one day after LNC cell transfer. Mice were controlled daily and clinical EAE 
symptoms were scored: 0 – no obvious changes in motor functions; 1 – decreased tail tonus; 2- 
abnormal gait (ataxia and/or impaired righting reflex; 3 – partial hind limb paralysis; 4 – 
complete hind limb paralysis; 5 – complete hind and fore limb paralysis; 6 – moribund or dead.  
 
14.7.6 Induction of tolerance towards tumor growth 
B16.F0 melanoma and CMT93 colon carcinoma tumor cell lines were cultured in 
DMEM+GlutaMAX (GIBCO) medium, supplemented with 8% FCS and 50U/ml of penicillin and 
50mg/ml streptomycin (GIBCO). Tumor cell lysate was generated by 5 consecutive freeze/thaw 
cycles in liquid nitrogen. Lysate was centrifuged at1500g for 5min before use. Mock or IL-35 
transduced DCs were pulsed with respective lysate in a 1:4 lysate to DC ratio and 100U/ml 
recombinant IFNγ (eBioscience). 5 and 3 days before and 3 days after tumor cell transfer, 3x106 
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dendritic cells were subcutaneously injected in the flank. Tumor was induced by s.c. injection of 
2x105 B16.F0 or 2x106 CMT93 cells into the same flank. Tumor growth was followed by 
measuring length and width using a caliper. Tumor volume was measured using the formula 𝑉 =
𝜋
6
∙ 1.58 ∙ (𝑙𝑒𝑛𝑔𝑡ℎ ∙ 𝑤𝑖𝑑𝑡ℎ)
3
2 as described by [203]. 
 
14.7.7 Skin graft experiments 
2.5x106 of the respective DC lines were intravenously injected into the recipient mice 3 days 
before and 1 day after skin transplantation. Skin grafting was performed by as described by 
Golshayan et al. [158]: A longitudinal incision was made on the anterior neck of anaesthetized 
mice and thymus removed by application of negative pressure through an inserted glass pipette. 
Full-thickness tail skin was grafted on the flank of recipients. Graft sites were protected under 
sterile gauze and plaster until day 10, observed daily afterwards and considered rejected when 
no viable skin remained. Graft survivals between groups were compared using the log-Rank test. 
No additional immunosuppression was administered. 
 
14.7.8 Tumor experiments 
DC were incubated with freeze-thawed tumor lysates at a ratio of 2 tumor cell equivalents to 1 
DC (i.e., 2:1) in complete medium. After an 18-hour incubation, the DCs were harvested, washed 
twice in sterile PBS and resuspended in PBS for further use. 
Starting one day after tumor inoculation mice were scored and monitored twice a week and after 
each vaccination as followed: 
Score Symptoms 
0 
no visible impairment, normal gait and behavior including explorative behavior in new 
environment (grid), no steps missed on the grid, no visible or palpable  tumor 
1 
no visible impairment, normal gait and behavior including explorative behavior in new 
environment (grid), tumor visible, tumor volume ≤ 500mm3 
2 
reduced activity, less motile then healthy animals, reduced explorative behavior, signs of 
discomfort (hunched back position, lack of grooming), tumor volume  < 2000mm3, signs of 
ulceration (reddening, tendering) of skin on tumor 
3 
apathia, reduced activity, signs of stress and discomfort, (central) necrosis of tumor, tumor 
volume ≥ 2000 mm3 
Table 16 Scoring sheet for Tumor experiments 
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Behavior and condition were observed in the cage without manipulation and on the grid of a cage. 
Tumor length and width were measured using a caliper. Tumor volume was calculated using the 
formula Volume =
𝜋
6
× 1.58(𝑙 × 𝑤)
3
2. Mice were given a clinical score according to the table above. 
Two weeks after tumor inoculation or as soon as an animal reached a score of 2, the health was 
checked daily. Mice were sacrificed when they reached a maximal score of 3. 
 
14.8 Statistical Analysis 
Unless otherwise stated, statistical analysis was performed applying unpaired, two-sided 
Student’s T – test using Microsoft Excel or Graphpad Prism. Differences were considered 
significant when * p<0.05, ** p≤0.005, *** p≤0.001 
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16 Abbreviations 
 
APC  Antigen presenting cells  
BCR B Cell Receptor 
BMDC Bone Marrow Derived DC 
CFA Complete Freud’s Adjuvant 
CD  Cluster of differentiation  
CHO  Chinese hamster ovary  
CNS  Central nervous system  
CpG CpG oligodeoxynucleotides 
CTL Cytotoxic T lymphocyte 
DC  Dendritic cell  
EAE Experimental Autoimmue Encephalitis 
FACS  Fluorescence-activated cell sorting  
GM-CSF  Granulocyte/macrophage colony stimulating 
factor  
i.p.  Intraperitoneal  
i.v.  Intravenous 
ICS  Intra cellular staining  
IDO Indolamin-2,3-Dioxygenase 
IFN-γ  Interferon γ  
IL  Interleukin  
int  intermediate  
LPS Lipopolysaccharide 
M-CSF  Macrophage colony stimulating factor  
MDSC Myeloid derived suppressor cell 
MLR Mixed Lymphocyte Reaction 
MS Multiple Sclerosis 
NK Natural Killer Cell 
PAMP Pattern Associated Molecular Pattern 
p.i.  Post injection  
pI:C Polyinosinic:polycytidylic acid 
pfu  Plaque forming unit  
PRR Pattern Recognition Receptor 
RAG  Recombination-activating gene  
s.c. subcutaneous 
TAA  Tumor associated antigen  
TAM  Tumor associated macrophages  
TCR T cell receptor 
TGF-β  Transforming growth factor β  
Tk  Thymidine kinase  
TLR  Toll-like receptor  
Treg Regulatory T cells 
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Figure 35 pMD2g VSV-G envelope expression vector 
 
 
Figure 36 psPAX2 lentiviral packaging plasmid 
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Figure 37 pRRLSIN.cPPT.PGK-GFP.WPRE lentiviral expression vector 
 
 
Figure 38 pWP-(SIN-cPPT-WPRE)-CMV-IRES-GFP lentiviral expression vector 
  
pWP-(SIN-cPPT-WPRE)-CMV-
IRES-GFP 
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